5 reaction Allergic
5 reaction
fluorouracil infusion reaction Allergic
fluorouracil infusion reaction
cisplatin occurred patient carcinoma cavity cirrhosis
5 infusion occurred induced impaired
5 infusion occurred function renal
5 infusion occurred function
fluorouracil occurred induced impaired
fluorouracil occurred function renal
fluorouracil occurred function
5 infusion occurred reaction allergic
5 infusion occurred reaction
fluorouracil occurred reaction allergic
fluorouracil occurred reaction
cisplatin occurred induced impaired
cisplatin occurred function renal
cisplatin occurred function
cisplatin occurred patient carcinoma
cisplatin occurred patient carcinoma cavity of
cisplatin occurred patient carcinoma cavity the
cisplatin occurred patient carcinoma cavity oral
cisplatin occurred patient carcinoma cavity
cisplatin occurred reaction allergic
cisplatin occurred reaction
5 infusion occurred patient carcinoma
5 infusion occurred patient carcinoma cavity of
5 infusion occurred patient carcinoma cavity the
5 infusion occurred patient carcinoma cavity oral
5 infusion occurred patient carcinoma cavity
fluorouracil occurred patient carcinoma
fluorouracil occurred patient carcinoma cavity of
fluorouracil occurred patient carcinoma cavity the
fluorouracil occurred patient carcinoma cavity oral
fluorouracil occurred patient carcinoma cavity
5 infusion occurred patient carcinoma cavity cirrhosis
fluorouracil occurred patient carcinoma cavity cirrhosis
cisplatin occurred reaction consisting edema angioneurotic
cisplatin occurred reaction consisting edema
diphenhydramine Oral ineffective preventing recurrence reaction allergic
diphenhydramine Oral ineffective preventing recurrence reaction
prednisone diphenhydramine Oral ineffective preventing recurrence reaction allergic
prednisone diphenhydramine Oral ineffective preventing recurrence reaction
testosterone patients referred dysfunction erectile
testosterone patients referred dysfunction
testosterone screened basis desire gynecomastia
testosterone gynecomastia
testosterone heptylate consisted hyperprolactinemia
heptylate consisted hyperprolactinemia
bromocriptine hypogonadism
bromocriptine hypogonadism consisted hyperprolactinemia
testosterone heptylate consisted hypogonadism
heptylate consisted hypogonadism
testosterone determination discovered tumors pituitary
testosterone determination discovered tumors
testosterone levels Most seemed result luteinizing dysfunction hypothalamic
testosterone levels Most seemed result luteinizing dysfunction
testosterone levels Most seemed result have role dysfunction erectile
testosterone levels Most seemed result have role dysfunction
testosterone prolactin cannot erectile
testosterone prolactin cannot dysfunction
testosterone desire gynecomastia
vasopressin gene expression Upregulation insipidus diabetes
vasopressin gene expression Upregulation insipidus
lithium nuclei gene expression Upregulation insipidus diabetes
lithium nuclei gene expression Upregulation insipidus
lithium polyuria
Li lithium polyuria
arginine gene expression investigated lithium polyuria
vasopressin gene expression investigated lithium polyuria
AVP gene expression investigated lithium polyuria
AVP elevation contribute dehydration
AVP expression upregulation elevation contribute dehydration
Li SON expression upregulation elevation contribute dehydration induced rat insipidus diabetes
Li SON expression upregulation elevation contribute dehydration induced rat insipidus
AVP elevation contribute dehydration induced rat insipidus diabetes
AVP elevation contribute dehydration induced rat insipidus
AVP expression upregulation elevation contribute dehydration induced rat insipidus diabetes
AVP expression upregulation elevation contribute dehydration induced rat insipidus
Li SON expression upregulation elevation contribute dehydration
lidocaine man bolus resulted depression
lidocaine represented had conditions predisposed development bradyarrhythmias
UM administered tachycardias ventricular
UM administered tachycardias
272 administered tachycardias ventricular
272 administered tachycardias
N 272 administered tachycardias ventricular
N 272 administered tachycardias
N N 272 administered tachycardias ventricular
N N 272 administered tachycardias
dimethylpropranolol N 272 administered tachycardias ventricular
dimethylpropranolol N 272 administered tachycardias
UM converted tachycardia ventricular
UM converted tachycardia
272 converted tachycardia ventricular
272 converted tachycardia
oxygen therapy cystitis hemorrhagic
oxygen therapy cystitis
cyclophosphamide control therapy cystitis hemorrhagic
cyclophosphamide control therapy cystitis
cyclophosphamide therapy granulomatosis Wegener
cyclophosphamide therapy granulomatosis Wegener '
cyclophosphamide therapy granulomatosis s
cyclophosphamide therapy granulomatosis
cyclophosphamide due case cystitis hemorrhagic
cyclophosphamide due case cystitis
prostaglandin F irrigation treatment failed control hemorrhage
F irrigation treatment failed control hemorrhage
2 alpha F irrigation treatment failed control hemorrhage
alpha F irrigation treatment failed control hemorrhage
cyclophosphamide treatment alternative offer cystitis hemorrhagic
cyclophosphamide treatment alternative offer cystitis
steroids efficacy seizures
steroids demonstrate actions relevance host disorders neurological
steroids demonstrate actions relevance host disorders neurological and
steroids demonstrate actions relevance host disorders neurological psychiatric
steroids demonstrate actions relevance host disorders
steroid modulate effects cocaine engendered administration kindling seizure
gamma modulate effects cocaine engendered administration kindling seizure
aminobutyric acid gamma modulate effects cocaine engendered administration kindling seizure
acid gamma modulate effects cocaine engendered administration kindling seizure
GABA receptor acid gamma modulate effects cocaine engendered administration kindling seizure
Allopregnanolone tested ability suppress expression development seizures
3 alpha Allopregnanolone tested ability suppress expression development seizures
alpha Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
5 alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
pregnan alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
20 one hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
one hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
pregnanolone Allopregnanolone tested ability suppress expression development seizures
3 alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
5 beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
pregnan beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
20 one hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
one hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
allopregnanolone alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
ganaxolone Allopregnanolone tested ability suppress expression development seizures
3 alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
3 beta alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
beta alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
methyl alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
5 alpha alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
alpha alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
pregnan alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
20 alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
one alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
allopregnanolone suppressed expression seizures
GABA modulators suppressed expression seizures
ganaxolone allopregnanolone suppressed expression seizures
prazosin taking change resolve incontinence
Bradykinin antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
Bradykinin antagonists inhibitors vincristine induced hyperalgesia model neuropathy
Bradykinin antagonists inhibitors vincristine induced hyperalgesia
nitric synthase antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
nitric synthase antagonists inhibitors vincristine induced hyperalgesia model neuropathy
oxide synthase antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
oxide synthase antagonists inhibitors vincristine induced hyperalgesia model neuropathy
nitric synthase antagonists inhibitors vincristine induced hyperalgesia
oxide synthase antagonists inhibitors vincristine induced hyperalgesia
vincristine induced hyperalgesia model chemotherapy diabetic
vincristine induced hyperalgesia model neuropathy
HOE bradykinin antagonists action influence model diabetic
HOE bradykinin antagonists action influence model diabetic streptozotocin
HOE bradykinin antagonists action influence model diabetic streptozotocin induced
HOE bradykinin antagonists action influence model diabetic and
HOE bradykinin antagonists action influence model diabetic neuropathy toxic
HOE bradykinin antagonists action influence model diabetic neuropathy vincristine
HOE bradykinin antagonists action influence model diabetic neuropathy vincristine induced
HOE bradykinin antagonists action influence model diabetic neuropathy
140 HOE bradykinin antagonists action influence model diabetic
140 HOE bradykinin antagonists action influence model diabetic streptozotocin
140 HOE bradykinin antagonists action influence model diabetic streptozotocin induced
140 HOE bradykinin antagonists action influence model diabetic and
140 HOE bradykinin antagonists action influence model diabetic neuropathy toxic
140 HOE bradykinin antagonists action influence model diabetic neuropathy vincristine
140 HOE bradykinin antagonists action influence model diabetic neuropathy vincristine induced
140 HOE bradykinin antagonists action influence model diabetic neuropathy
des HOE action influence model diabetic
des HOE action influence model diabetic streptozotocin
des HOE action influence model diabetic streptozotocin induced
des HOE action influence model diabetic and
des HOE action influence model diabetic neuropathy toxic
des HOE action influence model diabetic neuropathy vincristine
des HOE action influence model diabetic neuropathy vincristine induced
des HOE action influence model diabetic neuropathy
Arg HOE action influence model diabetic
Arg HOE action influence model diabetic streptozotocin
Arg HOE action influence model diabetic streptozotocin induced
Arg HOE action influence model diabetic and
Arg HOE action influence model diabetic neuropathy toxic
Arg HOE action influence model diabetic neuropathy vincristine
Arg HOE action influence model diabetic neuropathy vincristine induced
Arg HOE action influence model diabetic neuropathy
10 HOE action influence model diabetic
10 HOE action influence model diabetic streptozotocin
10 HOE action influence model diabetic streptozotocin induced
10 HOE action influence model diabetic and
10 HOE action influence model diabetic neuropathy toxic
10 HOE action influence model diabetic neuropathy vincristine
10 HOE action influence model diabetic neuropathy vincristine induced
10 HOE action influence model diabetic neuropathy
HOE action influence model diabetic
HOE action influence model diabetic streptozotocin
HOE action influence model diabetic streptozotocin induced
HOE action influence model diabetic and
HOE action influence model diabetic neuropathy toxic
HOE action influence model diabetic neuropathy vincristine
HOE action influence model diabetic neuropathy vincristine induced
HOE action influence model diabetic neuropathy
140 HOE action influence model diabetic
140 HOE action influence model diabetic streptozotocin
140 HOE action influence model diabetic streptozotocin induced
140 HOE action influence model diabetic and
140 HOE action influence model diabetic neuropathy toxic
140 HOE action influence model diabetic neuropathy vincristine
140 HOE action influence model diabetic neuropathy vincristine induced
140 HOE action influence model diabetic neuropathy
NO synthase constitutive inhibitor influence model diabetic
NO synthase constitutive inhibitor influence model diabetic streptozotocin
NO synthase constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase constitutive inhibitor influence model diabetic and
NO synthase constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase constitutive inhibitor influence model diabetic neuropathy
NO synthase inhibitor constitutive inhibitor influence model diabetic
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase inhibitor constitutive inhibitor influence model diabetic and
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy
NO synthase inhibitor constitutive inhibitor influence model diabetic
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase inhibitor constitutive inhibitor influence model diabetic and
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy
bradykinin antagonists action influence model diabetic
bradykinin antagonists action influence model diabetic streptozotocin
bradykinin antagonists action influence model diabetic streptozotocin induced
bradykinin antagonists action influence model diabetic and
bradykinin antagonists action influence model diabetic neuropathy toxic
bradykinin antagonists action influence model diabetic neuropathy vincristine
bradykinin antagonists action influence model diabetic neuropathy vincristine induced
bradykinin antagonists action influence model diabetic neuropathy
bradykinin receptors inhibition confirm paper results RESULTS reduces hyperalgesia diabetic
bradykinin receptors inhibition confirm paper results RESULTS reduces hyperalgesia
NO synthase inducible confirm paper results RESULTS reduces hyperalgesia diabetic
NO synthase inducible confirm paper results RESULTS reduces hyperalgesia
NO activity neuronal inducible confirm paper results RESULTS reduces hyperalgesia diabetic
NO activity neuronal inducible confirm paper results RESULTS reduces hyperalgesia
bradykinin inducible products involved hyperalgesia
NO activation inducible products involved hyperalgesia
NO activation inducible products involved hyperalgesia
des HOE activity L 140 neuropathy toxic
des HOE activity L 140 neuropathy
Arg 140 neuropathy toxic
Arg 140 neuropathy
10 140 neuropathy toxic
10 140 neuropathy
HOE 140 neuropathy toxic
HOE 140 neuropathy
140 neuropathy toxic
140 neuropathy
HOE activity L 140 neuropathy toxic
HOE activity L 140 neuropathy
140 HOE activity L 140 neuropathy toxic
140 HOE activity L 140 neuropathy
bradykinin activity participates streptozotocin induced hyperalgesia
bradykinin activity participates seemed bradykinin hyperalgesia
bradykinin seemed participates streptozotocin induced hyperalgesia
bradykinin hyperalgesia
NO synthase participates streptozotocin induced hyperalgesia
NO synthase participates seemed bradykinin hyperalgesia
NO pathway neuronal seemed participates streptozotocin induced hyperalgesia
NO pathway neuronal seemed bradykinin hyperalgesia
NO inhibitors antagonists doses administration effective alleviation pain neuropathic
NO inhibitors antagonists doses administration effective alleviation pain
bradykinin antagonists doses administration effective alleviation pain neuropathic
bradykinin antagonists doses administration effective alleviation pain
caffeine migraine
ergotamine mg comparison caffeine migraine
rizatriptan mg comparison caffeine migraine
5 selective agonist onset action treatment migraine
- agonist onset action treatment migraine
HT agonist onset action treatment migraine
Rizatriptan agonist onset action treatment migraine
caffeine tablets patients treating attack migraine
ergotamine assessed caffeine tablets patients treating attack migraine
rizatriptan tablet assessed caffeine tablets patients treating attack migraine
rizatriptan % Faster reason relief headache
caffeine ergotamine preferred % Faster reason relief headache
ergotamine preferred % Faster reason relief headache
rizatriptan favor co endpoint free pain
ergotamine caffeine treated % Forty pain
caffeine treated % Forty pain
rizatriptan pain
rizatriptan caffeine treated % Forty pain
rizatriptan % relief Headache
rizatriptan caffeine superior relief Headache
caffeine superior relief Headache
caffeine relief Headache
ergotamine % relief Headache
ergotamine superior relief Headache
ergotamine caffeine patients % free pain
caffeine patients % free pain
rizatriptan taking patients % free pain
Rizatriptan superior ergotamine proportions patients nausea phonophobia
caffeine ergotamine proportions patients nausea phonophobia
ergotamine proportions patients nausea phonophobia
Rizatriptan superior ergotamine proportions patients nausea vomiting
caffeine ergotamine proportions patients nausea
ergotamine proportions patients nausea photophobia
ergotamine proportions patients nausea vomiting
Rizatriptan superior ergotamine proportions patients nausea photophobia
caffeine ergotamine proportions patients nausea vomiting
caffeine ergotamine proportions patients nausea photophobia
ergotamine proportions patients nausea
caffeine events dizziness 6 nausea
caffeine events dizziness 6 somnolence
caffeine events dizziness
ergotamine rizatriptan caffeine events dizziness
ergotamine rizatriptan caffeine events dizziness 6 somnolence
ergotamine rizatriptan caffeine events dizziness 6 nausea
rizatriptan caffeine events dizziness 6 somnolence
rifampin therapy tuberculosis pulmonary
rifampin therapy tuberculosis
isoniazid rifampin regimen 10 underwent discovered developed signs failure renal
isoniazid rifampin regimen 10 underwent discovered developed signs failure
rifampin regimen 10 underwent tuberculosis pulmonary
rifampin regimen 10 underwent tuberculosis
isoniazid rifampin regimen 10 underwent tuberculosis pulmonary
isoniazid rifampin regimen 10 underwent tuberculosis
lithium anticonvulsants use type diagnosis structured Patients experienced compared switch manic
lithium anticonvulsants use type diagnosis structured Patients experienced compared switch manic hypomanic
lithium anticonvulsants use type diagnosis II vs DSM
lithium anticonvulsants use type diagnosis II vs IV
lithium anticonvulsants use type diagnosis II vs bipolar
lithium anticonvulsants use type diagnosis II vs I
lithium anticonvulsants use type diagnosis II bipolar
lithium anticonvulsants use type diagnosis II
lithium anticonvulsants use type diagnosis number episodes manic
amsacrine CI study 921 non
amsacrine CI study cell small
amsacrine CI study cell
amsacrine CI study cell cancer lung
amsacrine CI study cell cancer
CI study 921 non
CI study cell small
CI study cell
CI study cell cancer lung
CI study cell cancer
921 non
921 study cell small
921 study cell
921 study cell cancer lung
921 study cell cancer
NSC 921 non
NSC 921 study cell small
NSC 921 study cell
NSC 921 study cell cancer lung
NSC 921 study cell cancer
343499 NSC 921 non
343499 NSC 921 study cell small
343499 NSC 921 study cell
343499 NSC 921 study cell cancer lung
343499 NSC 921 study cell cancer
suxamethonium dose spasm threatening developed primigravida year case congenita myotonia
suxamethonium dose spasm threatening developed primigravida year case congenita
Pethidine associated pethidine control postoperative
Pethidine associated pethidine control pain
pethidine control postoperative
pethidine control pain
pethidine doses received male year controlled pump management control postoperative
pethidine doses received male year controlled pump management control pain
DFU Comparison toxicity
piroxicam study DFU Comparison toxicity
DFU COX piroxicam toxicity
5 DFU COX piroxicam toxicity
5 5 DFU COX piroxicam toxicity
dimethyl 5 DFU COX piroxicam toxicity
3 dimethyl 5 DFU COX piroxicam toxicity
3 dimethyl 5 DFU COX piroxicam toxicity
fluorophenyl 3 dimethyl 5 DFU COX piroxicam toxicity
4 5 DFU COX piroxicam toxicity
4 phenyl 4 5 DFU COX piroxicam toxicity
methylsulphonyl 4 phenyl 4 5 DFU COX piroxicam toxicity
phenyl 4 5 DFU COX piroxicam toxicity
2 5 DFU COX piroxicam toxicity
5 H 2 5 DFU COX piroxicam toxicity
H 2 5 DFU COX piroxicam toxicity
furanon 2 5 DFU COX piroxicam toxicity
piroxicam toxicity
piroxicam septal analysis ventricular
piroxicam septal
piroxicam septal VSD
piroxicam septal and
piroxicam septal midline
piroxicam septal MD
piroxicam septal defects
piroxicam dose treated rats found toxicity
DFU toxicity
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal breast
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal head
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers
fluorouracil IMPORTANCE mainstay treatment colorectal
fluorouracil IMPORTANCE mainstay treatment colorectal breast
fluorouracil IMPORTANCE mainstay treatment colorectal and
fluorouracil IMPORTANCE mainstay treatment colorectal head
fluorouracil IMPORTANCE mainstay treatment colorectal and
fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
fluorouracil IMPORTANCE mainstay treatment colorectal cancers
5 fluorouracil IMPORTANCE mainstay treatment colorectal
5 fluorouracil IMPORTANCE mainstay treatment colorectal breast
5 fluorouracil IMPORTANCE mainstay treatment colorectal and
5 fluorouracil IMPORTANCE mainstay treatment colorectal head
5 fluorouracil IMPORTANCE mainstay treatment colorectal and
5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal breast
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal and
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal head
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal and
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment tumors
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal breast
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal head
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment tumors
fluorouracil IMPORTANCE mainstay treatment tumors
5 fluorouracil IMPORTANCE mainstay treatment tumors
FU 5 fluorouracil IMPORTANCE mainstay treatment tumors
capecitabine safety gain populations patients disease age renal
capecitabine safety gain populations patients disease age and
capecitabine safety gain populations patients disease age kidney
capecitabine safety gain populations patients disease
Capecitabine has given patients dysfunctions age hepatic
Capecitabine has given patients dysfunctions age and
Capecitabine has given patients dysfunctions age renal
Capecitabine has given patients dysfunctions
metocurine abolished rigidity
antidepressant fluoxetine exposure disease patients disability motor
antidepressant fluoxetine exposure disease patients disability
antidepressant fluoxetine exposure disease Parkinson idiopathic
antidepressant fluoxetine exposure disease Parkinson
antidepressant fluoxetine exposure disease Parkinson '
antidepressant fluoxetine exposure disease s
antidepressant fluoxetine exposure disease
fluoxetine exposure disease Parkinson idiopathic
fluoxetine exposure disease Parkinson
fluoxetine exposure disease Parkinson '
fluoxetine exposure disease s
fluoxetine exposure disease
dopamine capacity fluoxetine patients Parkinson
dopamine capacity fluoxetine patients Parkinson '
dopamine capacity fluoxetine patients s
dopamine capacity fluoxetine patients disease
fluoxetine patients Parkinson
fluoxetine patients Parkinson '
fluoxetine patients s
fluoxetine patients disease
gentamicin regimen Nephrotoxicity
cephalothin Nephrotoxicity
gentamicin therapy sodium combination receiving necrosis characterized clinically failure oliguric
gentamicin therapy sodium combination receiving necrosis characterized clinically failure renal
gentamicin therapy sodium combination receiving necrosis characterized clinically failure
sulfate therapy sodium combination receiving necrosis characterized clinically failure oliguric
sulfate therapy sodium combination receiving necrosis characterized clinically failure renal
sulfate therapy sodium combination receiving necrosis characterized clinically failure
cephalothin sodium combination receiving necrosis characterized clinically failure oliguric
cephalothin sodium combination receiving necrosis characterized clinically failure renal
cephalothin sodium combination receiving necrosis characterized clinically failure
sodium combination receiving necrosis characterized clinically failure oliguric
sodium combination receiving necrosis characterized clinically failure renal
sodium combination receiving necrosis characterized clinically failure
Thiopentone pretreatment pain
lidocaine reduces incidence pain
thiopentone reduces reduces incidence pain
amantadine activity depressed
amines results suggest decrease account depression behavioral
amines results suggest decrease account depression
catecholamine rate decrease account depression behavioral
catecholamine rate decrease account depression
norepinephrine methylation rate decrease account depression behavioral
norepinephrine methylation rate decrease account depression
Nicotine appear enhance thrombosis
Papaverine hydrochloride direct vasodilator used manage vasospasm
hydrochloride direct vasodilator used manage vasospasm
papaverine cases described dysfunction cranial
papaverine cases described dysfunction nerve
papaverine cases described dysfunction
papaverine received vasospasm
papaverine used manage vasospasm
papaverine treatment vasospasm
papaverine avoid deficits cranial
papaverine avoid deficits nerve
papaverine avoid deficits
ibuprofen use associated described child developed syndrome vanishing
ibuprofen use associated described child developed syndrome bile
ibuprofen use associated described child developed syndrome duct
ibuprofen use associated described child developed syndrome
ursodeoxycholic acid therapy unrelenting disease cholestatic
ursodeoxycholic acid therapy unrelenting disease
acid therapy unrelenting disease cholestatic
acid therapy unrelenting disease
tacrolimus acid therapy unrelenting cirrhosis
prednisone acid therapy unrelenting cirrhosis
prednisone acid therapy unrelenting disease cholestatic
prednisone acid therapy unrelenting disease
ursodeoxycholic acid therapy unrelenting cirrhosis
acid therapy unrelenting cirrhosis
tacrolimus acid therapy unrelenting disease cholestatic
tacrolimus acid therapy unrelenting disease
atorvastatin effects Anti hypertension
superoxide production increased deficiency Dexamethasone characterized hypertension
O superoxide production increased deficiency Dexamethasone characterized hypertension
2 - O superoxide production increased deficiency Dexamethasone characterized hypertension
- O superoxide production increased deficiency Dexamethasone characterized hypertension
nitric oxide associated dysfunction characterized hypertension
oxide associated dysfunction characterized hypertension
NO oxide associated dysfunction characterized hypertension
Atorvastatin possesses reduced O production forms hypertension
Ato possesses reduced O production forms hypertension
O production forms hypertension
2 O production forms hypertension
NO availability improve reported properties possesses reduced O production forms hypertension
clozapine commencement developed year schizophrenia
clozapine remains standard treatment psychosis
alcohol consumption patients failure Acute
alcohol consumption patients failure liver
alcohol consumption patients failure
paracetamol ingesting failure Acute
paracetamol ingesting failure liver
paracetamol ingesting failure
alcohol development hepatotoxicity
alcohol consumers developed failure liver
alcohol consumers developed failure
alcohol consumption days paracetamol 3 developed failure liver
alcohol consumption days paracetamol 3 developed failure
alcohol consumption g factors patients possible failure liver
alcohol consumption g factors patients possible failure
scopolamine caused amnesia
L glyceryl Effect phosphorylcholine amnesia
alpha glyceryl Effect phosphorylcholine amnesia
glyceryl Effect phosphorylcholine amnesia
phosphorylcholine amnesia
L effects alpha glycerylphosphorylcholine impairment memory
L effects alpha glycerylphosphorylcholine impairment
alpha glycerylphosphorylcholine impairment memory
alpha glycerylphosphorylcholine impairment
glycerylphosphorylcholine impairment memory
glycerylphosphorylcholine impairment
L glycerylphosphorylcholine impairment memory
L glycerylphosphorylcholine impairment
alpha L glycerylphosphorylcholine impairment memory
alpha L glycerylphosphorylcholine impairment
GFC L glycerylphosphorylcholine impairment memory
GFC L glycerylphosphorylcholine impairment
beta reactions allergic
beta reactions
lactam antibiotics evaluated group patients reactions allergic
lactam antibiotics evaluated group patients reactions
penicillin derivatives reacting allergic
penicillin derivatives reacting allergic had responses allergic
beta allergic
lactam antibiotics had allergic
beta allergic had responses allergic
lactam antibiotics had responses allergic
beta diagnosed allergic
lactam antibiotics diagnosed allergic
PG tolerance selected cases allergy
BPO negative test negative MDM
PG negative MDM
PG reported tolerated patients allergic
azathioprine agents associated have risk development leukemia acute
azathioprine agents associated have risk development leukemia nonlymphocytic
azathioprine agents associated have risk development leukemia
Cyclophosphamide therapy increases risk carcinoma
Cyclophosphamide therapy increases risk carcinoma bladder of
Cyclophosphamide therapy increases risk carcinoma bladder the
Cyclophosphamide therapy increases risk carcinoma bladder
cyclophosphamide azathioprine treated arthritis rheumatoid
cyclophosphamide azathioprine treated arthritis
cyclophosphamide azathioprine treated arthritis patients incidence most cancers
azathioprine treated arthritis rheumatoid
azathioprine treated arthritis
azathioprine treated arthritis patients incidence most cancers
alkylating agents drugs use reserved collected Data risk malignancy arthritis rheumatoid
alkylating agents drugs use reserved collected Data risk malignancy arthritis
agents drugs use reserved collected Data risk malignancy arthritis rheumatoid
agents drugs use reserved collected Data risk malignancy arthritis
alkylating agents drugs use treatment arthritis rheumatoid
alkylating agents drugs use treatment arthritis
agents drugs use treatment arthritis rheumatoid
agents drugs use treatment arthritis
alkylating agents drugs use reserved collected Data risk malignancy
agents drugs use reserved collected Data risk malignancy
Ifosfamide encephalopathy presenting asterixis
ifosfamide infusion developed plasmacytoma
ifosfamide administration discontinued resolved asterixis
ifosfamide findings infusion asterixis
IFX use associated suggest presence asterixis
Methamphetamine induced neurotoxicity
DA neurons neurodegeneration
DA system models neurotoxicity
DA system selective hypothesized plays role induced neurotoxicity
METH caused damage selective system models neurotoxicity
METH caused damage selective hypothesized plays role induced neurotoxicity
METH role plays hypothesized selective system models neurotoxicity
METH role induced neurotoxicity
MPTP METH caused damage selective system models neurotoxicity
MPTP METH caused damage selective hypothesized plays role induced neurotoxicity
DA system selective damage CNS
DA system selective damage
METH treated examined neurotoxicity
METH activation neurotoxicity
bupivacaine prilocaine incidence symptoms Transient
bupivacaine prilocaine incidence symptoms neurologic
bupivacaine prilocaine incidence symptoms
bupivacaine infrequent follow symptoms transient
bupivacaine infrequent follow symptoms neurologic
bupivacaine infrequent follow symptoms
bupivacaine infrequent follow symptoms TNSs
bupivacaine lidocaine prilocaine compares duration risk TNSs
bupivacaine receiving patients none Nine patients receiving TNSs
bupivacaine receiving patients none Nine RESULTS had TNSs
gemcitabine chemotherapy approach carcinoma nonsmall
gemcitabine chemotherapy approach carcinoma cell
gemcitabine chemotherapy approach carcinoma lung
gemcitabine chemotherapy approach carcinoma
cisplatin Paclitaxel chemotherapy approach carcinoma nonsmall
cisplatin Paclitaxel chemotherapy approach carcinoma cell
cisplatin Paclitaxel chemotherapy approach carcinoma lung
cisplatin Paclitaxel chemotherapy approach carcinoma
Paclitaxel chemotherapy approach carcinoma nonsmall
Paclitaxel chemotherapy approach carcinoma cell
Paclitaxel chemotherapy approach carcinoma lung
Paclitaxel chemotherapy approach carcinoma
Cisplatin BACKGROUND based improve quality life carcinoma nonsmall
Cisplatin BACKGROUND based improve quality life carcinoma cell
Cisplatin BACKGROUND based improve quality life carcinoma lung
Cisplatin BACKGROUND based improve quality life carcinoma
Cisplatin BACKGROUND based improve quality life NSCLC
gemcitabine combination paclitaxel toxicity
gemcitabine combination paclitaxel toxicity feasibility determine treat NSCLC
cisplatin paclitaxel toxicity
cisplatin paclitaxel toxicity feasibility determine treat NSCLC
paclitaxel toxicity feasibility determine treat NSCLC
paclitaxel toxicity
gemcitabine 1 cisplatin Day treated chemotherapy patients NSCLC
cisplatin Day treated chemotherapy patients NSCLC
paclitaxel combination treated chemotherapy patients NSCLC
gemcitabine paclitaxel tolerated shows NSCLC
cisplatin paclitaxel tolerated shows NSCLC
paclitaxel tolerated shows NSCLC
metronidazole treat infection
salbutamol doses administration assessed patients disease obstructive
salbutamol doses administration assessed patients disease lung
salbutamol doses administration assessed patients disease
4 bolus done tumors
' 4 bolus done tumors
0 tetrahydropyranyladriamycin done tumors
tetrahydropyranyladriamycin done tumors
Pirarubicin tetrahydropyranyladriamycin done tumors
carbamazepine presenting reaction eosinophilia
carbamazepine presented erythroderma eosinophilia
dopamine neurotransmission dysfunction associated Schizophrenia
N D antagonists produce schizophrenic
methyl D antagonists produce schizophrenic
D antagonists produce schizophrenic
aspartate receptor D antagonists produce schizophrenic
NMDA receptor D antagonists produce schizophrenic
NMDA receptor system dysfunctioning idea led observation produce schizophrenic
glutamate D antagonists produce schizophrenic
NMDA Nr challenge models hyperactivity
SSR properties investigating focus models hyperactivity
103800 SSR properties investigating focus models hyperactivity
NMDA antagonist hyperactivity
NMDA antagonist hyperactivity 801 hyperactivity
NMDA Nr hyperactivity 801 hyperactivity
NMDA Nr hyperactivity
SSR blocked hyperactivity
103800 SSR blocked hyperactivity
SSR blocked hyperactivity 801 hyperactivity
103800 SSR blocked hyperactivity 801 hyperactivity
dopamine transporter observed induced hyperactivity
SSR 103800 failed affect induced hyperactivity
103800 failed affect induced hyperactivity
aripiprazole clozapine olanzapine atypical antipsychotics classical effective models hyperactivity
haloperidol classical effective models hyperactivity
olanzapine atypical antipsychotics classical effective models hyperactivity
clozapine olanzapine atypical antipsychotics classical effective models hyperactivity
SSR 103800 produce catalepsy
103800 produce catalepsy
tyrosine phosphatase nephrosis
PAN injection days as include phase proteinuria associated effacement phase proteinuria associated glomerulosclerosis
Valproate syndrome manifest individuals epileptic
Nitro ester protector ototoxicity
L Nitro ester protector ototoxicity
arginine ester protector ototoxicity
methyl ester protector ototoxicity
ester protector ototoxicity
gentamicin ototoxicity
gentamicin caused loss high
gentamicin caused loss frequency
gentamicin caused loss hearing
gentamicin caused loss
nitro act high
nitro act high loss frequency
nitro act high loss hearing
nitro act high loss
L nitro act high
L nitro act high loss frequency
L nitro act high loss hearing
L nitro act high loss
arginine ester act high
arginine ester act high loss frequency
arginine ester act high loss hearing
arginine ester act high loss
methyl ester act high
methyl ester act high loss frequency
methyl ester act high loss hearing
methyl ester act high loss
ester act high
ester act high loss frequency
ester act high loss hearing
ester act high loss
L ester act high
L ester act high loss frequency
L ester act high loss hearing
L ester act high loss
NAME L ester act high
NAME L ester act high loss frequency
NAME L ester act high loss hearing
NAME L ester act high loss
nitric oxide inhibitor nitro act high
nitric oxide inhibitor nitro act high loss frequency
nitric oxide inhibitor nitro act high loss hearing
nitric oxide inhibitor nitro act high loss
oxide inhibitor nitro act high
oxide inhibitor nitro act high loss frequency
oxide inhibitor nitro act high loss hearing
oxide inhibitor nitro act high loss
NO oxide inhibitor nitro act high
NO oxide inhibitor nitro act high loss frequency
NO oxide inhibitor nitro act high loss hearing
NO oxide inhibitor nitro act high loss
Aminoglycoside antibiotics used inhibitor nitro act high
Aminoglycoside antibiotics used inhibitor nitro act high loss frequency
Aminoglycoside antibiotics used inhibitor nitro act high loss hearing
Aminoglycoside antibiotics used inhibitor nitro act high loss
NO production involves need problem ototoxicity
NO production involves mechanism ototoxic
NO inhibitors use assess need problem ototoxicity
NO inhibitors use assess need involves mechanism ototoxic
aminoglycoside prevention assess need problem ototoxicity
aminoglycoside prevention assess need involves mechanism ototoxic
NO production involves need assess prevention loss sensorineural
NO production involves need assess prevention loss hearing
NO production involves need assess prevention loss
NO inhibitors use assess prevention loss sensorineural
NO inhibitors use assess prevention loss hearing
NO inhibitors use assess prevention loss
aminoglycoside prevention loss sensorineural
aminoglycoside prevention loss hearing
aminoglycoside prevention loss
L induced loss hearing
L induced loss
NAME gentamicin L induced loss hearing
NAME gentamicin L induced loss
cimetidine mg continuous hour receiving developed year man leukemia
cimetidine mg continuous hour receiving developed year history disease cardiac
cimetidine mg continuous hour receiving developed year history disease
cimetidine related arrhythmias
ranitidine treatment recur related arrhythmias
methyl dopa treated histories psychiatric
dopa treated histories psychiatric
gemfibrozil cyclosporin treated patients lovastatin reported associated myoglobinuria
lovastatin reported Myopathy
niacin cyclosporin treated patients lovastatin reported associated myoglobinuria
cyclosporin treated patients lovastatin reported associated failure renal
cyclosporin treated patients lovastatin reported associated failure
niacin cyclosporin treated patients lovastatin reported associated failure renal
niacin cyclosporin treated patients lovastatin reported associated failure
cyclosporin treated patients lovastatin reported associated myoglobinuria
gemfibrozil cyclosporin treated patients lovastatin reported associated failure renal
gemfibrozil cyclosporin treated patients lovastatin reported associated failure
sodium nitroprusside than greater hemorrhage
nitroprusside than greater hemorrhage
sodium nitroprusside infusion decreased decreased decreased hemorrhage
nitroprusside infusion decreased decreased decreased hemorrhage
sodium nitroprusside infusion decreased decreased decreased hemorrhage HEM
nitroprusside infusion decreased decreased decreased hemorrhage HEM
SNP nitroprusside infusion decreased decreased decreased hemorrhage
SNP nitroprusside infusion decreased decreased decreased hemorrhage HEM
SNP group that lower hypotension HEM
SNP group Hg / Hg group HEM
SNP HEM
scopolamine induced Components dementia
s effects dementia
limonene anti effects dementia
s limonene anti effects dementia
perillyl alcohol observed limonene anti effects dementia
alcohol observed limonene anti effects dementia
s associative showed improve memory
s associative showed improve memory impaired
perillyl alcohol relieved s associative showed improve memory
perillyl alcohol relieved s associative showed improve memory impaired
alcohol relieved s associative showed improve memory
alcohol relieved s associative showed improve memory impaired
s relieved deficit
s relieved deficit memory of
s relieved deficit memory associative
s relieved deficit memory
perillyl alcohol relieved deficit
perillyl alcohol relieved deficit memory of
perillyl alcohol relieved deficit memory associative
perillyl alcohol relieved deficit memory
alcohol relieved deficit
alcohol relieved deficit memory of
alcohol relieved deficit memory associative
alcohol relieved deficit memory
aminoglycosides dose appeared Ototoxicity
aminoglycosides dose drugs ototoxic
furosemide aminoglycosides dose appeared Ototoxicity
furosemide aminoglycosides dose drugs ototoxic
carmofur result syndrome organic
carmofur result syndrome personality
carmofur result syndrome
Raloxifene Evaluation Outcomes METHODS enrolled 7 women osteoporosis
Raloxifene increase 9 7 2 3 % % CI cancer endometrial
Raloxifene increase 9 7 2 3 % % CI cancer
Raloxifene increase 9 7 2 3 % % CI hyperplasia endometrial
Raloxifene increase 9 7 2 3 % % CI hyperplasia
Raloxifene increase 9 7 2 3 % % CI disease gallbladder
Raloxifene increase 9 7 2 3 % % CI disease
Raloxifene increase cataracts
Raloxifene associated was risk cataracts cancer endometrial
Raloxifene associated was risk cataracts cancer
Raloxifene associated was risk cataracts hyperplasia endometrial
Raloxifene associated was risk cataracts hyperplasia
Raloxifene associated was risk cataracts disease gallbladder
Raloxifene associated was risk cataracts disease
Raloxifene associated was risk cataracts
calcium blockers administration levels reduction led relief pain
cyclosporine effect Syndrome CIPS
tacrolimus cyclosporine effect Syndrome CIPS
angiotensin inhibitor Effects converting coagulation intravascular
angiotensin inhibitor Effects converting coagulation
Captopril enzyme converting coagulation intravascular
Captopril enzyme converting coagulation
Captopril enzyme insufficiency pulmonary
Captopril enzyme insufficiency pulmonary and
Captopril enzyme insufficiency pulmonary renal
Captopril enzyme insufficiency
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary and
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary renal
angiotensin inhibitor Effects converting enzyme insufficiency
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling insufficiency
acid injection fibrinolysis coagulation Induction gives resembling pulmonary
acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
acid injection fibrinolysis coagulation Induction gives resembling insufficiency
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
AMCA acid injection fibrinolysis coagulation Induction gives resembling insufficiency
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
AMCA acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
AMCA acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
Captopril Injection reduced insufficiency pulmonary
Captopril Injection reduced insufficiency pulmonary and
Captopril Injection reduced insufficiency pulmonary renal
Captopril Injection reduced insufficiency
angiotensin inhibitor converting reduced insufficiency pulmonary
angiotensin inhibitor converting reduced insufficiency pulmonary and
angiotensin inhibitor converting reduced insufficiency pulmonary renal
angiotensin inhibitor converting reduced insufficiency
Captopril prevented damage Renal
Captopril prevented damage
urea increase reflected damage Renal
urea increase reflected damage
Captopril reduce produced damage kidney
Captopril reduce produced damage
verapamil effect ulcers
verapamil effect rats atherosclerotic
verapamil effect ulcers gastric
verapamil effect ulcers hemorrhagic
histamine release diffusion generation modulating rats atherosclerosis
histamine release diffusion generation modulating hemorrhage ulcer
histamine release diffusion generation modulating hemorrhage gastric
histamine release diffusion generation modulating hemorrhage
verapamil model ulcer
histamine concentration diffusion areas ulcer
luminal content diffusion areas ulcer
calcium concentration parameters atherosclerotic
calcium concentration parameters obtained rats atherosclerotic
histamine release diffusion observed accompanied ulcers
luminal content diffusion observed accompanied ulcers
histamine correlation found rats atherosclerotic
histamine histamine ulcer
histamine hemorrhage gastric
histamine hemorrhage
verapamil dose ulcer
verapamil dose ulcer hemorrhagic
verapamil ameliorated release diffusion ulcer
verapamil ameliorated release diffusion ulcer produce Atherosclerosis
histamine release diffusion ulcer produce Atherosclerosis
histamine release diffusion ulcer
verapamil ameliorated release diffusion ulcer gastric
verapamil ameliorated release diffusion ulcer hemorrhagic
histamine release diffusion ulcer gastric
histamine release diffusion ulcer hemorrhagic
cephalosporins associated defects birth
cephalosporins associated defects
erythromycins associated defects birth
erythromycins associated defects
penicillins Reassuringly erythromycins associated defects birth
penicillins Reassuringly erythromycins associated defects
carboplatin injection Severe toxicity ocular
carboplatin injection Severe toxicity ocular and
carboplatin injection Severe toxicity ocular orbital
carboplatin injection Severe toxicity
carboplatin glioblastomas
carboplatin said have effects cisplatin known toxicity ocular
carboplatin said have effects cisplatin known toxicity ocular and
carboplatin said have effects cisplatin known toxicity ocular orbital
carboplatin said have effects cisplatin known toxicity
cisplatin known toxicity ocular
cisplatin known toxicity ocular and
cisplatin known toxicity ocular orbital
cisplatin known toxicity
carboplatin injection experienced case ocular
carboplatin injection experienced case ocular and
carboplatin injection experienced case ocular toxicity orbital
carboplatin injection experienced case ocular toxicity
carboplatin injection received glioblastomas
carboplatin toxicity
carboplatin injection performing aware toxicity ocular
carboplatin injection performing aware toxicity
xanthine oxidase Role hypertension
nitric oxide associated hypertension
oxide associated hypertension
nitric oxide associated hypertension GC HT
oxide associated hypertension GC HT
xanthine oxidase role studied dexamethasone hypertension
xanthine oxidase role studied dexamethasone hypertension dex HT
Allopurinol prevent HT
allopurinol failed prevent hormone induced hypertension
allopurinol failed together suggests determinant HT
estradiol - therapy estrogen women atherosclerosis
- therapy estrogen women atherosclerosis
and - therapy estrogen women atherosclerosis
testosterone esters - therapy estrogen women atherosclerosis
esters - therapy estrogen women atherosclerosis
estrogen women atherosclerosis
alcohol use diabetes
cholesterol level diabetes
apomorphine induced catalepsy
amphetamine behavior climbing induced designed induced catalepsy
histamine H effect study designed induced catalepsy
apomorphine used induced Catalepsy
amphetamine apomorphine used induced Catalepsy
R cause catalepsy
alpha R cause catalepsy
methylhistamine R cause catalepsy
RAMH methylhistamine R cause catalepsy
THP reduced amphetamine induced hyperactivity
THP exhibited antipsychotic like induced hyperactivity
apomorphine reducing induced like induced catalepsy
amphetamine reducing like induced catalepsy
haloperidol potentiating like induced hyperactivity
apomorphine reducing induced hyperactivity
oxygen level correlated NIN
topiramate prevention impairments memory
topiramate prevention impairments memory and
topiramate prevention impairments memory learning
topiramate prevention impairments
Cocaine causes impairments memory
Cocaine causes impairments memory and
Cocaine causes impairments memory learning
Cocaine causes impairments
cocaine toxicity
cocaine brain induced status association stress increase toxicity
cocaine administration model evaluated activity stress activity effect topiramate therapy addiction cocaine
cocaine administration model evaluated activity stress activity effect topiramate therapy addiction
nitric synthase stress activity effect topiramate therapy addiction cocaine
nitric synthase stress activity effect topiramate therapy addiction
oxide synthase stress activity effect topiramate therapy addiction cocaine
oxide synthase stress activity effect topiramate therapy addiction
topiramate therapy addiction cocaine
topiramate therapy addiction
folate concentrations efficacy toxicity
carbamazepine treatment efficacy toxicity
propylene glycol vehicle found exhibit seizures
glycol vehicle found exhibit seizures
propylene glycol vehicle found inhibited gain weight
propylene glycol vehicle found inhibited gain
glycol vehicle found inhibited gain weight
glycol vehicle found inhibited gain
CBZ measure found Seizures
CBZ measure found seizures
CBZ administration h dose induced seizures
CBZ administration h toxic measured gain weight
CBZ administration h toxic measured gain
HFDE protective induced dose h toxic measured gain weight
HFDE protective induced dose h toxic measured gain
calcitonin injections induced hyperactivity
Methamphetamine stimulant increases produce effects dysrhythmias hallucinations
Methamphetamine stimulant increases produce effects dysrhythmias behavior violent
Methamphetamine stimulant increases produce effects dysrhythmias behavior
Methamphetamine stimulant increases produce effects dysrhythmias cardiac
Methamphetamine stimulant increases produce effects dysrhythmias
Methamphetamine stimulant increases produce effects dysrhythmias hypertension
methamphetamine abusing patients present hygiene caries mouth meth
methamphetamine abusing patients present hygiene caries mouth
methamphetamine abusing patients present wear tooth
methamphetamine abusing patients present wear
methamphetamine abusing patients present hygiene caries xerostomia
methamphetamines abusing patients manage recognize help presented case showing manifestations mouth meth
methamphetamines abusing patients manage recognize help presented case showing manifestations mouth
Pyrrolidine dithiocarbamate protects cortex model status
Pyrrolidine dithiocarbamate protects cortex model epilepticus
dithiocarbamate protects cortex model status
dithiocarbamate protects cortex model epilepticus
oxygen species production activation implicated damage neuronal
oxygen species production activation implicated damage
PDTC epilepticus status
PDTC epilepticus
PDTC epilepticus status
PDTC epilepticus
PDTC exert development epilepticus status
PDTC exert development epilepticus
PDTC vehicle treated rats epilepticus status
PDTC vehicle treated rats epilepticus
PDTC inhibitor NF protected affect loss neuronal
PDTC inhibitor NF protected affect loss
oxygen species generation plays role seizure
oxygen species generation associated damage neuronal
oxygen species generation associated damage
Flestolol produced induced tachycardia
Flestolol reduced tachyarrhythmia supraventricular
Flestolol reduced tachyarrhythmia
flestolol infusion found safe pain chest
flestolol infusion found safe pain
flestolol infusion found patients angina unstable
flestolol infusion found patients angina
green tea Effect induced infarction myocardial
green tea Effect induced infarction
tea Effect induced infarction myocardial
tea Effect induced infarction
vitamin combination tea Effect induced infarction myocardial
vitamin combination tea Effect induced infarction
E combination tea Effect induced infarction myocardial
E combination tea Effect induced infarction
green tea effects ATPases infarction myocardial
green tea effects ATPases infarction
tea effects ATPases infarction myocardial
tea effects ATPases infarction
vitamin E tea effects ATPases infarction myocardial
vitamin E tea effects ATPases infarction
E tea effects ATPases infarction myocardial
E tea effects ATPases infarction
green tea effect indicate ISO induced infarction myocardial
green tea effect indicate ISO induced infarction
tea effect indicate ISO induced infarction myocardial
tea effect indicate ISO induced infarction
vitamin E tea effect indicate ISO induced infarction myocardial
vitamin E tea effect indicate ISO induced infarction
E tea effect indicate ISO induced infarction myocardial
E tea effect indicate ISO induced infarction
dacarbazine therapy melanoma
DTIC therapy melanoma
dacarbazine therapy melanoma
DTIC therapy melanoma
paracetamol cause cancer necrosis renal
paracetamol cause cancer necrosis papillary
paracetamol cause cancer necrosis
paracetamol cause cancer urothelial
paracetamol cause cancer
paracetamol phenacetin consumption associated cancer
paracetamol phenacetin consumption associated cancer pelvis of
paracetamol phenacetin consumption associated cancer pelvis the
paracetamol phenacetin consumption associated cancer pelvis renal
paracetamol phenacetin consumption associated cancer pelvis
paracetamol phenacetin consumption associated cancer pelvis ureter
paracetamol phenacetin consumption associated cancer pelvis or
paracetamol phenacetin consumption associated cancer pelvis bladder
paracetamol phenacetin consumption associated cancer necrosis renal
paracetamol phenacetin consumption associated cancer necrosis papillary
paracetamol phenacetin consumption associated cancer necrosis
phenacetin consumption associated cancer
phenacetin consumption associated cancer pelvis of
phenacetin consumption associated cancer pelvis the
phenacetin consumption associated cancer pelvis renal
phenacetin consumption associated cancer pelvis
phenacetin consumption associated cancer pelvis ureter
phenacetin consumption associated cancer pelvis or
phenacetin consumption associated cancer pelvis bladder
phenacetin increased cancer
phenacetin increased cancer pelvis of
phenacetin increased cancer pelvis the
phenacetin increased cancer pelvis renal
phenacetin increased cancer pelvis
phenacetin increased cancer pelvis and
phenacetin increased cancer pelvis bladder
phenacetin increased increased cancer ureteric
phenacetin increased increased cancer
paracetamol consumption necrosis renal
paracetamol consumption necrosis papillary
paracetamol consumption necrosis
paracetamol consumption any cancers
paracetamol consumption substantiate was suggestion association cancer
paracetamol consumption substantiate was suggestion association cancer ureter of
paracetamol consumption substantiate was suggestion association cancer ureter the
paracetamol consumption substantiate was suggestion association cancer ureter
lignocaine instillation tinnitus
lidocaine Treatment tinnitus
lignocaine instillation treating IST
lidocaine lignocaine instillation treating IST
isosorbide dinitrate administration wall infarction suffered old necrosis
dinitrate administration wall infarction suffered old necrosis
Simvastatin ezetimibe failure hepatic
Simvastatin ezetimibe failure
ezetimibe failure hepatic
ezetimibe failure
ezetimibe published events hepatotoxic
simvastatin mg necessitating developed failure fulminant
simvastatin mg necessitating developed failure hepatic
simvastatin mg necessitating developed failure
simvastatin maintained evidence hepatotoxicity
escitalopram Simvastatinezetimibe taking depression
Simvastatinezetimibe taking depression
escitalopram Simvastatinezetimibe discontinued excluded causes hepatotoxicity
uridine glucoronosyltransferases undergoes inhibited glucuronidation resulting exposure hepatotoxicity
diphosphate glucoronosyltransferases undergoes inhibited glucuronidation resulting exposure hepatotoxicity
simvastatin exposure hepatotoxicity
Ezetimibe undergoes inhibited glucuronidation resulting exposure hepatotoxicity
simvastatin acid glucuronidation resulting exposure hepatotoxicity
hydroxy acid glucuronidation resulting exposure hepatotoxicity
acid glucuronidation resulting exposure hepatotoxicity
simvastatin report ezetimibe failure liver
simvastatin report ezetimibe failure
ezetimibe failure liver
ezetimibe failure
simvastatin exposure mechanism simvastatinezetimibe induced hepatotoxicity
ezetimibe inhibition exposure mechanism simvastatinezetimibe induced hepatotoxicity
methotrexate toxicity high posterior syndrome leukoencephalopathy
methotrexate toxicity high posterior stroke
methotrexate toxicity high posterior syndrome secretion inappropriate
methotrexate toxicity high posterior syndrome secretion antidiuretic
methotrexate toxicity high posterior syndrome secretion hormone
methotrexate toxicity high posterior syndrome secretion
methotrexate toxicity high posterior stroke epilepsy temporal
methotrexate toxicity high posterior stroke epilepsy lobe
methotrexate toxicity high posterior stroke epilepsy
methotrexate toxicity
serotonin secondary inhibitors incontinence
cyclophosphamide high based cancer breast
cyclophosphamide high based cancer
cyclophosphamide high observed toxicity Cardiac
cyclophosphamide high observed toxicity
melphalan paclitaxel combined We DESIGN regimen patients cancer breast
melphalan paclitaxel combined We DESIGN regimen patients cancer
carboplatin cyclophosphamide DESIGN regimen patients cancer breast
carboplatin cyclophosphamide DESIGN regimen patients cancer
cyclophosphamide DESIGN regimen patients cancer breast
cyclophosphamide DESIGN regimen patients cancer
paclitaxel combined We DESIGN regimen patients cancer breast
paclitaxel combined We DESIGN regimen patients cancer
thiotepa cyclophosphamide DESIGN regimen patients cancer breast
thiotepa cyclophosphamide DESIGN regimen patients cancer
anthracyclines use age women cancer breast
anthracyclines use age women cancer
anthracyclines use age hypertension
anthracyclines use age mellitus diabetes
anthracyclines use age mellitus
cyclophosphamide women age hypertension
cyclophosphamide women age mellitus diabetes
cyclophosphamide women age mellitus
cyclophosphamide women cancer breast
cyclophosphamide women cancer
anthracyclines use age women cyclophosphamide high regimen failure congestive
anthracyclines use age women cyclophosphamide high regimen failure heart
anthracyclines use age women cyclophosphamide high regimen failure
anthracyclines use age women cyclophosphamide high regimen failure CHF
cyclophosphamide toxicity cardiac
cyclophosphamide toxicity
steroids resolved angioedema
diphenhydramine hydrochloride steroids resolved angioedema
Octreotide induced hypertension hypoxemia
octreotide developed enhance resolution fistula
nitroprusside discontinuation observed hypertension
Cyproterone acetate licensed treatment women acne hirsutism
acetate licensed treatment women acne hirsutism
CPA EE acetate licensed treatment women acne hirsutism
Cyproterone acetate licensed treatment women acne
acetate licensed treatment women acne
CPA EE acetate licensed treatment women acne
Cyproterone acetate licensed option syndrome polycystic
Cyproterone acetate licensed option syndrome ovary
Cyproterone acetate licensed option syndrome
acetate licensed option syndrome polycystic
acetate licensed option syndrome ovary
acetate licensed option syndrome
Cyproterone acetate licensed option syndrome PCOS
acetate licensed option syndrome PCOS
CPA EE acetate licensed option syndrome polycystic
CPA EE acetate licensed option syndrome ovary
CPA EE acetate licensed option syndrome
CPA EE acetate licensed option syndrome PCOS
ethinyl estradiol combined acetate licensed treatment women acne hirsutism
estradiol combined acetate licensed treatment women acne hirsutism
EE acetate licensed treatment women acne hirsutism
ethinyl estradiol combined acetate licensed treatment women acne
estradiol combined acetate licensed treatment women acne
EE acetate licensed treatment women acne
ethinyl estradiol combined acetate licensed option syndrome polycystic
ethinyl estradiol combined acetate licensed option syndrome ovary
ethinyl estradiol combined acetate licensed option syndrome
estradiol combined acetate licensed option syndrome polycystic
estradiol combined acetate licensed option syndrome ovary
estradiol combined acetate licensed option syndrome
ethinyl estradiol combined acetate licensed option syndrome PCOS
estradiol combined acetate licensed option syndrome PCOS
EE acetate licensed option syndrome polycystic
EE acetate licensed option syndrome ovary
EE acetate licensed option syndrome
EE acetate licensed option syndrome PCOS
oral contraceptives associated thromboembolism venous
oral contraceptives associated thromboembolism
contraceptives associated thromboembolism venous
contraceptives associated thromboembolism
oral contraceptives associated thromboembolism VTE
contraceptives associated thromboembolism VTE
CPA EE associated VTE risk estimate aged years acne hirsutism
CPA EE associated VTE risk estimate aged years acne
CPA EE associated VTE risk estimate aged years acne PCOS
EE associated VTE risk estimate aged years acne hirsutism
EE associated VTE risk estimate aged years acne
EE associated VTE risk estimate aged years acne PCOS
CPA EE women acne hirsutism
CPA EE women acne
CPA EE women acne PCOS
EE women acne hirsutism
EE women acne
EE women acne PCOS
5 patients supervision discontinued observed pain tachyarrhythmia
FU treatment supervision discontinued observed pain tachyarrhythmia
fentanyl administration effects include rigidity chest
fentanyl administration effects include rigidity wall
fentanyl administration effects include rigidity
fentanyl infusion result mimicking hydronephrosis
LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
LEV treated FINDINGS 28 year man suffering epilepsy
LEV treated FINDINGS 28 year man suffering seizures
valproate added LEV treated FINDINGS 28 year man suffering seizures
VPA valproate added LEV treated FINDINGS 28 year man suffering seizures
valproate added LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
valproate added LEV treated FINDINGS 28 year man suffering epilepsy
VPA valproate added LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
VPA valproate added LEV treated FINDINGS 28 year man suffering epilepsy
LEV discontinuation improved decreased frequency seizure
ifosfamide toxicity children treated tumors malignant
ifosfamide toxicity children treated tumors mesenchymal
ifosfamide toxicity children treated tumors
ifosfamide protocol received children tumors malignant
ifosfamide protocol received children tumors mesenchymal
ifosfamide protocol received children tumors
ifosfamide protocol Society -RSB- Malignant
ifosfamide protocol Society -RSB- Mesenchymal
ifosfamide protocol Society -RSB- Tumor
creatinine clearance electrolytes proteinuria
phosphate reabsorption electrolytes proteinuria
phosphate reabsorption electrolytes glucosuria
creatinine clearance electrolytes glucosuria
phosphate reabsorption electrolytes aminoaciduria
creatinine clearance electrolytes aminoaciduria
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome Fanconi
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome Fanconi '
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome s
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome TDFS
phosphate reabsorption microglobulinuria included identified included patients developed toxicity
ifosfamide predominance involvement tumor
ifosfamide 2 correlated toxicity
ifosfamide efficacy evaluated treatment tumors mesenchymal
ifosfamide efficacy evaluated treatment tumors
MZ dose age myocardiopathy
MZ dose age myocardiopathy MP
MZ dose age myocardiopathy duration test regurgitation mitral
MZ dose age myocardiopathy duration test regurgitation
MZ dose age myocardiopathy duration test regurgitation MR
MZ dose age stroke
MZ use caused hypoxia presented hypoxia due obstruction airway
MZ use caused hypoxia presented hypoxia due obstruction
MZ doses MR MP
MZ doses MR
methyldopa related disease liver
methyldopa related disease
methyldopa taking another showed died presented failure hepatic
methyldopa taking another showed died presented failure
methyldopa episode recommenced developed hepatitis fulminant
methyldopa episode recommenced developed hepatitis
methyldopa hepatic
methyldopa dysfunction
streptomycin effects neurotoxic
lidocaine relieved spasm
sodium pentothal infused minimize ischaemia cerebral
sodium pentothal infused minimize ischaemia
pentothal infused minimize ischaemia cerebral
pentothal infused minimize ischaemia
lidocaine given counteract vasospasm
caffeine toxicity
acetaminophen Reduction toxicity
caffeine effects augment reported focused reduced toxicity
caffeine toxicity
acetaminophen presence reduced toxicity
acetaminophen increased interval administration onset convulsions
acetaminophen pretreatment pretreatment acetaminophen reduced incidence seizures
acetaminophen pretreatment pretreatment acetaminophen increased interval administration onset convulsions
acetaminophen reduced incidence seizures
acetaminophen reduced caffeine 5 seizures
acetaminophen modify seizures
Bupropion toxicity
Zyban Bupropion toxicity
diazepam treated treated tachycardia
adenosine treated tachycardia
adenosine treated treated seizures
diazepam treated seizures
Zyban caused overdose
Zyban caused neurological
Zyban caused neurological and
Zyban caused neurological toxicity cardiovascular
Zyban caused neurological toxicity
cimetidine was liver
cimetidine was liver or
cimetidine was liver disease kidney
cimetidine was liver disease
cimetidine levels had disease liver
cimetidine levels had disease liver or
cimetidine levels had disease kidney
cimetidine levels had disease
terbutaline treatment labor preterm
terbutaline treatment labor
terbutaline labor preterm
terbutaline labor
cisplatin study therapy cancers head
cisplatin study therapy cancers head and
cisplatin study therapy cancers head neck
cisplatin study therapy cancers
paclitaxel cisplatin study therapy cancers head
paclitaxel cisplatin study therapy cancers head and
paclitaxel cisplatin study therapy cancers head neck
paclitaxel cisplatin study therapy cancers
cisplatin combination used reported cancer head
cisplatin combination used reported cancer head and
cisplatin combination used reported cancer head neck
cisplatin combination used reported cancer
cisplatin combination used improved duration patients ovarian
cisplatin combination used improved duration patients cancer
paclitaxel reported used improved duration patients ovarian
paclitaxel reported used improved duration patients cancer
Taxol Bristol paclitaxel reported used improved duration patients ovarian
Taxol Bristol paclitaxel reported used improved duration patients cancer
paclitaxel combination used improved duration patients ovarian
paclitaxel combination used improved duration patients cancer
paclitaxel reported cancer head
paclitaxel reported cancer head and
paclitaxel reported cancer head neck
paclitaxel reported cancer
Taxol Bristol paclitaxel reported cancer head
Taxol Bristol paclitaxel reported cancer head and
Taxol Bristol paclitaxel reported cancer head neck
Taxol Bristol paclitaxel reported cancer
paclitaxel combination used reported cancer head
paclitaxel combination used reported cancer head and
paclitaxel combination used reported cancer head neck
paclitaxel combination used reported cancer
cisplatin escalating response determine trial initiated stimulating untreated head
cisplatin escalating response determine trial initiated stimulating untreated head and
cisplatin escalating response determine trial initiated stimulating untreated head carcinoma neck
cisplatin escalating response determine trial initiated stimulating untreated head carcinoma
cisplatin escalating response toxicity
paclitaxel doses escalating response toxicity
paclitaxel doses escalating response determine trial initiated stimulating untreated head
paclitaxel doses escalating response determine trial initiated stimulating untreated head and
paclitaxel doses escalating response determine trial initiated stimulating untreated head carcinoma neck
paclitaxel doses escalating response determine trial initiated stimulating untreated head carcinoma
paclitaxel doses escalating incorporate permitted permits toxicity
cisplatin first advanced head
cisplatin first advanced head and
cisplatin first advanced head neck
cisplatin first advanced cancer
Paclitaxel cisplatin first advanced head
Paclitaxel cisplatin first advanced head and
Paclitaxel cisplatin first advanced head neck
Paclitaxel cisplatin first advanced cancer
desferrioxamine receiving toxicity Ocular
desferrioxamine receiving toxicity Ocular and
desferrioxamine receiving toxicity Ocular auditory
desferrioxamine receiving toxicity
desferrioxamine receiving period monitored detection toxicity audiovisual
desferrioxamine receiving period monitored detection toxicity
dyschromatopsy
dyschromatopsy characterized pigmentary
dyschromatopsy characterized pigmentary deposits retinal
dyschromatopsy characterized pigmentary deposits
dyschromatopsy characterized origin toxicity Visual
dyschromatopsy characterized origin toxicity
dyschromatopsy characterized associated loss a
dyschromatopsy characterized associated loss
dyschromatopsy characterized associated loss acuity of
dyschromatopsy characterized associated loss acuity visual
dyschromatopsy characterized associated loss acuity
Desferrioxamine withdrawal resulted patient reversal loss hearing
Desferrioxamine withdrawal resulted patient reversal loss
aluminium
desferrioxamine doses receiving patients appeared coincided normalization levels ferritin aluminium
aluminium ferritin levels normalization coincided appeared toxicity
desferrioxamine doses receiving patients appeared toxicity
desferrioxamine receiving patients complication toxicity audiovisual
desferrioxamine receiving patients complication toxicity
Ginsenoside Rg restores impairment
Ginsenoside Rg restores impairment learning of
Ginsenoside Rg restores impairment learning
Rg restores impairment
Rg restores impairment learning of
Rg restores impairment learning
1 Rg restores impairment
1 Rg restores impairment learning of
1 Rg restores impairment learning
Rg ameliorate impairment learning
Rg ameliorate impairment
1 Rg ameliorate impairment learning
1 Rg ameliorate impairment
ginsenoside extracted Rg ameliorate impairment learning
ginsenoside extracted Rg ameliorate impairment
Rg effect investigate learning
Rg effect investigate learning impairment
1 Rg effect investigate learning
1 Rg effect investigate learning impairment
deferoxamine therapy receiving studies neurotoxicity auditory
deferoxamine therapy receiving studies neurotoxicity
iron therapy receiving anemia
deferoxamine documented Visual
deferoxamine documented Visual and
deferoxamine documented Visual auditory
deferoxamine documented neurotoxicity
deferoxamine anemia
iron therapy receiving anemia deferoxamine documented Visual
iron therapy receiving anemia deferoxamine documented Visual and
iron therapy receiving anemia deferoxamine documented Visual auditory
iron therapy receiving anemia deferoxamine documented neurotoxicity
deferoxamine doses receiving recommended mg kg degree abnormality auditory
deferoxamine doses receiving recommended mg kg degree abnormality
deferoxamine doses receiving recommended demonstrated toxicity
deferoxamine receiving receiving demonstrated deterioration provided convincing cause administration ototoxicity
deferoxamine relation cause administration ototoxicity
pyridoxine responsive convulsions
isoniazid mg infant day 17 kg admitted tuberculosis
pyridoxine hours ceased fits
pyridoxine deficiency aetiology suggesting ceased fits
zidovudine individuals use toxicity didanosine antibody HIV
zidovudine individuals use toxicity didanosine antibody
zidovudine individuals positive
AZT zidovudine individuals use toxicity didanosine antibody HIV
AZT zidovudine individuals use toxicity didanosine antibody
AZT zidovudine individuals positive
didanosine toxicity
ddI didanosine toxicity
zidovudine individuals use toxicity
AZT zidovudine individuals use toxicity
didanosine antibody HIV
didanosine antibody
didanosine toxicity use individuals positive
ddI didanosine antibody HIV
ddI didanosine antibody
ddI didanosine toxicity use individuals positive
didanosine normal returned mild developed characteristic diabetes
p shown factor digluconate associated cystitis
choloroaniline factor digluconate associated cystitis
Picloxydine irrigations appeared have incidence cystitis
doxorubicin model damage diagnosis investigated examined development disorders cardiac
doxorubicin model damage diagnosis investigated examined development disorders
DOX doxorubicin model damage diagnosis investigated examined development disorders cardiac
DOX doxorubicin model damage diagnosis investigated examined development disorders
DOX rats Eighteen died toxicity
DOX given rats hearts evaluation revealed degrees fibrosis
DOX injury ischemic
DOX injury
DOX was is induced cardiotoxicity
DOX indicates rats cTnT induced cardiotoxicity
docetaxel cancer prostate
docetaxel cancer
thalidomide docetaxel cancer prostate
thalidomide docetaxel cancer
docetaxel treated cancer prostate
docetaxel treated cancer
thalidomide treated cancer prostate
thalidomide treated cancer
docetaxel treatment cancer prostate
docetaxel treatment cancer
thalidomide addition docetaxel treatment cancer prostate
thalidomide addition docetaxel treatment cancer
cocaine abusers hospitalized evidence injury myocardial
cocaine abusers hospitalized evidence injury
cocaine electrocardiograms compared ECGs controls schizophrenic
cocaine abusers Eleven had evidence injury defined infarction ischemia
cocaine abusers Eleven had evidence injury myocardial
cocaine abusers Eleven had evidence injury
telithromycin mg PO treat infection upper
telithromycin mg PO treat infection respiratory
telithromycin mg PO treat infection tract
telithromycin mg PO treat infection
telithromycin cause score 8 scale adverse
telithromycin cause score 8 scale drug
telithromycin cause score 8 scale reaction
tacrolimus mapping imaging neurotoxicity
tacrolimus developed complications neurologic
tacrolimus developed complications
tacrolimus lesions outcomes predicting useful Diffusion induced neurotoxicity
dexamethasone given rats had glomeruli glomerulosclerosis
dexamethasone shows results reduction number glomerulosclerosis
methamphetamine Attenuation neurotoxicity
lipopolysaccharide pretreatment mice neurotoxicity
methamphetamine induced damage dopaminergic
methamphetamine induced damage terminal
methamphetamine induced damage
dopamine induced modulating neurotoxicity
methamphetamine modulating neurotoxicity
lipopolysaccharide roles neurotoxicity
Lipopolysaccharide pretreatment affect temperature hyperthermia
dopamine neurotoxicity
methamphetamine exerting concluded dopamine neurotoxicity
lipopolysaccharide pretreatment concluded dopamine neurotoxicity
dyazide therapy complicating nephrolithiasis
hydrochlorothiazide years reported case nephrolithiasis
triamterene therapy years reported case nephrolithiasis
triamterene nephrolithiasis case reported years therapy hypertension
hydrochlorothiazide years therapy hypertension
triamterene therapy hypertension
Curcumin ameliorates dysfunction cognitive
Curcumin ameliorates dysfunction
curcumin administration effect investigate impairment cognitive
curcumin administration effect investigate impairment
curcumin administration prevented impairment cognitive
curcumin administration prevented impairment
curcumin has effect mitigating deterioration
curcumin has effect mitigating deterioration functions of
curcumin has effect mitigating deterioration functions cognitive
curcumin has effect mitigating deterioration functions
curcumin considered phenobarbitone preventing impairment cognitive
curcumin considered phenobarbitone preventing impairment
CsA treated group worst showed analysis grade fibrosis
SRL CsA treated group worst showed analysis grade fibrosis
FK 506 showed degree fibrosis
506 showed degree fibrosis
SRL combination 506 showed degree fibrosis
ritodrine labor preterm
ritodrine labor
ritodrine effects interactions risk patients receiving ritodrine labor preterm
ritodrine effects interactions risk patients receiving ritodrine labor
ritodrine infusion cessation result complications cardiovascular
ritodrine infusion cessation result complications
phenylephrine treat tachycardia
phenylephrine treat patients hypotensive
Ro 4368554 restores models deficiency memory
Ro 4368554 restores models deficiency
4368554 restores models deficiency memory
4368554 restores models deficiency
metrifonate i kg reversed induced deficits memory
metrifonate i kg reversed induced deficits
TRP scopolamine depletion induced deficits memory
TRP scopolamine depletion induced deficits
Ro reversed induced deficits memory
Ro reversed induced deficits
4368554 Ro reversed induced deficits memory
4368554 Ro reversed induced deficits
Ro 4368554 improve reversed cholinergic deficit memory
Ro 4368554 improve reversed cholinergic deficit
4368554 improve reversed cholinergic deficit memory
4368554 improve reversed cholinergic deficit
Ro memory facilitation involved suggesting reversed cholinergic deficit memory
Ro memory facilitation involved suggesting reversed cholinergic deficit
4368554 Ro memory facilitation involved suggesting reversed cholinergic deficit memory
4368554 Ro memory facilitation involved suggesting reversed cholinergic deficit
5 involved suggesting reversed cholinergic deficit memory
5 involved suggesting reversed cholinergic deficit
HT 5 involved suggesting reversed cholinergic deficit memory
HT 5 involved suggesting reversed cholinergic deficit
Estradiol reduces seizure
Estradiol reduces seizure induced injury hippocampal
Estradiol reduces seizure induced injury
kainic acid induced injury hippocampal
kainic acid induced injury
acid induced injury hippocampal
acid induced injury
kainic acid induced injury epilepticus status
kainic acid induced injury epilepticus
acid induced injury epilepticus status
acid induced injury epilepticus
kainic acid induced injury epilepticus SE
acid induced injury epilepticus SE
17 beta effects pilocarpine SE
beta effects pilocarpine SE
estradiol effects pilocarpine SE
17 beta alter extent CA evaluated SE
beta alter extent CA evaluated SE
Estradiol alter extent CA evaluated SE
silver extent CA evaluated SE
estradiol threshold seizure
ciprofloxacin suspect infection urinary
ciprofloxacin suspect infection tract
ciprofloxacin suspect infection
dopamine formation dopa Mediation bradycardia
L bradycardia
dopa Mediation bradycardia
DL dopa Threo enhanced bradycardia
Threo enhanced bradycardia
dihydroxyphenylserine had enhanced bradycardia
L Threo enhanced bradycardia
dopa Threo enhanced bradycardia
dopamine 63 beta have effect hypotension
dopamine 63 beta have effect hypotension bradycardia
L effect dopa hypotension
dopa hypotension
FLA beta have effect hypotension bradycardia
63 beta have effect hypotension bradycardia
L effect dopa hypotension bradycardia
dopa hypotension bradycardia
FLA beta have effect hypotension
63 beta have effect hypotension
L restored bradycardia
dopa L restored bradycardia
5 decreased decreased bradycardia
HTP decreased decreased bradycardia
L stimulation enhances bradycardia
dopa enhances bradycardia
isoflurane anaesthesia fusion postero underwent patients using measured evaluate effect E trimethaphan induced hypotension
tobramycin nephrotoxicity
gentamicin tobramycin nephrotoxicity
tobramycin sulfate sulfate continue demonstrate ototoxicity nephrotoxicity
sulfate sulfate continue demonstrate ototoxicity nephrotoxicity
Gentamicin sulfate continue demonstrate ototoxicity
sulfate continue demonstrate ototoxicity
tobramycin sulfate sulfate continue demonstrate ototoxicity
sulfate sulfate continue demonstrate ototoxicity
Gentamicin sulfate continue demonstrate ototoxicity nephrotoxicity
sulfate continue demonstrate ototoxicity nephrotoxicity
aminoglycoside development followed failure renal
aminoglycoside development followed failure
gamma effects induced seizures
hexachlorocyclohexane effects induced seizures
lindane hexachlorocyclohexane effects induced seizures
Gamma shown decrease threshold seizure
hexachlorocyclohexane shown decrease threshold seizure
Gamma shown decrease pentylenetrazol h seizures
hexachlorocyclohexane shown decrease pentylenetrazol h seizures
gamma hexachlorocyclohexane shown decrease threshold seizure
HCH gamma hexachlorocyclohexane shown decrease threshold seizure
gamma hexachlorocyclohexane shown decrease pentylenetrazol h seizures
HCH gamma hexachlorocyclohexane shown decrease pentylenetrazol h seizures
lindane ingredient hexachlorocyclohexane shown decrease threshold seizure
lindane ingredient hexachlorocyclohexane shown decrease pentylenetrazol h seizures
gamma exposure h pentylenetrazol decrease threshold seizure
HCH threshold h pentylenetrazol decrease threshold seizure
gamma exposure h seizures
HCH threshold h seizures
gamma exposure h seizures h pentylenetrazol decrease threshold seizure
HCH h pentylenetrazol decrease threshold seizure
gamma exposure h seizures
HCH h seizures
gamma kg severity response seizure
HCH gamma kg severity response seizure
gamma administration activity seizure
HCH administration activity seizure
gamma h observed increased hour inducing administration activity seizure
HCH gamma h observed increased hour inducing administration activity seizure
gamma PTX occur activity seizure
HCH decreased suggest occur activity seizure
gamma PTX occur suggest decreased HCH response seizure
HCH response seizure
gamma linked h site responsible decrease activity seizure
HCH GABA gamma linked h site responsible decrease activity seizure
GABA gamma linked h site responsible decrease activity seizure
Alpha prevents damage mitochondrial
Alpha prevents damage
lipoic acid prevents damage mitochondrial
lipoic acid prevents damage
acid prevents damage mitochondrial
acid prevents damage
Alpha prevents damage neurotoxicity
lipoic acid prevents damage neurotoxicity
acid prevents damage neurotoxicity
Alpha prevents neuropathy
lipoic acid prevents neuropathy
acid prevents neuropathy
alpha neuroprotective chemotherapy induced plays damage mitochondrial
alpha neuroprotective chemotherapy induced plays damage
lipoic acid neuroprotective chemotherapy induced plays damage mitochondrial
lipoic acid neuroprotective chemotherapy induced plays damage
acid neuroprotective chemotherapy induced plays damage mitochondrial
acid neuroprotective chemotherapy induced plays damage
alpha effects neuroprotective plays damage mitochondrial
alpha effects neuroprotective plays damage
lipoic acid alpha neuroprotective chemotherapy induced plays damage mitochondrial
lipoic acid alpha neuroprotective chemotherapy induced plays damage
acid alpha neuroprotective chemotherapy induced plays damage mitochondrial
acid alpha neuroprotective chemotherapy induced plays damage
alpha neuroprotective chemotherapy induced neurotoxicity
lipoic acid neuroprotective chemotherapy induced neurotoxicity
acid neuroprotective chemotherapy induced neurotoxicity
alpha effects neuroprotective plays induced neurotoxicity
lipoic acid alpha neuroprotective chemotherapy induced neurotoxicity
acid alpha neuroprotective chemotherapy induced neurotoxicity
alpha neuroprotective chemotherapy induced plays role cascade toxic
alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
alpha neuroprotective chemotherapy induced plays role cascade
lipoic acid neuroprotective chemotherapy induced plays role cascade toxic
lipoic acid neuroprotective chemotherapy induced plays role cascade neurodegenerative
lipoic acid neuroprotective chemotherapy induced plays role cascade
acid neuroprotective chemotherapy induced plays role cascade toxic
acid neuroprotective chemotherapy induced plays role cascade neurodegenerative
acid neuroprotective chemotherapy induced plays role cascade
alpha effects neuroprotective plays role cascade toxic
alpha effects neuroprotective plays role cascade neurodegenerative
alpha effects neuroprotective plays role cascade
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade toxic
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade
acid alpha neuroprotective chemotherapy induced plays role cascade toxic
acid alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
acid alpha neuroprotective chemotherapy induced plays role cascade
alpha acid preventing damage axonal
alpha acid preventing damage
lipoic acid preventing damage axonal
lipoic acid preventing damage
acid preventing damage axonal
acid preventing damage
alpha preventing damage axonal
alpha preventing damage
lipoic acid alpha acid preventing damage axonal
lipoic acid alpha acid preventing damage
acid alpha acid preventing damage axonal
acid alpha acid preventing damage
paclitaxel cisplatin cause impairment mitochondrial
paclitaxel cisplatin cause impairment
cisplatin cause impairment mitochondrial
cisplatin cause impairment
Alpha exerts rescues toxicity mitochondrial
Alpha exerts rescues toxicity
lipoic acid exerts rescues toxicity mitochondrial
lipoic acid exerts rescues toxicity
acid exerts rescues toxicity mitochondrial
acid exerts rescues toxicity
Alpha exerts chemotherapy induced neurotoxicity
lipoic acid exerts chemotherapy induced neurotoxicity
acid exerts chemotherapy induced neurotoxicity
paclitaxel event toxicity mitochondrial
paclitaxel event toxicity
paclitaxel induced neurotoxicity
cisplatin paclitaxel induced neurotoxicity
cisplatin paclitaxel event toxicity mitochondrial
cisplatin paclitaxel event toxicity
alpha suggest reduce risk developing toxicity peripheral
alpha suggest reduce risk developing toxicity nerve
alpha suggest reduce risk developing toxicity
lipoic acid reduce risk developing toxicity peripheral
lipoic acid reduce risk developing toxicity nerve
lipoic acid reduce risk developing toxicity
acid reduce risk developing toxicity peripheral
acid reduce risk developing toxicity nerve
acid reduce risk developing toxicity
prostaglandin E effects hypotension haemodilution
E effects hypotension haemodilution
1 E effects hypotension haemodilution
prostaglandin E hypotension haemodilution
E hypotension haemodilution
1 E hypotension haemodilution
PGE 1 E hypotension haemodilution
1 PGE 1 E hypotension haemodilution
dextran solution amount replacing withdrawing produced Haemodilution
bilirubin SGOT showed showed decrease decrease min start hypotension
PGE min hypotension haemodilution
1 PGE min hypotension haemodilution
Simvastatin induced syndrome myonecrosis
Simvastatin induced syndrome myonecrosis associated hypothyroidism
simvastatin thyroxine presented syndrome myonecrosis
simvastatin thyroxine taking male hypothyroid
thyroxine taking male hypothyroid
thyroxine presented syndrome myonecrosis
thyroxine presented syndrome compartment
thyroxine presented syndrome
fucoidan treatment Effect hemorrhage intracerebral
fucoidan treatment Effect hemorrhage
fucoidan reported reduce damage brain
fucoidan reported reduce damage
fucoidan reported model hemorrhage intracerebral
fucoidan reported model hemorrhage
Fucoidan treated exhibited tended have inflammation
Fucoidan treated exhibited had hematomas
Fucoidan treated exhibited tended have inflammation vicinity hematoma
oxygen species implicated induced antioxidants reducing proteinuria
oxygen species implicated induced nephropathy
haloperidol behaviors disease Alzheimer
haloperidol behaviors disease Alzheimer '
haloperidol behaviors disease s
haloperidol behaviors disease
haloperidol behaviors psychosis disruptive
haloperidol behaviors
haloperidol behaviors psychosis
haloperidol doses effects compare patients disease Alzheimer
haloperidol doses effects compare patients disease Alzheimer '
haloperidol doses effects compare patients disease s
haloperidol doses effects compare patients disease
haloperidol doses effects compare treatment behaviors psychosis disruptive
haloperidol doses effects compare treatment behaviors
haloperidol doses effects compare treatment behaviors psychosis
haloperidol 2 trial 6 / compared outpatients disease Alzheimer
haloperidol 2 trial 6 / compared outpatients disease Alzheimer '
haloperidol 2 trial 6 / compared outpatients disease s
haloperidol 2 trial 6 / compared outpatients disease
haloperidol 6 / compared outpatients disease Alzheimer
haloperidol 6 / compared outpatients disease Alzheimer '
haloperidol 6 / compared outpatients disease s
haloperidol 6 / compared outpatients disease
haloperidol efficacious efficacious agitation psychomotor
haloperidol efficacious efficacious agitation
haloperidol low factor efficacious efficacious agitation psychomotor
haloperidol low factor efficacious efficacious agitation
haloperidol efficacious factor psychosis
haloperidol low factor psychosis
haloperidol observed window apply neuroleptics used patients Alzheimer
haloperidol observed window apply neuroleptics used patients Alzheimer '
haloperidol observed window apply neuroleptics used patients s
haloperidol observed window apply neuroleptics used patients disease
haloperidol observed window apply neuroleptics used behaviors psychosis disruptive
haloperidol observed window apply neuroleptics used behaviors
haloperidol observed window apply neuroleptics used behaviors psychosis
PG test passive prevented amnesia
9 prevented amnesia
PG induced amnesia
9 able PG induced amnesia
Selegiline hypotension disease Parkinson
Selegiline hypotension disease Parkinson '
Selegiline hypotension disease s
Selegiline hypotension disease
L day selegiline receive randomized patients mortality found trial Parkinson
L day selegiline receive randomized patients mortality found trial Parkinson '
L day selegiline receive randomized patients mortality found trial s
L day selegiline receive randomized patients mortality found trial Disease
dopa OBJECTIVES trial Parkinson
dopa OBJECTIVES trial Parkinson '
dopa OBJECTIVES trial s
dopa OBJECTIVES trial Disease
L day selegiline receive randomized patients disease Parkinson
L day selegiline receive randomized patients disease Parkinson '
L day selegiline receive randomized patients disease s
L day selegiline receive randomized patients disease
dopa OBJECTIVES trial found mortality patients disease Parkinson
dopa OBJECTIVES trial found mortality patients disease Parkinson '
dopa OBJECTIVES trial found mortality patients disease s
dopa OBJECTIVES trial found mortality patients disease
L day selegiline receive randomized patients disease PD
dopa OBJECTIVES trial found mortality patients disease PD
L taking those dopa OBJECTIVES trial Parkinson
L taking those dopa OBJECTIVES trial Parkinson '
L taking those dopa OBJECTIVES trial s
L taking those dopa OBJECTIVES trial Disease
dopa L taking those dopa OBJECTIVES trial Parkinson
dopa L taking those dopa OBJECTIVES trial Parkinson '
dopa L taking those dopa OBJECTIVES trial s
dopa L taking those dopa OBJECTIVES trial Disease
L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson
L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson '
L taking those dopa OBJECTIVES trial found mortality patients disease s
L taking those dopa OBJECTIVES trial found mortality patients disease
dopa L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson
dopa L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson '
dopa L taking those dopa OBJECTIVES trial found mortality patients disease s
dopa L taking those dopa OBJECTIVES trial found mortality patients disease
L taking those dopa OBJECTIVES trial found mortality patients disease PD
dopa L taking those dopa OBJECTIVES trial found mortality patients disease PD
selegiline receive randomized patients mortality found trial Parkinson
selegiline receive randomized patients mortality found trial Parkinson '
selegiline receive randomized patients mortality found trial s
selegiline receive randomized patients mortality found trial Disease
selegiline receive randomized patients disease Parkinson
selegiline receive randomized patients disease Parkinson '
selegiline receive randomized patients disease s
selegiline receive randomized patients disease
selegiline receive randomized patients disease PD
L selegiline therapy associated hypotension systolic
L selegiline therapy associated hypotension orthostatic
L selegiline therapy associated hypotension
dopa associated hypotension systolic
dopa associated hypotension orthostatic
dopa associated hypotension
selegiline receiving patients PD
selegiline marked six patients PD
L selegiline finding confirms associated hypotension orthostatic
L selegiline finding confirms associated hypotension
dopa associated hypotension orthostatic
dopa associated hypotension
mexiletine I Report findings arrhythmia
mexiletine form effects evaluated infarction myocardial
mexiletine form effects evaluated infarction
Mexitil effects evaluated infarction myocardial
Mexitil effects evaluated infarction
Perlongets Mexitil effects evaluated infarction myocardial
Perlongets Mexitil effects evaluated infarction
mexiletine group deaths
E terfenadine compounds known increase cause investigated TDP
4031 terfenadine compounds known increase cause investigated TDP
cefazedone cefonicid effects model hematotoxicity
cefonicid effects model hematotoxicity
cephalosporin hematotoxicity
Cephalosporin antibiotics cause variety disturbances hematologic
Cephalosporin antibiotics cause variety disturbances
cefazedone beagle cefonicid dogs administration caused studies toxicity
cefonicid dogs administration caused studies toxicity
cefazedone kg mg receiving dogs % occurred compromising cytopenias
cefonicid mg receiving dogs % occurred compromising cytopenias
cefazedone cefonicid tested dogs reproduced syndrome hematologic
cefazedone cefonicid tested dogs reproduced syndrome
cefonicid tested dogs reproduced syndrome hematologic
cefonicid tested dogs reproduced syndrome
cephalosporin rechallenge reproduced syndrome hematologic
cephalosporin rechallenge reproduced syndrome
cefazedone cefonicid doses administration induce similar hematotoxicity
cefazedone cefonicid doses administration induce conclude described dyscrasias blood
cefazedone cefonicid doses administration induce conclude described dyscrasias
cefonicid doses administration induce similar hematotoxicity
cefonicid doses administration induce conclude described dyscrasias blood
cefonicid doses administration induce conclude described dyscrasias
cephalosporin similar hematotoxicity
cephalosporin similar induce conclude described dyscrasias blood
cephalosporin similar induce conclude described dyscrasias
tincture effect infarction myocardial
tincture effect infarction
of Crataegus tincture effect infarction myocardial
of Crataegus tincture effect infarction
Crataegus tincture effect infarction myocardial
Crataegus tincture effect infarction
TCR effect investigate induced infarction myocardial
TCR effect investigate induced infarction
ethinyl treatment cholestasis extrahepatic
ethinyl treatment cholestasis
estradiol treatment cholestasis extrahepatic
estradiol treatment cholestasis
EE treatment cholestasis extrahepatic
EE treatment cholestasis
pyridoxine disorder behavioral
pyridoxine disorder
isoniazid administration difficulties hyperkinesis irritability
isoniazid administration difficulties sleeping
isoniazid administration difficulties
pyridoxine withdrawal associated return hyperkinesis
halogenated hydroxyquinolines Neurotoxicity
hydroxyquinolines Neurotoxicity
halogenated hydroxyquinolines presented cases reactions neurotoxic
hydroxyquinolines presented cases reactions neurotoxic
clioquinol dose ingestion related encephalopathy consisted disturbance neurological
clioquinol dose ingestion related encephalopathy consisted disturbance
clioquinol received enteropathica acrodermatitis
clioquinol received enteropathica
levodopa stimulation dyskinesias disease Parkinson
levodopa stimulation dyskinesias disease Parkinson '
levodopa stimulation dyskinesias disease s
levodopa stimulation dyskinesias disease
ursodeoxycholic acid response Composition stones gall
ursodeoxycholic acid response Composition stones bladder
ursodeoxycholic acid response Composition stones
acid response Composition stones gall
acid response Composition stones bladder
acid response Composition stones
Octreotide treatment acromegaly
octreotide treated patients acromegalic
cholesterol contained showed analysis stones gall
cholesterol contained showed analysis stones
cholesterol rich suggesting partial dissolution gall
cholesterol rich suggesting partial dissolution stone
cholesterol rich small stones gall
cholesterol rich small stones
cholesterol rich small have common disease gall
cholesterol rich small have common disease stone
cholesterol rich small have common disease
cholesterol rich small have duct stones gall
cholesterol rich small have duct stones
calcium containing stones duct have small stones gall
calcium containing stones duct have small stones
calcium containing stones duct have common disease gall
calcium containing stones duct have common disease stone
calcium containing stones duct have common disease
calcium containing stones gall
calcium containing stones
metoclopramide took disorder gastrointestinal
metoclopramide took disorder
Cocaine induced disorder rates symptoms psychiatric
cocaine induced disorder rates symptoms psychiatric
cocaine induced disorder CIMD
cocaine outpatients cocaine induced disorder CIMD
cocaine compared measures symptoms psychiatric
cocaine outpatients cocaine compared measures symptoms psychiatric
Caffeine induced arrhythmia cardiac
Caffeine induced arrhythmia
caffeine concentration containing consuming developed describe 25 prolapse mitral
caffeine concentration containing consuming developed describe 25 prolapse valve
caffeine concentration containing consuming developed describe 25 prolapse
acetylcholine subunits alpha necessary induced seizures
nicotine necessary induced hypolocomotion
acetylcholine subunits alpha necessary induced hypolocomotion
acetylcholine receptors Binding series behaviors go seizures
acetylcholine receptors Binding series behaviors go exploration tremors
nicotine Binding series behaviors go seizures death
acetylcholine receptors Binding series behaviors go seizures death
nicotine Binding series behaviors go exploration tremors
nicotine examined homozygous seizures hypolocomotion
nicotine mediators induced hypolocomotion
dopamine explored success risk defects visual
dopamine explored success risk defects field
dopamine explored success risk defects
dopamine explored success risk defects VFD
DA dopamine explored success risk defects visual
DA dopamine explored success risk defects field
DA dopamine explored success risk defects
DA dopamine explored success risk defects VFD
dopamine explored success treating abuse substance
dopamine explored success treating abuse
DA dopamine explored success treating abuse substance
DA dopamine explored success treating abuse
GVG effects dopamine explored success treating abuse substance
GVG effects dopamine explored success treating abuse
cocaine GVG effects dopamine explored success treating abuse substance
cocaine GVG effects dopamine explored success treating abuse
cocaine GVG effects dopamine explored success risk defects visual
cocaine GVG effects dopamine explored success risk defects field
cocaine GVG effects dopamine explored success risk defects
cocaine GVG effects dopamine explored success risk defects VFD
calcium blockers exposed fetuses alterations Cardiovascular
calcium blockers exposed fetuses alterations
calcium blocker induced alterations cardiovascular
calcium blocker induced alterations
calcium blockers induce malformations cardiovascular
calcium blockers induce malformations
calcium blockers one administered examined malformations cardiovascular
calcium blockers one administered examined malformations
calcium blockers each observed incidence malformations cardiovascular
calcium blockers each observed incidence malformations
procainamide administered treatment contractions flutter atrial
procainamide administered treatment contractions flutter
procainamide administered treatment contractions premature
procainamide administered treatment contractions ventricular
procainamide administered treatment contractions
procainamide produce Q prolonged
procainamide produce Q
procainamide produce Q syndrome T
procainamide produce Q syndrome
steroid injection syndrome Cauda
steroid injection syndrome equina
steroid injection syndrome
steroid injections therapy methods radiculopathy
triamcinolone injection caused syndrome cauda
triamcinolone injection caused syndrome equina
triamcinolone injection caused syndrome
steroid injection scheduled woman back low
steroid injection scheduled woman back
steroid injection scheduled woman back and
steroid injection scheduled woman back pain right
steroid injection scheduled woman back pain leg
steroid injection scheduled woman back pain
steroid injections vigilance deterioration neurologic
steroid injections vigilance deterioration
dopamine produce induce hypothermia
dopamine agonist Apomorphine selected effects ability induce hypothermia
agonist Apomorphine selected effects ability induce hypothermia
haloperidol efficacy studies model disease Parkinson
haloperidol efficacy studies model disease Parkinson '
haloperidol efficacy studies model disease s
haloperidol efficacy studies model disease
risperidone reduction syndrome Withdrawal
risperidone reduction syndrome emergent
risperidone reduction syndrome rabbit
risperidone reduction syndrome
dopamine antagonist serotonin mechanism withdrawal
dopamine antagonist serotonin mechanism related RS emergent
dopamine antagonist serotonin mechanism related RS
dopamine antagonist serotonin mechanism development RS
risperidone profile related mechanism withdrawal
risperidone profile related RS emergent
risperidone profile related RS
serotonin mechanism withdrawal
serotonin mechanism related RS emergent
serotonin mechanism related RS
serotonin system influence suggesting mechanism withdrawal
serotonin system influence suggesting mechanism related RS emergent
serotonin system influence suggesting mechanism related RS
serotonin mechanism development RS
serotonin system influence suggesting mechanism development RS
cocaine intoxications abnormalities movement
cocaine intoxications abnormalities
cocaine intoxications abnormalities known hyperkinesias Choreatiform
cocaine intoxications abnormalities known hyperkinesias
heroine abusing methadone report movements euphoria choreoathetoid
heroine abusing methadone report movements
cocaine life short occur some seizures strokes
cocaine characterized resulted death
cocaine characterized prolonged resulted death
BE induced those prolonged characterized resulted death
BE induced those prolonged resulted death
mazindol dystrophy Duchenne
mazindol dystrophy
mazindol trial controlled boys dystrophy Duchenne
mazindol trial controlled boys dystrophy
Mazindol doses slow progression weakness
Mazindol doses slow dystrophy Duchenne
Mazindol doses slow dystrophy
NRA hyperactivity
0160 NRA hyperactivity
clozapine hyperactivity
amiloride syndrome Attenuation diabetes
amiloride syndrome Attenuation diabetes insipidus
amiloride syndrome like
amiloride syndrome
lithium effect polydipsia polyuria
lithium concentration polydipsia polyuria
lithium effect polydipsia
lithium concentration polydipsia
LiCl treated chronically rats investigated effect polydipsia polyuria
LiCl treated chronically rats investigated effect polydipsia
amiloride effect polydipsia polyuria
amiloride effect polydipsia
amiloride attenuation diabetes
amiloride attenuation insipidus
amiloride attenuation syndrome like
amiloride attenuation syndrome
potassium level elevation ratio reduction accompanied attenuation diabetes
potassium level elevation ratio reduction accompanied attenuation insipidus
potassium level elevation ratio reduction accompanied attenuation syndrome like
potassium level elevation ratio reduction accompanied attenuation syndrome
lithium concluded relieve patients suffering polydipsia polyuria
lithium levels result relieve patients suffering polydipsia polyuria
lithium concluded relieve patients suffering polydipsia
lithium levels result relieve patients suffering polydipsia
amiloride administration concluded relieve patients suffering polydipsia polyuria
amiloride supplementation result relieve patients suffering polydipsia polyuria
amiloride administration concluded relieve patients suffering polydipsia
amiloride supplementation result relieve patients suffering polydipsia
epinephrine treatment priapism
N effects seizure
2 urea effects seizure
propylpentanoyl 2 urea effects seizure
urea effects seizure
amino neurotransmitters urea effects seizure
acid neurotransmitters urea effects seizure
VPU exhibiting kg protecting rats seizure
VPA exhibiting kg protecting rats seizure
VPA value mg seizure
glutamate reduction offset suggested finding seizure
VPU protect finding seizure
aspartate glutamate reduction offset suggested finding seizure
VPA VPU protect finding seizure
amino neurotransmitters reduction minor suggested finding seizure
acid neurotransmitters reduction minor suggested finding seizure
glutamate increases account induced finding induced seizure
VPU reduce finding induced seizure
aspartate glutamate increases account induced finding induced seizure
VPA induced seizure
antidepressant use syndrome Rabbit
antidepressant use syndrome
desipramine toxicity
desipramine toxicity
quinine available banned cramps nocturnal
quinine available banned cramps leg
quinine available banned cramps
quinine containing products produce complications neurological
quinine containing products produce complications
cortisol humans transport L induced hypertension
L induced hypertension
arginine transport L induced hypertension
cortisol implicated arginine induced hypertension
L arginine induced hypertension
arginine induced hypertension
nitric system implicated arginine induced hypertension
oxide system implicated arginine induced hypertension
cortisol conclude associated increases
cortisol conclude associated increases pressure in
cortisol conclude associated increases pressure blood
cortisol conclude associated increases pressure
l abnormalities associated increases
l abnormalities associated increases pressure in
l abnormalities associated increases pressure blood
l abnormalities associated increases pressure
arginine system l abnormalities associated increases
arginine system l abnormalities associated increases pressure in
arginine system l abnormalities associated increases pressure blood
arginine system l abnormalities associated increases pressure
thienodiazepine derivative clotiazepam administration onset developed hepatitis
thienodiazepine derivative clotiazepam administration onset developed necrosis extensive
thienodiazepine derivative clotiazepam administration onset developed necrosis hepatocellular
thienodiazepine derivative clotiazepam administration onset developed necrosis
clotiazepam administration onset developed necrosis extensive
clotiazepam administration onset developed necrosis hepatocellular
clotiazepam administration onset developed necrosis
benzodiazepines administration interfere induce relapse hepatitis
benzodiazepines hepatotoxicity is suggests shows induce hepatitis
benzodiazepines hepatotoxicity
Statins cause myopathy hyperCKaemia
Warfarin induced hemorrhage
warfarin therapy man 28 case sustained developed pain
warfarin therapy man 28 case sustained developed pain contracture
warfarin form represents induced Anticoagulant induced characterized pain
warfarin form represents induced Anticoagulant induced characterized region degrees contracture
warfarin form represents induced Anticoagulant induced neuropathy peripheral
warfarin form represents induced Anticoagulant induced neuropathy
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor and
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor sensory
warfarin form represents induced Anticoagulant induced characterized region degrees impairment
diethylstilbestrol associated Angiosarcoma
diethylstilbestrol associated Angiosarcoma liver of
diethylstilbestrol associated Angiosarcoma liver the
diethylstilbestrol associated Angiosarcoma liver
diethylstilbestrol differentiated adenocarcinoma
diethylstilbestrol differentiated adenocarcinoma liver of
diethylstilbestrol differentiated adenocarcinoma liver the
diethylstilbestrol differentiated adenocarcinoma liver
diethylstilbestrol differentiated occurred Angiosarcoma
diethylstilbestrol differentiated occurred Angiosarcoma liver of
diethylstilbestrol differentiated occurred Angiosarcoma liver the
diethylstilbestrol differentiated occurred Angiosarcoma liver
glutamate uptake dyskinesia orofacial
glutamate uptake dyskinesia
glutamate uptake decrease correlates increase incidence diskinesia orofacial
glutamate uptake decrease correlates increase incidence diskinesia
warfarin contributed haemorrhage
warfarin contributed considered complication bleeding
warfarin patients 24 haemorrhage
warfarin patients 24 haemorrhage contributed considered complication bleeding
morphine therapy patients cancer
ketamine patients cancer
morphine responsive Pain
N aspartate effective improving analgesia pain neuropathic
N aspartate effective improving analgesia pain
methyl N aspartate effective improving analgesia pain neuropathic
methyl N aspartate effective improving analgesia pain
D methyl N aspartate effective improving analgesia pain neuropathic
D methyl N aspartate effective improving analgesia pain
aspartate effective improving analgesia pain neuropathic
aspartate effective improving analgesia pain
NMDA antagonists effective improving analgesia pain neuropathic
NMDA antagonists effective improving analgesia pain
ketamine antagonists effective improving analgesia syndromes pain
ketamine antagonists effective improving analgesia pain neuropathic
ketamine antagonists effective improving analgesia pain
N aspartate effective improving analgesia syndromes pain
methyl N aspartate effective improving analgesia syndromes pain
D methyl N aspartate effective improving analgesia syndromes pain
aspartate effective improving analgesia syndromes pain
NMDA antagonists effective improving analgesia syndromes pain
ketamine doses bolus given patients unrelieved pain
morphine study unrelieved patients cancer
morphine study unrelieved pain
ketamine doses bolus given patients cancer
Ketamine reduced intensity pain
morphine analgesia pain neuropathic
morphine analgesia pain
Ketamine improve analgesia syndromes pain
Ketamine improve analgesia pain neuropathic
Ketamine improve analgesia pain
morphine analgesia syndromes pain
tacrolimus cyclosporine toxicity
cyclosporine toxicity
amiodarone administration tachycardia supraventricular
amiodarone administration tachycardia
amiodarone administration Wolff
amiodarone administration Parkinson
amiodarone administration syndrome White
amiodarone administration syndrome
amiodarone administration boy cardiomyopathy primary
amiodarone administration boy cardiomyopathy
amiodarone dosage Reduction resulted disappearance persistence bradycardia sinus
amiodarone dosage Reduction resulted disappearance persistence bradycardia
GR accumbens shell induced hyperactivity locomotor
GR accumbens shell induced hyperactivity
55562 GR accumbens shell induced hyperactivity locomotor
55562 GR accumbens shell induced hyperactivity
GR antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
55562 GR antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
ampicillin treated septicemia
gentamicin ampicillin treated septicemia
penicillins allergy
penicillins allergy manifestation myocarditis Hypersensitivity
penicillins allergy manifestation myocarditis
Tamoxifen drug prescribed chemotherapy cancer breast
Tamoxifen drug prescribed chemotherapy cancer
TAM Tamoxifen drug prescribed chemotherapy cancer breast
TAM Tamoxifen drug prescribed chemotherapy cancer
alpha concentrations prevented effect hemolytic
tocopherol acetate indicating prevented effect hemolytic
alpha concentrations prevented indicating related TAM hemolysis
tocopherol acetate indicating related TAM hemolysis
alpha tocopherol acetate indicating prevented effect hemolytic
T alpha tocopherol acetate indicating prevented effect hemolytic
alpha tocopherol acetate indicating related TAM hemolysis
T alpha tocopherol acetate indicating related TAM hemolysis
alpha tocopherol acetate indicating prevented effect hemolytic
tocopherol acetate indicating prevented effect hemolytic
acetate indicating prevented effect hemolytic
alpha tocopherol acetate indicating related TAM hemolysis
tocopherol acetate indicating related TAM hemolysis
acetate indicating related TAM hemolysis
alpha acetate indicating prevented effect hemolytic
TAc alpha acetate indicating prevented effect hemolytic
alpha acetate indicating related TAM hemolysis
TAc alpha acetate indicating related TAM hemolysis
hydroxyl acetate indicating prevented effect hemolytic
hydroxyl acetate indicating related TAM hemolysis
oxygen consumption hemolysis
K leakage preceded Hemolysis
K leakage preceded excluding colloid mechanism hemolysis
tocopherols hemolysis
disulfiram developed syndrome tachycardia hypotension arterial
disulfiram developed syndrome tachycardia hypotension
disulfiram developed syndrome tachycardia flushing
disulfiram developed syndrome tachycardia
doxorubicin cardiotoxicity
adriamycin use limits complication toxicity Cardiac
adriamycin use limits complication toxicity
clozapine treated inpatients psychiatric
L complications arise patients Parkinson
L complications arise patients Parkinson '
L complications arise patients s
L complications arise patients disease
DOPA L complications arise patients Parkinson
DOPA L complications arise patients Parkinson '
DOPA L complications arise patients s
DOPA L complications arise patients disease
L complications arise patients PD
DOPA L complications arise patients PD
L treatment arise patients Parkinson
L treatment arise patients Parkinson '
L treatment arise patients s
L treatment arise patients disease
DOPA arise patients Parkinson
DOPA arise patients Parkinson '
DOPA arise patients s
DOPA arise patients disease
L treatment arise patients PD
DOPA arise patients PD
bromocriptine DOPA changes model PD
L saline treated PD
DOPA changes model PD
6 obtained samples level occurring changes model PD
hydroxydopamine occurring changes model PD
clozapine threshold lowered have risk EPS
clozapine agranulocytosis threshold lowered have risk EPS
clozapine threshold lowered have associated degrees sedation dysfunction sexual
clozapine threshold lowered have associated degrees sedation dysfunction
clozapine agranulocytosis threshold lowered have associated degrees sedation dysfunction sexual
clozapine agranulocytosis threshold lowered have associated degrees sedation dysfunction
clozapine threshold seizure
clozapine agranulocytosis threshold seizure
clozapine threshold lowered have associated degrees sedation gain weight
clozapine threshold lowered have associated degrees sedation gain
clozapine agranulocytosis threshold lowered have associated degrees sedation gain weight
clozapine agranulocytosis threshold lowered have associated degrees sedation gain
MK catalepsy
801 haloperidol catalepsy
serotonin release correlation concentration related attack migraine
NO attack migraine
calcitonin gene increase attack migraine
gene increase attack migraine
related attack migraine
peptide concentration related attack migraine
CGRP concentration related attack migraine
serotonin concentration content headache attack migraine
5 concentration content headache attack migraine
hydroxytriptamine 5 concentration content headache attack migraine
5 5 concentration content headache attack migraine
HT 5 5 concentration content headache attack migraine
serotonin concentration content headache
5 concentration content headache
hydroxytriptamine 5 concentration content headache
5 5 concentration content headache
HT 5 5 concentration content headache
nitroglycerin provoked concentration content headache attack migraine
nitroglycerin provoked concentration content headache
calcitonin gene investigate was provoked concentration content headache
gene investigate was provoked concentration content headache
related concentration content headache
peptide concentration content headache
CGRP concentration content headache
calcitonin gene investigate was provoked concentration content headache attack migraine
gene investigate was provoked concentration content headache attack migraine
related concentration content headache attack migraine
peptide concentration content headache attack migraine
CGRP concentration content headache attack migraine
nitroglycerin application collected collected min beginning attack migraine
CGRP concentration increased attack migraine
CGRP concentration increased returned cessation migraine
CGRP concentrations failed change headache
CGRP concentrations failed change change subjects attack migraine
5 higher tended lower subjects experienced attack migraine
HT content tended lower subjects experienced attack migraine
CGRP concentration higher tended lower subjects experienced attack migraine
serotonin content decreased significantly observed nitroglycerin subjects attack migraine
serotonin content decreased significantly observed patients attack migraine
nitroglycerin subjects attack migraine
nitroglycerin observed patients attack migraine
CGRP timing headache
CGRP relationship suggests fact CGRP timing headache
CGRP timing headache migraine
CGRP fact suggests relationship CGRP migraine
CGRP relationship suggests fact CGRP timing headache migraine
CGRP migraine
serotonin release provoke migraine
serotonin release provoke counteract headache
CGRP release headache
CGRP release headache counteract provoke migraine
Clonidine attention
Clonidine deficit
Clonidine deficit analysis changes II disorder hyperactivity
Clonidine deficit analysis changes II disorder
methylphenidate children attention
methylphenidate children attention deficit
methylphenidate disorder hyperactivity
methylphenidate disorder
methylphenidate disorder ADHD
clonidine used or disorder methylphenidate children attention
clonidine used or disorder methylphenidate children attention deficit
clonidine used or disorder hyperactivity
clonidine used or disorder
clonidine used or disorder ADHD
methylphenidate assigned children ADHD
methylphenidate clonidine assigned children ADHD
clonidine assigned children ADHD
clonidine assigned children ADHD
clonidine common Drowsiness
methylphenidate or used Clonidine appears safe tolerated ADHD
Clonidine appears safe tolerated ADHD
clonidine monitor advise likelihood drowsiness
acetaminophen produce toxicities cardiovascular
acetaminophen produce toxicities
acetaminophen demonstrated produce symptoms anaphylaxis
acetaminophen administration developed patients ill critically
acetaminophen administration developed patients ill
levonorgestrel dose presence identified years had infarction myocardial
levonorgestrel dose presence identified years had infarction
levonorgestrel 925 women had infarction myocardial
levonorgestrel 925 women had infarction
estrogen dose presence identified years had infarction myocardial
estrogen dose presence identified years had infarction
estrogen dose levonorgestrel 925 women had infarction myocardial
estrogen dose levonorgestrel 925 women had infarction
8 administration monkeys rhesus Toxicity
aminoquinoline 8 administration monkeys rhesus Toxicity
8 aminoquinoline 8 administration monkeys rhesus Toxicity
-LSB- 8 administration monkeys rhesus Toxicity
4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
amino l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
methylbutyl l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
amino -RSB- -LSB- 8 administration monkeys rhesus Toxicity
-RSB- -LSB- 8 administration monkeys rhesus Toxicity
5 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
l -RSB- -LSB- 8 administration monkeys rhesus Toxicity
hexyloxy l -RSB- -LSB- 8 administration monkeys rhesus Toxicity
6 8 administration monkeys rhesus Toxicity
methoxy 8 administration monkeys rhesus Toxicity
4 8 administration monkeys rhesus Toxicity
methylquinoline 8 administration monkeys rhesus Toxicity
WR methylquinoline 8 administration monkeys rhesus Toxicity
242511 WR methylquinoline 8 administration monkeys rhesus Toxicity
WR doses RESULTS produced methemoglobinemia
242511 WR doses RESULTS produced methemoglobinemia
WR 242511 pursued pretreatment poisoning
242511 pursued pretreatment poisoning
WR 242511 pursued concluded dissociated toxicity
242511 pursued concluded dissociated toxicity
benzylisoquinolinium NMBA short besylate associated paralysis
thallium dipyridamole hyperemia
Pentoxifylline inhibit dipyridamole hyperemia
Trental Pentoxifylline inhibit dipyridamole hyperemia
Dipyridamole performed patients unable exercise disease peripheral
Dipyridamole performed patients unable exercise disease vascular
Dipyridamole performed patients unable exercise disease
thallium Dipyridamole performed patients unable exercise disease peripheral
thallium Dipyridamole performed patients unable exercise disease vascular
thallium Dipyridamole performed patients unable exercise disease
methylxanthine derivative improve claudication intermittent
methylxanthine derivative improve claudication
thallium induced hyperemia
theophylline methylxanthines induced hyperemia
methylxanthines induced hyperemia
pentoxifylline inhibits thallium induced hyperemia
theophylline lower decreased hyperemia
pentoxifylline dose decreased hyperemia
pentoxyifylline inhibit dipyridamole induced hyperemia
U injection causes hypertension
II causes hypertension
U injection causes hypertension bradycardia
II causes hypertension bradycardia
corticosterone level had induced erection penile
corticosterone level had induced erection
U administration II had induced erection penile
U administration II had induced erection
II had induced erection penile
II had induced erection
U II involved aspects disorders psychiatric
U II involved aspects disorders
- II involved aspects disorders psychiatric
- II involved aspects disorders
II involved aspects disorders psychiatric
II involved aspects disorders
Acetazolamide induced nephrolithiasis
Acetazolamide induced nephrolithiasis implications treatment disorders neuromuscular
Acetazolamide induced nephrolithiasis implications treatment disorders
acetazolamide complication Nephrolithiasis
propafenone overdose induced Ebstein
propafenone overdose induced Ebstein '
propafenone overdose induced syndrome platypnea anomaly s
propafenone overdose induced syndrome platypnea anomaly
propafenone overdose
propafenone overdose induced syndrome platypnea
propafenone overdose induced syndrome platypnea orthodeoxia
propafenone overdose induced syndrome like
propafenone overdose induced syndrome
propafenone overdose precipitated occurred shunt blood ovale patent
propafenone overdose precipitated occurred shunt blood ovale foramen
propafenone overdose precipitated occurred shunt blood ovale
propafenone overdose
corticosteroids exchange treatment discontinuation led resolution MAHA
aspirin exchange treatment discontinuation led resolution MAHA
dipyridamole exchange treatment discontinuation led resolution MAHA
cyclosporin react A immuno drug known induce MAHA
A immuno drug known induce MAHA
CyA A immuno drug known induce MAHA
oxcarbazepine switched treat haloperidol patients schizophrenic
oxcarbazepine switched treat haloperidol patients schizophrenic organic
oxcarbazepine switched treat haloperidol patients psychotic
Carbamazepine switched treat haloperidol patients schizophrenic organic
Carbamazepine switched treat haloperidol patients psychotic
chlorpromazine haloperidol patients schizophrenic
haloperidol patients schizophrenic
haloperidol patients schizophrenic organic
haloperidol patients psychotic
clozapine haloperidol patients schizophrenic
clozapine haloperidol patients schizophrenic organic
clozapine haloperidol patients psychotic
Carbamazepine switched treat haloperidol patients schizophrenic
chlorpromazine haloperidol patients schizophrenic organic
chlorpromazine haloperidol patients psychotic
calcium Effects blockers induced toxicity
bupivacaine blockers induced toxicity
calcium blockers influence investigate bupivacaine induced toxicity
bupivacaine induced toxicity
bepridil pronounced modified decreased time convulsions
calcium blockers decreased time convulsions
lactate elevates mice AIDS
lactate elevates causes cardiomyopathy
lactate AIDS
LA lactate AIDS
lactate implicated implicated mechanisms dysfunction mitochondrial
lactate implicated implicated mechanisms dysfunction
LA lactate implicated implicated mechanisms dysfunction mitochondrial
LA lactate implicated implicated mechanisms dysfunction
lactate implicated implicated cardiomyopathy
lactate implicated implicated cardiomyopathy CM
LA lactate implicated implicated cardiomyopathy
LA lactate implicated implicated cardiomyopathy CM
zidovudine combination treated n week hemizygous mice AIDS
lamivudine zidovudine combination treated n week hemizygous mice AIDS
indinavir zidovudine combination treated n week hemizygous mice AIDS
calcium SERCA mRNA echocardiography quantitation abundance markers CM
LA determination echocardiography quantitation abundance markers CM
LA caused mice AIDS
LA caused CM
epinephrine administer scene paramedics led onset distress respiratory
epinephrine administer scene paramedics led onset distress
epinephrine administer scene paramedics led onset distress rash
Epinephrine has viewed use paramedics patients reaction hypertension
Epinephrine has viewed use paramedics patients reaction allergic
Epinephrine has viewed use paramedics patients reaction
heparin treated stopped months onset anuria
dipyridamole heparin treated stopped months onset anuria
ephedrine doses adding propofol obtund response hypotensive
ephedrine addition appears method obtunding response hypotensive
ephedrine any patients use recommend risk tachycardia inducing ischemia myocardial
ephedrine any patients use recommend risk tachycardia inducing ischemia
propofol use recommend risk tachycardia inducing ischemia myocardial
propofol use recommend risk tachycardia inducing ischemia
amphotericin B administration developed patient cirrhosis
B administration developed patient cirrhosis
amphotericin B administration developed patient cirrhosis sporotrichosis
B administration developed patient cirrhosis sporotrichosis
fangchinoline tetrandrine Effects thrombosis
tetrandrine Effects mice aggregation platelet
tetrandrine Effects mice aggregation
tetrandrine Effects thrombosis
fangchinoline tetrandrine Effects mice aggregation platelet
fangchinoline tetrandrine Effects mice aggregation
TET effects investigate thrombosis induced epinephrine aggregation coagulation blood
TET effects investigate thrombosis induced epinephrine aggregation coagulation
FAN TET effects investigate thrombosis
TET effects investigate thrombosis induced epinephrine aggregation platelet
TET effects investigate thrombosis induced epinephrine aggregation
epinephrine aggregation platelet
epinephrine aggregation
EP epinephrine aggregation platelet
EP epinephrine aggregation
FAN TET effects investigate thrombosis induced epinephrine aggregation coagulation blood
FAN TET effects investigate thrombosis induced epinephrine aggregation coagulation
epinephrine aggregation coagulation blood
epinephrine aggregation coagulation
EP epinephrine aggregation coagulation blood
EP epinephrine aggregation coagulation
TET effects investigate thrombosis
FAN TET effects investigate thrombosis induced epinephrine aggregation platelet
FAN TET effects investigate thrombosis induced epinephrine aggregation
acetylsalicylic acid showed showed inhibition thrombosis
acid showed showed inhibition thrombosis
ASA mg acid showed showed inhibition thrombosis
FAN TET administration showed inhibition thrombosis
TET administration showed inhibition thrombosis
TET showed aggregations platelet
TET showed aggregations
FAN TET showed aggregations platelet
FAN TET showed aggregations
lindane treatment consider initiated Treatment scabies
gamma hexachloride lindane treatment consider initiated Treatment scabies
benzene hexachloride lindane treatment consider initiated Treatment scabies
hexachloride lindane treatment consider initiated Treatment scabies
pilocarpine reported seizures
pilocarpine reported used localize genes seizure
pilocarpine seizures
pilocarpine tested A induced seizures
divalproex reduced deficits cognitive
divalproex reduced deficits cognitive and
divalproex reduced deficits cognitive functional
divalproex reduced deficits
sodium divalproex reduced deficits cognitive
sodium divalproex reduced deficits cognitive and
sodium divalproex reduced deficits cognitive functional
sodium divalproex reduced deficits
Lithium remains treatment disorder bipolar
Lithium remains treatment disorder
lithium effects management polyuria
lithium effects remain written management polyuria
lithium effects management polyuria tremor
lithium effects remain written management polyuria tremor
divalproex alleviate impairments cognitive
divalproex alleviate impairments cognitive and
divalproex alleviate impairments cognitive functional
divalproex alleviate impairments
sodium divalproex alleviate impairments cognitive
sodium divalproex alleviate impairments cognitive and
sodium divalproex alleviate impairments cognitive functional
sodium divalproex alleviate impairments
lithium switching patients bipolar
divalproex switching patients bipolar
sodium divalproex switching patients bipolar
divalproex sodium lithium substitution helpful reducing cognitive
divalproex sodium lithium substitution helpful reducing cognitive motivational
divalproex sodium lithium substitution helpful reducing cognitive or
divalproex sodium lithium substitution helpful reducing cognitive deficits creative
divalproex sodium lithium substitution helpful reducing cognitive deficits
sodium lithium substitution helpful reducing cognitive
sodium lithium substitution helpful reducing cognitive motivational
sodium lithium substitution helpful reducing cognitive or
sodium lithium substitution helpful reducing cognitive deficits creative
sodium lithium substitution helpful reducing cognitive deficits
lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
lithium patients bipolar
divalproex sodium lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
sodium lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
divalproex sodium alternative lithium patients experiencing deficits cognitive
divalproex sodium alternative lithium patients experiencing deficits
sodium alternative lithium patients experiencing deficits cognitive
sodium alternative lithium patients experiencing deficits
divalproex sodium alternative lithium patients experiencing deficits loss
divalproex sodium alternative lithium patients experiencing deficits loss creativity of
divalproex sodium alternative lithium patients experiencing deficits loss creativity
sodium alternative lithium patients experiencing deficits loss
sodium alternative lithium patients experiencing deficits loss creativity of
sodium alternative lithium patients experiencing deficits loss creativity
divalproex sodium alternative lithium patients experiencing deficits impairments functional
divalproex sodium alternative lithium patients experiencing deficits impairments
sodium alternative lithium patients experiencing deficits impairments functional
sodium alternative lithium patients experiencing deficits impairments
lithium patients bipolar
divalproex sodium alternative lithium patients bipolar
sodium alternative lithium patients bipolar
doxorubicin function indicator echocardiography survivors cancer
Dobutamine echocardiography survivors cancer
dobutamine infusion using performed develop due test damage cardiac
dobutamine infusion using performed develop due test damage
doxorubicin due develop performed using differentiate long survivors cancer
doxorubicin treated cancer
dobutamine infusion using differentiate long survivors cancer
doxorubicin due test damage cardiac
doxorubicin due test damage
doxorubicin treated cancer survivors long differentiate using performed develop due test damage cardiac
doxorubicin treated cancer survivors long differentiate using performed develop due test damage
lithium exposed screening Cross induced malformations cardiac
lithium exposed screening Cross induced malformations
lithium presence assessment provide gestation exposed screening Cross induced malformations cardiac
lithium presence assessment provide gestation exposed screening Cross induced malformations
cocaine nephritis Henoch cases hypertension microangiopathy nephritis lupus
cocaine nephritis Henoch cases hypertension microangiopathy nephritis
cocaine nephritis Henoch cases hypertension microangiopathy thrombotic
cocaine nephritis Henoch cases hypertension microangiopathy
cocaine nephritis glomerulonephritis
cocaine nephritis Henoch
cocaine nephritis Schonlein
cocaine nephritis
cocaine nephritis Henoch cases hypertension malignant
cocaine nephritis Henoch cases hypertension
Norepinephrine signaling critical induced anxiety
dopamine beta performance induced anxiety
norepinephrine lack mice performance induced anxiety
NE norepinephrine lack mice performance induced anxiety
disulfiram administration mice Cocaine induced attenuated anxiety
dopamine beta disulfiram administration mice Cocaine induced attenuated anxiety
prazosin had C type pretreatment antagonist anxiety
yohimbine prazosin had C type pretreatment antagonist anxiety
propranolol cocaine antagonist anxiety
prazosin enalapril safety phase patients failure congestive
prazosin enalapril safety phase patients failure heart
prazosin enalapril safety phase patients failure
enalapril safety phase patients failure congestive
enalapril safety phase patients failure heart
enalapril safety phase patients failure
angiotensin introduction converting treatment patients failure congestive
angiotensin introduction converting treatment patients failure heart
angiotensin introduction converting treatment patients failure
converting treatment patients failure congestive
converting treatment patients failure heart
converting treatment patients failure
enzyme inhibitors converting treatment patients failure congestive
enzyme inhibitors converting treatment patients failure heart
enzyme inhibitors converting treatment patients failure
ACE inhibitors converting treatment patients failure congestive
ACE inhibitors converting treatment patients failure heart
ACE inhibitors converting treatment patients failure
inhibitors converting treatment patients failure congestive
inhibitors converting treatment patients failure heart
inhibitors converting treatment patients failure
enalapril safety assess designed compared incidence hypotension
enalapril hypotension
danazol treatment hamartoma Bile
danazol treatment hamartoma duct
danazol treatment hamartoma
danazol treatment patient developed hamartoma bile
danazol treatment patient developed hamartoma duct
danazol treatment patient developed hamartoma
lidocaine hyperalgesia
ketamine lidocaine hyperalgesia
lidocaine ketamine hyperalgesia
lidocaine brush pain
ketamine hyperalgesia
ketamine lidocaine brush pain
Ketamine reduced evoked hyperalgesia
Ketamine reduced evoked tended reduce brush pain
Lidocaine reduced area hyperalgesia
lidocaine ketamine hyperalgesia
lidocaine ketamine effects suggest mediated types hyperalgesia
ketamine hyperalgesia
ketamine effects suggest mediated types hyperalgesia
MPEP action associated neurotoxicity
dopamine outflow decrease associated neurotoxicity
dopamine outflow decrease hyperthermia
methamphetamine antagonist action associated neurotoxicity
MPEP action associated decrease hyperthermia
methamphetamine neurones toxicity
MPEP mGluR blockade protect neurones toxicity
dopamine efflux induced induced decrease hyperthermia
MPEP rendered Neuroprotection associated induced induced decrease hyperthermia
diethylstilbestrol exposed adenocarcinoma clear
diethylstilbestrol exposed adenocarcinoma cell
diethylstilbestrol exposed adenocarcinoma
diethylstilbestrol exposed adenocarcinoma vagina of
diethylstilbestrol exposed adenocarcinoma vagina the
diethylstilbestrol exposed adenocarcinoma vagina
azathioprine Treatment psoriasis
Azathioprine treatment benefited 19 patients suffering psoriasis
azathioprine therapy continued detected damage liver
azathioprine therapy continued detected damage
ephedrine reduces induced hypotension
ephedrine reduces
ephedrine reduces oxygenation frontal
ephedrine reduces oxygenation lobe
ephedrine reduces oxygenation
Phenylephrine reduces induced hypotension
ephedrine phenylephrine effect describe induced hypotension
phenylephrine effect describe induced hypotension
ephedrine maintains has CONCLUSIONS utilization hypotension
phenylephrine correct hypotension
IH induced cardiotoxicity
636 proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
grape proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
seed proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
extract protection damage associated amiodarone induced cardiotoxicity
acetaminophen associated amiodarone toxicity lung
acetaminophen associated amiodarone toxicity
doxorubicin toxicity amiodarone associated induced nephrotoxicity
IH induced amiodarone associated deaths apoptotic necrotic
636 proanthocyanidin extract protection damage associated deaths apoptotic necrotic
grape proanthocyanidin extract protection damage associated deaths apoptotic necrotic
seed proanthocyanidin extract protection damage associated deaths apoptotic necrotic
proanthocyanidin extract protection damage associated deaths apoptotic necrotic
extract protection damage associated deaths apoptotic necrotic
doxorubicin toxicity lung
doxorubicin toxicity
IH induced amiodarone associated induced nephrotoxicity
636 proanthocyanidin extract protection damage associated induced nephrotoxicity
grape proanthocyanidin extract protection damage associated induced nephrotoxicity
seed proanthocyanidin extract protection damage associated induced nephrotoxicity
proanthocyanidin extract protection damage associated induced nephrotoxicity
extract protection damage associated induced nephrotoxicity
IH induced amiodarone toxicity lung
IH induced amiodarone toxicity
636 proanthocyanidin extract protection damage associated amiodarone toxicity lung
636 proanthocyanidin extract protection damage associated amiodarone toxicity
grape proanthocyanidin extract protection damage associated amiodarone toxicity lung
grape proanthocyanidin extract protection damage associated amiodarone toxicity
seed proanthocyanidin extract protection damage associated amiodarone toxicity lung
seed proanthocyanidin extract protection damage associated amiodarone toxicity
proanthocyanidin extract protection damage associated amiodarone toxicity lung
proanthocyanidin extract protection damage associated amiodarone toxicity
extract protection damage associated amiodarone toxicity lung
extract protection damage associated amiodarone toxicity
acetaminophen associated amiodarone induced cardiotoxicity
amiodarone associated induced nephrotoxicity
amiodarone induced cardiotoxicity
IH ability assessed seed proanthocyanidin induced cardiotoxicity
636 IH ability assessed seed proanthocyanidin induced cardiotoxicity
grape seed proanthocyanidin induced cardiotoxicity
seed proanthocyanidin induced cardiotoxicity
proanthocyanidin induced cardiotoxicity
extract proanthocyanidin induced cardiotoxicity
GSPE extract proanthocyanidin induced cardiotoxicity
acetaminophen prevent extract proanthocyanidin induced toxicity lung
acetaminophen prevent extract proanthocyanidin induced toxicity
AAP acetaminophen prevent extract proanthocyanidin induced toxicity lung
AAP acetaminophen prevent extract proanthocyanidin induced toxicity
doxorubicin toxicity induced proanthocyanidin induced nephrotoxicity
DOX doxorubicin toxicity induced proanthocyanidin induced nephrotoxicity
doxorubicin toxicity lung
doxorubicin toxicity
DOX doxorubicin toxicity lung
DOX doxorubicin toxicity
IH ability assessed seed proanthocyanidin induced nephrotoxicity
636 IH ability assessed seed proanthocyanidin induced nephrotoxicity
grape seed proanthocyanidin induced nephrotoxicity
seed proanthocyanidin induced nephrotoxicity
proanthocyanidin induced nephrotoxicity
extract proanthocyanidin induced nephrotoxicity
GSPE extract proanthocyanidin induced nephrotoxicity
IH ability assessed seed proanthocyanidin induced toxicity lung
IH ability assessed seed proanthocyanidin induced toxicity
636 IH ability assessed seed proanthocyanidin induced toxicity lung
636 IH ability assessed seed proanthocyanidin induced toxicity
grape seed proanthocyanidin induced toxicity lung
grape seed proanthocyanidin induced toxicity
seed proanthocyanidin induced toxicity lung
seed proanthocyanidin induced toxicity
proanthocyanidin induced toxicity lung
proanthocyanidin induced toxicity
extract proanthocyanidin induced toxicity lung
extract proanthocyanidin induced toxicity
GSPE extract proanthocyanidin induced toxicity lung
GSPE extract proanthocyanidin induced toxicity
acetaminophen prevent extract proanthocyanidin induced cardiotoxicity
AAP acetaminophen prevent extract proanthocyanidin induced cardiotoxicity
amiodarone nephrotoxicity
AMI nephrotoxicity
amiodarone nephrotoxicity induced proanthocyanidin induced cardiotoxicity
AMI nephrotoxicity induced proanthocyanidin induced cardiotoxicity
GSPE preexposure absence revealed moderate damage tissue
GSPE preexposure absence revealed moderate damage
GSPE blocked organs necrosis
ipratropium effects bromide disease chronic
ipratropium effects bromide disease obstructive
ipratropium effects bromide disease pulmonary
ipratropium effects bromide disease
bromide disease chronic
bromide disease obstructive
bromide disease pulmonary
bromide disease
theophylline bromide disease chronic
theophylline bromide disease obstructive
theophylline bromide disease pulmonary
theophylline bromide disease
ipratropium aerosol dose effects tablets compared double controlled disease chronic
ipratropium aerosol dose effects tablets compared double controlled disease obstructive
ipratropium aerosol dose effects tablets compared double controlled disease pulmonary
ipratropium aerosol dose effects tablets compared double controlled disease
bromide aerosol dose effects tablets compared double controlled disease chronic
bromide aerosol dose effects tablets compared double controlled disease obstructive
bromide aerosol dose effects tablets compared double controlled disease pulmonary
bromide aerosol dose effects tablets compared double controlled disease
theophylline tablets compared double controlled disease chronic
theophylline tablets compared double controlled disease obstructive
theophylline tablets compared double controlled disease pulmonary
theophylline tablets compared double controlled disease
theophylline use involve systems cardiovascular
theophylline use involve systems cardiovascular and
theophylline use involve systems cardiovascular gastrointestinal
theophylline use involve systems
ipratropium bronchodilator theophylline patients obstruction chronic
ipratropium bronchodilator theophylline patients obstruction airflow
ipratropium bronchodilator theophylline patients obstruction
theophylline patients obstruction chronic
theophylline patients obstruction airflow
theophylline patients obstruction
nitrendipine nephrosclerosis rats hypertension renovascular
nitrendipine nephrosclerosis rats hypertension
calcium blocker effect nitrendipine nephrosclerosis
calcium blocker effect nitrendipine nephrosclerosis rats hypertension renovascular
calcium blocker effect nitrendipine nephrosclerosis rats hypertension
nitrendipine treatment effect studied rats kidney hypertension renovascular
nitrendipine treatment effect studied rats kidney hypertension
angiotensin converting pressure albuminuria
enalapril converting angiotensin effect studied rats kidney hypertension renovascular
enalapril converting angiotensin effect studied rats kidney hypertension
enalapril converting pressure albuminuria
angiotensin effect studied rats kidney hypertension renovascular
angiotensin effect studied rats kidney hypertension
calcium nitrendipine treatment effect angiotensin converting pressure albuminuria
calcium nitrendipine treatment effect studied rats kidney hypertension renovascular
calcium nitrendipine treatment effect studied rats kidney hypertension
nitrendipine assigned rats hypertensive
nitrendipine assigned groups controls hypertensive
enalapril controls groups assigned rats hypertensive
enalapril controls hypertensive
enalapril treatment change excretion glomerulosclerosis
nitrendipine contrast controls hr hypertensive
nitrendipine treated controls hypertensive
nitrendipine increased index glomerulosclerosis
nitrendipine group higher in treated controls hypertensive
enalapril treated controls hypertensive
perhexiline maleate noted used treatment pectoris angina
perhexiline maleate noted used treatment pectoris
maleate noted used treatment pectoris angina
maleate noted used treatment pectoris
MFL leucovorin FU mitoxantrone toxicity
mitoxantrone toxicity
leucovorin FU mitoxantrone treated cancer breast
leucovorin FU mitoxantrone treated cancer
leucovorin FU mitoxantrone toxicity
5 dose mitoxantrone treated cancer breast
5 dose mitoxantrone treated cancer
FU mitoxantrone treated cancer breast
FU mitoxantrone treated cancer
MFL leucovorin FU mitoxantrone treated cancer breast
MFL leucovorin FU mitoxantrone treated cancer
mitoxantrone treated cancer breast
mitoxantrone treated cancer
5 dose mitoxantrone toxicity
FU mitoxantrone toxicity
leucovorin treated cancer breast
leucovorin treated cancer
5 infusion day m mitoxantrone treated cancer breast
5 infusion day m mitoxantrone treated cancer
FU infusion day m mitoxantrone treated cancer breast
FU infusion day m mitoxantrone treated cancer
mitoxantrone treated cancer breast
mitoxantrone treated cancer
MFL regimen achieves induces toxicity
regimen achieves induces toxicity
propranolol disease Parkinson
propranolol disease Parkinson '
propranolol disease s
propranolol disease
propranolol dyskinesia
levodopa Improvement dyskinesia propranolol disease Parkinson
levodopa Improvement dyskinesia propranolol disease Parkinson '
levodopa Improvement dyskinesia propranolol disease s
levodopa Improvement dyskinesia propranolol disease
propranolol low received patients suffering disease Parkinson
propranolol low received patients suffering disease Parkinson '
propranolol low received patients suffering disease s
propranolol low received patients suffering disease
propranolol low received patients suffering disease PD
propranolol low received patients suffering dyskinesia
levodopa improve induced dyskinesia PD
Thalidomide limited single activity non
Thalidomide limited single lymphomas Hodgkin
Thalidomide limited single lymphomas
Thalidomide limited single B Leukemia
Thalidomide limited single trial Cancer
Thalidomide agent activity myeloma lymphoma lymphoplasmacytic
Thalidomide agent activity myeloma lymphoma
Thalidomide agent activity myeloma lymphoma mantle
Thalidomide agent activity myeloma lymphoma cell
Thalidomide agent activity myeloma lymphoma
Thalidomide agent activity myeloma multiple
Thalidomide agent activity myeloma
thalidomide mg received lymphomas
thalidomide lymphomas
lenalidomide agent reported level demonstrate thalidomide lymphomas
maltolyl p compound attenuates deficits cognitive
maltolyl p compound attenuates deficits
p compound attenuates deficits cognitive
p compound attenuates deficits
coumarate p compound attenuates deficits cognitive
coumarate p compound attenuates deficits
maltolyl p compound attenuates shows models vitro dementia
p compound attenuates shows models vitro dementia
coumarate p compound attenuates shows models vitro dementia
maltolyl p improve decline cognitive
maltolyl p improve decline
p improve decline cognitive
p improve decline
coumarate improve decline cognitive
coumarate improve decline
amyloid peptide injected p improve decline cognitive
amyloid peptide injected p improve decline
beta peptide injected p improve decline cognitive
beta peptide injected p improve decline
peptide injected p improve decline cognitive
peptide injected p improve decline
1 peptide injected p improve decline cognitive
1 peptide injected p improve decline
42 1 peptide injected p improve decline cognitive
42 1 peptide injected p improve decline
Maltolyl p found attenuate deficits cognitive
Maltolyl p found attenuate deficits
p found attenuate deficits cognitive
p found attenuate deficits
coumarate found attenuate deficits cognitive
coumarate found attenuate deficits
amyloid peptide hippocampus observed death reduce attenuate deficits cognitive
amyloid peptide hippocampus observed death reduce attenuate deficits
beta peptide hippocampus observed death reduce attenuate deficits cognitive
beta peptide hippocampus observed death reduce attenuate deficits
peptide hippocampus observed death reduce attenuate deficits cognitive
peptide hippocampus observed death reduce attenuate deficits
1 peptide hippocampus observed death reduce attenuate deficits cognitive
1 peptide hippocampus observed death reduce attenuate deficits
42 1 peptide hippocampus observed death reduce attenuate deficits cognitive
42 1 peptide hippocampus observed death reduce attenuate deficits
maltolyl p suggests candidate characterized death decline
maltolyl p suggests candidate characterized death function of
maltolyl p suggests candidate characterized death function cognitive
maltolyl p suggests candidate characterized death function
p suggests candidate characterized death decline
p suggests candidate characterized death function of
p suggests candidate characterized death function cognitive
p suggests candidate characterized death function
coumarate candidate characterized death decline
coumarate candidate characterized death function of
coumarate candidate characterized death function cognitive
coumarate candidate characterized death function
maltolyl p suggests candidate disease Alzheimer
maltolyl p suggests candidate disease Alzheimer '
maltolyl p suggests candidate disease s
maltolyl p suggests candidate disease
p suggests candidate disease Alzheimer
p suggests candidate disease Alzheimer '
p suggests candidate disease s
p suggests candidate disease
coumarate candidate disease Alzheimer
coumarate candidate disease Alzheimer '
coumarate candidate disease s
coumarate candidate disease
maltolyl p suggests candidate characterized death neuronal
maltolyl p suggests candidate characterized death
p suggests candidate characterized death neuronal
p suggests candidate characterized death
coumarate candidate characterized death neuronal
coumarate candidate characterized death
VPA signs consciousness marked hyperammonemia
VPA signs consciousness marked slowing frequency seizure
Galanthamine hydrobromide used patient demonstrating effects overdosage
hydrobromide used patient demonstrating effects overdosage
nitrazepam overdose took received symptoms withdrawal
nitrazepam overdose took received symptoms
chlormethiazole doses received symptoms withdrawal
chlormethiazole doses received symptoms
alcohol symptoms withdrawal
alcohol symptoms
chlormethiazole doses received took overdose
alcohol symptoms received took overdose
chlormethiazole intoxication those two patient overdose
physostigmine attenuated potentiated hyperactivity
methscopolamine had effect hyperactivity
neostigmine methscopolamine had effect hyperactivity
serotonin depletor chlorophenylalamine pretreatment caused hyperactivity
p pretreatment caused hyperactivity
chlorophenylalamine pretreatment caused hyperactivity
Zonisamide broad drug used treat types seizures
midazolam arrest death
midazolam administration associated arrest death
carbon tetrachloride relationship Phenobarbitone enlargement
carbon tetrachloride relationship Phenobarbitone enlargement liver of
carbon tetrachloride relationship Phenobarbitone enlargement liver the
carbon tetrachloride relationship Phenobarbitone enlargement liver
tetrachloride relationship Phenobarbitone enlargement
tetrachloride relationship Phenobarbitone enlargement liver of
tetrachloride relationship Phenobarbitone enlargement liver the
tetrachloride relationship Phenobarbitone enlargement liver
Phenobarbitone induced cirrhosis
carbon tetrachloride relationship Phenobarbitone induced cirrhosis
tetrachloride relationship Phenobarbitone induced cirrhosis
carbon tetrachloride yield given induced enlargement
carbon tetrachloride yield given induced enlargement liver of
carbon tetrachloride yield given induced enlargement liver the
carbon tetrachloride yield given induced enlargement liver
tetrachloride yield given induced enlargement
tetrachloride yield given induced enlargement liver of
tetrachloride yield given induced enlargement liver the
tetrachloride yield given induced enlargement liver
carbon tetrachloride dose giving increased primed given induced enlargement
carbon tetrachloride dose giving increased primed given induced enlargement liver of
carbon tetrachloride dose giving increased primed given induced enlargement liver the
carbon tetrachloride dose giving increased primed given induced enlargement liver
tetrachloride dose giving increased primed given induced enlargement
tetrachloride dose giving increased primed given induced enlargement liver of
tetrachloride dose giving increased primed given induced enlargement liver the
tetrachloride dose giving increased primed given induced enlargement liver
carbon tetrachloride yield cirrhosis defined nodular normal g dl splenomegaly
tetrachloride yield cirrhosis defined nodular normal g dl splenomegaly
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
tetrachloride dose giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
phenobarbitone given yield cirrhosis defined nodular testicular atrophy
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular testicular atrophy
carbon tetrachloride yield cirrhosis defined nodular testicular atrophy
tetrachloride yield cirrhosis defined nodular testicular atrophy
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular testicular atrophy
tetrachloride dose giving increased primed given yield cirrhosis defined nodular testicular atrophy
phenobarbitone given yield cirrhosis defined nodular normal g dl splenomegaly
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
phenobarbitone given yield cirrhosis defined nodular ascites
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular ascites
carbon tetrachloride yield cirrhosis defined nodular ascites
tetrachloride yield cirrhosis defined nodular ascites
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular ascites
tetrachloride dose giving increased primed given yield cirrhosis defined nodular ascites
ceftriaxone induced hepatitis erythroblastocytopenia
beta antibiotic withholding returned was increase decrease concentration caused anemia erythroblastocytopenia
lactam antibiotic withholding returned was increase decrease concentration caused anemia erythroblastocytopenia
beta antibiotic withholding returned was increase decrease concentration caused anemia autoimmune
beta antibiotic withholding returned was increase decrease concentration caused anemia hemolytic
beta antibiotic withholding returned was increase decrease concentration caused anemia
lactam antibiotic withholding returned was increase decrease concentration caused anemia autoimmune
lactam antibiotic withholding returned was increase decrease concentration caused anemia hemolytic
lactam antibiotic withholding returned was increase decrease concentration caused anemia
bilirubin increase decrease concentration caused anemia autoimmune
bilirubin increase decrease concentration caused anemia hemolytic
bilirubin increase decrease concentration caused anemia
bilirubin increase decrease concentration caused anemia erythroblastocytopenia
nimodipine Effect stroke acute
nimodipine Effect stroke
Nimodipine Trial Stroke
Nimodipine Trial BACKGROUND reduction pressure outcome stroke acute
Nimodipine Trial BACKGROUND reduction pressure outcome stroke
nimodipine correlation found Trial Stroke
nimodipine correlation found Trial BACKGROUND reduction pressure outcome stroke acute
nimodipine correlation found Trial BACKGROUND reduction pressure outcome stroke
nimodipine mg METHODS allocated Patients diagnosis stroke ischemic
nimodipine mg METHODS allocated Patients diagnosis stroke
nimodipine mg mg METHODS allocated Patients diagnosis stroke ischemic
nimodipine mg mg METHODS allocated Patients diagnosis stroke
nimodipine stroke acute
nimodipine stroke
combination due hepatitis Granulomatous
combination due hepatitis
of amoxicillin combination due hepatitis Granulomatous
of amoxicillin combination due hepatitis
amoxicillin combination due hepatitis Granulomatous
amoxicillin combination due hepatitis
and amoxicillin combination due hepatitis Granulomatous
and amoxicillin combination due hepatitis
clavulanic acid amoxicillin combination due hepatitis Granulomatous
clavulanic acid amoxicillin combination due hepatitis
acid amoxicillin combination due hepatitis Granulomatous
acid amoxicillin combination due hepatitis
amiodarone therapy Pneumonitis effusion neuropathy
amiodarone therapy Pneumonitis effusion pleural
amiodarone therapy Pneumonitis effusion pleural and
amiodarone therapy Pneumonitis effusion pleural pericardial
amiodarone therapy Pneumonitis effusion
amiodarone treated patient disease sinuatrial
amiodarone treated patient disease
amiodarone treated control tachyarrhythmias supraventricular
amiodarone treated control tachyarrhythmias
steroid therapy need diagnosis pneumonitis
fusidic acid disease Crohn
fusidic acid disease Crohn '
fusidic acid disease s
fusidic acid disease
acid disease Crohn
acid disease Crohn '
acid disease s
acid disease
cyclosporin similar properties antibiotic Treatment disease Crohn
cyclosporin similar properties antibiotic Treatment disease Crohn '
cyclosporin similar properties antibiotic Treatment disease s
cyclosporin similar properties antibiotic Treatment disease
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn '
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease s
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease
acid treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn
acid treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn '
acid treatment pharmacodynamics active estimate undertaken need development treatments disease s
acid treatment pharmacodynamics active estimate undertaken need development treatments disease
fusidic acid benefit patients Crohn
fusidic acid benefit patients '
fusidic acid benefit patients s
fusidic acid benefit patients disease
acid benefit patients Crohn
acid benefit patients '
acid benefit patients s
acid benefit patients disease
fusidic acid use rationale exist level disease inflammatory
fusidic acid use rationale exist level disease bowel
fusidic acid use rationale exist level disease
acid use rationale exist level disease inflammatory
acid use rationale exist level disease bowel
acid use rationale exist level disease
cimetidine trough 0 less ml renal
cimetidine trough 0 less ml renal and
cimetidine trough 0 less ml liver
cimetidine trough 0 less ml dysfunction
risperidone profile produce efficacy symptoms psychotic
risperidone profile produce efficacy symptoms
creatinine > Controls CRF
creatinine > Controls ESRD
creatinine > n 748 CRF
creatinine > Controls ESRD
creatinine levels percentage patients syndrome hepatorenal
creatinine levels percentage patients syndrome
creatinine higher levels percentage patients syndrome hepatorenal
creatinine higher levels percentage patients syndrome
creatinine levels had patients CRF
creatinine levels had patients CRF ESRD
creatinine higher levels had patients CRF
creatinine higher levels had patients CRF ESRD
creatinine increase factors development CRF
creatinine increase factors ESRD
creatinine preoperative have likely have syndrome hepatorenal
creatinine preoperative have likely have syndrome
creatinine preoperative have Patients develop ESRD
creatinine increase predictive development CRF
creatinine increase predictive development CRF ESRD
pilocarpine induced Investigation involvement model epilepsy
pilocarpine model phase oxidase expression provoke provoke sufficient generation FR epilepticus status
pilocarpine model phase oxidase expression provoke provoke sufficient generation FR epilepticus
anthracycline induced cardiotoxicity
Anthracyclines drugs cause dose related cardiotoxicity
anthracycline therapy cardiotoxicity highlights need search methods sensitive predicting dysfunction cardiac
anthracycline therapy cardiotoxicity highlights need search methods sensitive predicting dysfunction
anthracycline therapy cardiotoxicity
daunorubicin treated leukemia acute
daunorubicin treated leukemia
DNR daunorubicin treated leukemia acute
DNR daunorubicin treated leukemia
daunorubicin treated leukemia induced cardiotoxicity
DNR daunorubicin treated leukemia induced cardiotoxicity
anthracycline induced leukemia acute
anthracycline induced leukemia
anthracycline induced cardiotoxicity
DNR treated patients leukemia acute
DNR treated patients leukemia
anthracycline indicator useful cardiotoxicity
etoposide cisplatinum acid adenocarcinoma gastric
etoposide cisplatinum acid adenocarcinoma
folinic acid adenocarcinoma gastric
folinic acid adenocarcinoma
acid adenocarcinoma gastric
acid adenocarcinoma
5 dose fluorouracil cisplatinum acid adenocarcinoma gastric
5 dose fluorouracil cisplatinum acid adenocarcinoma
fluorouracil cisplatinum acid adenocarcinoma gastric
fluorouracil cisplatinum acid adenocarcinoma
cisplatinum acid adenocarcinoma gastric
cisplatinum acid adenocarcinoma
folinic fluorouracil infusion lasting coma lapsed developed symptoms confusion irritability
acid infusion lasting coma lapsed developed symptoms confusion irritability
5 lasting coma lapsed developed symptoms confusion irritability
fluorouracil infusion lasting coma lapsed developed symptoms confusion irritability
5 dose due neurotoxicity
fluorouracil due neurotoxicity
folinic acid unlikely suspected fluorouracil due neurotoxicity
acid unlikely suspected fluorouracil due neurotoxicity
fluorocitrate fluoroacetate due neurotoxicity
thiamine deficiency fluoroacetate due neurotoxicity
fluoroacetate due neurotoxicity
dihydrouracil deficiency fluoroacetate due neurotoxicity
5 pathogenesis due neurotoxicity
fluorouracil neurotoxicity
folinic therapy become regimen cancers
acid therapy become regimen cancers
5 dose High become regimen cancers
fluorouracil High become regimen cancers
acetaminophen factor failure chronic
acetaminophen factor failure renal
acetaminophen factor failure
acetaminophen use associated failure chronic
acetaminophen use associated failure renal
acetaminophen use associated failure
acetaminophen use associated failure ESRD
acetaminophen phenacetin contribute burden ESRD
acetaminophen use increases risk ESRD
terbutaline treatment abnormalities Neuroinflammation
terbutaline treatment abnormalities Neuroinflammation behavioral
terbutaline treatment abnormalities
Terbutaline associated 2 agonist used arrest labor preterm
Terbutaline associated 2 agonist used arrest labor
ketoconazole treated syndrome Cushing
ketoconazole treated syndrome Cushing '
ketoconazole treated syndrome s
ketoconazole treated syndrome
cortisol levels plasma achieved demonstrated hypertension
pegylated interferon C chronic
pegylated interferon C hepatitis
pegylated interferon C
interferon C chronic
interferon C hepatitis
interferon C
ribavirin treatment interferon C chronic
ribavirin treatment interferon C hepatitis
ribavirin treatment interferon C
pegylated interferon administration alpha 2 ribavirin hepatitis chronic
pegylated interferon administration alpha 2 ribavirin hepatitis
pegylated interferon administration weeks experienced C
interferon administration alpha 2 ribavirin hepatitis chronic
interferon administration alpha 2 ribavirin hepatitis
interferon administration weeks experienced C
IFN interferon administration alpha 2 ribavirin hepatitis chronic
IFN interferon administration alpha 2 ribavirin hepatitis
IFN interferon administration weeks experienced C
alpha 2 ribavirin hepatitis chronic
alpha 2 ribavirin hepatitis
alpha administration weeks experienced C
2 ribavirin hepatitis chronic
2 ribavirin hepatitis
2 alpha administration weeks experienced C
b 2 ribavirin hepatitis chronic
b 2 ribavirin hepatitis
b 2 alpha administration weeks experienced C
pegylated interferon administration weeks experienced C CHC
interferon administration weeks experienced C CHC
IFN interferon administration weeks experienced C CHC
alpha administration weeks experienced C CHC
2 alpha administration weeks experienced C CHC
b 2 alpha administration weeks experienced C CHC
ribavirin hepatitis chronic
ribavirin hepatitis
ribavirin 2 alpha administration weeks experienced C
ribavirin 2 alpha administration weeks experienced C CHC
pegylated interferon administration weeks experienced diplopia
interferon administration weeks experienced diplopia
IFN interferon administration weeks experienced diplopia
alpha administration weeks experienced diplopia
2 alpha administration weeks experienced diplopia
b 2 alpha administration weeks experienced diplopia
ribavirin 2 alpha administration weeks experienced diplopia
pegylated alpha ribavirin CHC
IFN alpha ribavirin CHC
alpha ribavirin CHC
2 alpha ribavirin CHC
b alpha ribavirin CHC
IFN therapy complications review present reported myasthenia associated therapy alpha ribavirin CHC
ribavirin CHC
asenapine trial Efficacy schizophrenia
haloperidol asenapine trial Efficacy schizophrenia
Asenapine approved adults treatment schizophrenia
Asenapine approved approved episodes manic
Asenapine approved approved episodes associated disorder bipolar
Asenapine approved approved episodes associated disorder I
Asenapine approved approved episodes associated disorder
Asenapine approved approved episodes associated features psychotic
asenapine treatment patients schizophrenia
asenapine mg trial patients schizophrenia
haloperidol BID mg trial patients schizophrenia
captopril Reversibility induced insufficiency renal
captopril Reversibility induced insufficiency
captopril Reversibility induced case hypertension renovascular
captopril Reversibility induced case hypertension
captopril treatment function deterioration developed kidney artery report case hypertension
captopril induced failure renal
captopril induced failure
lamivudine ve virus infected co HIV
lamivudine ve virus infected co
lamivudine associated infection
na ve lamivudine associated infection implications co HBV
na ve lamivudine associated infection implications co HBV and
na ve lamivudine associated infection implications co HBV HIV
na ve lamivudine associated infection implications co
na ve lamivudine associated infection infected
na ve virus hepatitis
na ve virus B
na ve virus
na ve virus HBV
na ve virus infected
lamivudine associated infection implications co HBV
lamivudine associated infection implications co HBV and
lamivudine associated infection implications co HBV HIV
lamivudine associated infection implications co
lamivudine associated infection infected
lamivudine ve virus hepatitis
lamivudine ve virus B
lamivudine ve virus
lamivudine ve virus HBV
lamivudine ve virus infected
na ve virus infected co HIV
na ve virus infected co
na ve lamivudine associated infection
lamivudine investigate study infection ve co immunodeficiency human
lamivudine investigate study infection ve co immunodeficiency
lamivudine investigate study infection ve co virus
lamivudine investigate study infection ve co HIV
lamivudine investigate study infection ve co
lamivudine investigate study infection
lamivudine strains lamivudine investigate study infection ve co immunodeficiency human
lamivudine strains lamivudine investigate study infection ve co immunodeficiency
lamivudine strains lamivudine investigate study infection ve co virus
lamivudine strains lamivudine investigate study infection ve co HIV
lamivudine strains lamivudine investigate study infection ve co
lamivudine strains lamivudine investigate study infection
na ve infection study investigate lamivudine strains hepatitis
na ve infection study investigate lamivudine strains B
lamivudine strains hepatitis
lamivudine strains B
lamivudine strains hepatitis
lamivudine strains B
na ve co immunodeficiency human
na ve co immunodeficiency
na ve co virus
na ve co HIV
na ve co
na ve infection
lamivudine ve co HIV
lamivudine ve co
lamivudine ve studied infection
na ve lamivudine Thirty patients HBV
na ve lamivudine Thirty co HIV
na ve lamivudine Thirty co
na ve lamivudine Thirty co patients infected
na ve patients HBV
na ve patients infected
na ve mono HBV
na ve mono
na ve lamivudine Thirty patients infected
lamivudine Thirty patients HBV
lamivudine Thirty co HIV
lamivudine Thirty co
lamivudine Thirty co patients infected
lamivudine ve patients HBV
lamivudine ve patients infected
lamivudine ve mono HBV
lamivudine ve mono
lamivudine Thirty patients infected
na ve co HIV
na ve co
na ve studied infection
lamivudine detected 3 mono patients 10 HBV
lamivudine detected 3 mono co HIV
lamivudine detected 3 mono co
lamivudine detected 3 mono patients infected
lamivudine detected 3 mono patients hepatitis
lamivudine detected 3 mono patients B
na HBV
na HBV lamivudine co HIV
na HBV lamivudine co
na HBV lamivudine patients infected
lamivudine HBV
lamivudine co HIV
lamivudine co
lamivudine patients infected
lamivudine result remains applied Africa likely have implications management HBV
lamivudine result remains co HIV
lamivudine result remains co
lamivudine result remains co patients infected
bupivacaine injection deficit neurological
bupivacaine injection deficit
bupivacaine mg occurred case deficit neurological
bupivacaine mg occurred case deficit
Levodopa induced disease Parkinson
Levodopa induced disease Parkinson '
Levodopa induced disease s
Levodopa induced disease
Levodopa drug treatment disease Parkinson
Levodopa drug treatment disease Parkinson '
Levodopa drug treatment disease s
Levodopa drug treatment disease
dopamine use long precursor complicated fluctuations dyskinesias
dopamine subtypes mechanisms presynaptic role focus lines preclinical induced dyskinesias
glutamate receptors mechanisms presynaptic role focus lines preclinical induced dyskinesias
heparan sulphate Reduction induced nephropathy diabetic
heparan sulphate Reduction induced nephropathy
sulphate Reduction induced nephropathy diabetic
sulphate Reduction induced nephropathy
streptozotocin studied induction diabetes
Heparan sulphate associated glomerular studied induction diabetes
sulphate associated glomerular studied induction diabetes
cuprolinic blue employing associated glomerular studied induction diabetes
blue employing associated glomerular studied induction diabetes
streptozotocin rats diabetic
heparan barrier excretion rats diabetic
sulphate barrier excretion rats diabetic
Verapamil withdrawal woman hypertensive
captopril introduction coincided woman hypertension
verapamil withdrawal introduction coincided woman hypertension
captopril introduction coincided infarction myocardial
captopril introduction coincided infarction
corticosterone level occurs observed hypotension
cyclophosphamide granulomatosis cancer Wegener
cyclophosphamide granulomatosis cancer Wegener '
cyclophosphamide granulomatosis s
cyclophosphamide granulomatosis
cyclophosphamide relation cancer risk assess patients granulomatosis Wegener
cyclophosphamide relation cancer risk assess patients granulomatosis Wegener '
cyclophosphamide relation cancer risk assess patients granulomatosis s
cyclophosphamide relation cancer risk assess patients granulomatosis
cyclophosphamide relationship dose indicate operating granulomatosis Wegener
cyclophosphamide relationship dose indicate operating granulomatosis Wegener '
cyclophosphamide relationship dose indicate operating granulomatosis s
cyclophosphamide relationship dose indicate operating granulomatosis
bisphosphonate proteinuria failure acute
bisphosphonate proteinuria failure renal
bisphosphonate proteinuria failure
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis focal
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis segmental
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis
bisphosphonate proteinuria
alendronate administration patient glomerulosclerosis focal
alendronate administration patient glomerulosclerosis segmental
alendronate administration patient glomerulosclerosis
steroid therapy responding man syndrome nephrotic
steroid therapy responding man syndrome
steroid therapy responding man syndrome due glomerulosclerosis focal
steroid therapy responding man syndrome due glomerulosclerosis segmental
steroid therapy responding man syndrome due glomerulosclerosis
bisphosphonate administration days increased g failure acute
bisphosphonate administration days increased g failure renal
bisphosphonate administration days increased g failure
bisphosphonates intravenous aggravate failure proteinuria acute
bisphosphonates intravenous aggravate failure renal
bisphosphonates intravenous aggravate failure
bisphosphonates intravenous aggravate failure proteinuria
dobutamine detecting ECG lead assess using m Sestamibi single emission computed assess presence ischemia
Tc m Sestamibi single emission computed assess presence ischemia
99 m Sestamibi single emission computed assess presence ischemia
m Sestamibi single emission computed assess presence ischemia
Sestamibi single emission computed assess presence ischemia
Tc m using assess induced ischemia myocardial
Tc m using assess induced ischemia
99 m using assess induced ischemia myocardial
99 m using assess induced ischemia
m using assess induced ischemia myocardial
m using assess induced ischemia
Sestamibi m using assess induced ischemia myocardial
Sestamibi m using assess induced ischemia
corticosteroids reactions allergic
corticosteroids reactions
paramethasone different Corticosteroids produced reactions hypersensitivity
paramethasone caused allergy
Organophosphate induced convulsions damages neuropathological
Organophosphate induced convulsions damages
Organophosphate induced convulsions
acetylcholine levels elevates system irreversible result toxicity
ACh levels elevates system irreversible result toxicity
OPs toxicity
DFP treated showed OP induced signs toxicity
OP induced signs toxicity
atropine showed OP induced signs toxicity
DFP given prevented shortened occurrence signs poisoning
2 PAM CPA given prevented shortened occurrence signs poisoning
PAM CPA given prevented shortened occurrence signs poisoning
atropine DFP given prevented shortened occurrence signs poisoning
diazepam CPA given prevented shortened occurrence signs poisoning
CPA given prevented shortened occurrence signs poisoning
MK 801 offer protection toxicity
801 offer protection toxicity
DFP toxicity
Atropine offer protection toxicity
CPA prevented reduced toxicity
diazepam CPA prevented reduced toxicity
2 PAM CPA prevented reduced toxicity
PAM CPA prevented reduced toxicity
DFP toxicity reduced prevented occurrence signs poisoning
2 PAM CPA prevented occurrence signs poisoning
PAM CPA prevented occurrence signs poisoning
DFP toxicity
atropine combination PAM CPA prevented occurrence signs poisoning
atropine combination PAM CPA prevented reduced toxicity
diazepam CPA prevented occurrence signs poisoning
CPA prevented occurrence signs poisoning
aspirin reduces reduces risk stroke
warfarin reduces risk stroke
aspirin preventing strokes
warfarin superior aspirin preventing strokes
Ximelagatran found efficient antagonist prevention events embolic
Ximelagatran found efficient antagonist prevention events
vitamin K antagonist prevention events embolic
vitamin K antagonist prevention events
K antagonist prevention events embolic
K antagonist prevention events
vitamin K antagonist withdrawn tests abnormal
vitamin K antagonist withdrawn tests liver
vitamin K antagonist withdrawn tests function
K antagonist withdrawn tests abnormal
K antagonist withdrawn tests liver
K antagonist withdrawn tests function
warfarin superior platelet therapy events embolic
warfarin superior platelet therapy events
Clopidogrel Trial W demonstrated superior platelet therapy events embolic
Clopidogrel Trial W demonstrated superior platelet therapy events
clopidogrel aspirin therapy events embolic
clopidogrel aspirin therapy events
Irbesartan Trial W demonstrated superior platelet therapy events embolic
Irbesartan Trial W demonstrated superior platelet therapy events
Clopidogrel Trial Atrial
Clopidogrel Trial Fibrillation
clopidogrel aspirin therapy platelet superior demonstrated W Trial Atrial
clopidogrel aspirin therapy platelet superior demonstrated W Trial Fibrillation
aspirin therapy events embolic
aspirin therapy events
warfarin superior demonstrated W Trial Atrial
warfarin superior demonstrated W Trial Fibrillation
Irbesartan Trial Atrial
Irbesartan Trial Fibrillation
aspirin therapy platelet superior demonstrated W Trial Atrial
aspirin therapy platelet superior demonstrated W Trial Fibrillation
Idraparinux evaluated patients fibrillation atrial
Idraparinux evaluated patients fibrillation
angiotensin receptor inhibitors converting blocking hold remodelling cardiac
angiotensin receptor inhibitors converting blocking hold remodelling
II receptor inhibitors converting blocking hold remodelling cardiac
II receptor inhibitors converting blocking hold remodelling
angiotensin receptor inhibitors converting blocking hold promise fibrillation atrial
angiotensin receptor inhibitors converting blocking hold promise fibrillation
II receptor inhibitors converting blocking hold promise fibrillation atrial
II receptor inhibitors converting blocking hold promise fibrillation
Angiotensin converting blocking hold remodelling cardiac
Angiotensin converting blocking hold remodelling
Angiotensin converting blocking hold promise fibrillation atrial
Angiotensin converting blocking hold promise fibrillation
5 induced exencephaly
azacytidine 13 let induced exencephaly
angiotensin converting hypertension
tizanidine initiation Hypotension treated angiotensin converting hypertension
angiotensin treated Hypotension
angiotensin treated Adults have ability respond hypotension
angiotensin converting control hypertension
angiotensin chronically treatment spasticity
lisinopril treated chronically treatment spasticity
tizanidine addition hypotension developed hypertension
tizanidine addition hypotension developed hypertension control converting angiotensin chronically treatment spasticity
angiotensin converting control hypertension developed hypotension
lisinopril treated chronically angiotensin converting control hypertension
tizanidine agents interaction kept treat hypertension
tizanidine agents interaction kept treat hypertension spasticity
FK utility complicated hypertension nephrotoxicity
506 FK utility complicated hypertension nephrotoxicity
nitric activity 1 expression 1 hypertension
oxide activity 1 expression 1 hypertension
FR antagonist studied hypertension
139317 FR antagonist studied hypertension
FR administration prevented FK induced hypertension
139317 FR administration prevented FK induced hypertension
TRI antagonize hypothermia
5 potentiate antagonize hypothermia
hydroxytryptophan twitches 5 potentiate antagonize hypothermia
dopamine D hydroxy d induced hyperactivity
phenylephrine evoked stimulation aggressiveness
clonidine evoked aggressiveness
heparin collagenase 014 induction ICH fold 4 6 over seen animals bleeding
heparin collagenase 014 induction ICH
heparin collagenase 014 induction ICH fold 4 6 over seen animals ICH
NMDA enhancement antihyperalgesia model pain
NMDA enhancement differences comparisons models pain acute
NMDA enhancement differences comparisons models pain
morphine antihyperalgesia model pain
capsaicin model pain
morphine antihyperalgesia enhancement differences comparisons models pain acute
morphine antihyperalgesia enhancement differences comparisons models pain
capsaicin model antihyperalgesia enhancement differences comparisons models pain acute
capsaicin model antihyperalgesia enhancement differences comparisons models pain
N aspartate models acute
N aspartate models pain
methyl N aspartate models acute
methyl N aspartate models pain
D methyl N aspartate models acute
D methyl N aspartate models pain
aspartate models acute
aspartate models pain
NMDA antagonists aspartate models acute
NMDA antagonists aspartate models pain
morphine effects enhance aspartate models acute
morphine effects enhance aspartate models pain
dextromethorphan antinociception Enhancement seen males models acute
dextromethorphan antinociception Enhancement seen males models pain
morphine antinociception Enhancement seen males models acute
morphine antinociception Enhancement seen males models pain
NMDA antagonists interaction sexually demonstrate model pain
NMDA antagonists interaction sexually demonstrate model distinguished those observed models acute
NMDA antagonists interaction sexually demonstrate model distinguished those observed models pain
morphine antagonists interaction sexually demonstrate model pain
morphine antagonists interaction sexually demonstrate model distinguished those observed models acute
morphine antagonists interaction sexually demonstrate model distinguished those observed models pain
FK nephropathy
506 FK nephropathy
FK nephropathy nephropathy
506 FK nephropathy nephropathy
FK nephropathy nephropathy
506 nephropathy nephropathy
FK nephropathy
506 nephropathy
FK nephropathy nephropathy type rejection nephropathy IgA
FK nephropathy nephropathy type rejection nephropathy
506 FK nephropathy nephropathy type rejection nephropathy IgA
506 FK nephropathy nephropathy type rejection nephropathy
FK nephropathy type rejection nephropathy IgA
FK nephropathy type rejection nephropathy
506 nephropathy type rejection nephropathy IgA
506 nephropathy type rejection nephropathy
FK nephropathy
506 nephropathy
FK 506 consisted nephropathy
506 consisted nephropathy
FK 506 consisted vacuolization form fibrosis interstitial
FK 506 consisted vacuolization form fibrosis
506 consisted vacuolization form fibrosis interstitial
506 consisted vacuolization form fibrosis
FK higher group nephropathy
506 group nephropathy
FK higher those group nephropathy
506 group higher those group nephropathy
FK chronic group those higher group nephropathy
506 FK chronic group those higher group nephropathy
FK chronic group nephropathy
506 FK chronic group nephropathy
creatinine levels FK higher group nephropathy
creatinine levels FK higher those group nephropathy
FK 506 consists nephropathy
506 consists nephropathy
FK 506 consists demonstrates condition nephropathy
506 consists demonstrates condition nephropathy
FK 506 condition demonstrates consists nephropathy
506 condition demonstrates consists nephropathy
FK 506 condition nephropathy
506 condition nephropathy
Flurbiprofen arthritis juvenile
Flurbiprofen arthritis rheumatoid
Flurbiprofen arthritis
flurbiprofen treated patients had baseline indices arthritis
flurbiprofen treated patients arthritis juvenile
flurbiprofen treated patients arthritis rheumatoid
flurbiprofen treated patients arthritis
potassium known medications given suggestive relationship sulindac hyperkalemia
adriamycin carcinoma bladder
adriamycin carcinoma
Adriamycin administered resection T tumors bladder
Adriamycin administered resection T tumors
sulfasalazine therapy colitis ulcerative
sulfasalazine therapy colitis
sulfasalazine lupus manifested serositis
sulfasalazine treat disease inflammatory
sulfasalazine treat disease bowel
sulfasalazine treat disease
sulfasalazine signs aware Physicians use sulfasalazine treat disease inflammatory
sulfasalazine signs aware Physicians use sulfasalazine treat disease bowel
sulfasalazine signs aware Physicians use sulfasalazine treat disease
CC complications thromboembolic
CC intake disturbance uncommon include search literature complications thromboembolic
CC treating patients infertility
dapsone dose taking associated hemolysis
dapsone dose taking developed woman trait leprosy
sodium channel induced leads nephropathy
Doxorubicin induced leads nephropathy
sodium channel retention volume
sodium channel retention
sodium channel retention fibrosis
Doxorubicin induced channel retention volume
Doxorubicin induced channel retention
Doxorubicin induced channel retention fibrosis
aldosterone kinase shown participate mediate fibrosis
aldosterone levels increased mice nephrotic
sodium excretion reached associated gain weight
sodium excretion reached associated gain
urea concentrations increased course syndrome nephrotic
urea concentrations increased course syndrome
urea concentrations increased mice uremia
Simvastatin medications human
Simvastatin medications immunodeficiency
Simvastatin medications virus
amiodarone Simvastatin medications human
amiodarone Simvastatin medications immunodeficiency
amiodarone Simvastatin medications virus
sulphasalazine received disease inflammatory
sulphasalazine received disease bowel
sulphasalazine received disease
sulphasalazine received disease born infants found have anomalies congenital
sulphasalazine received disease born infants found have anomalies
haloperidol study found effective treatment syndromes psychotic
haloperidol study found effective treatment syndromes
haloperidol study found effective treatment syndromes belonging
haloperidol study found effective treatment syndromes belonging predominantly
haloperidol study found effective treatment syndromes belonging group to
haloperidol study found effective treatment syndromes belonging group the
haloperidol study found effective treatment syndromes belonging group schizophrenia
haloperidol study found effective treatment syndromes belonging group
sirolimus associated dysfunction proteinuria acute
sirolimus associated dysfunction renal
sirolimus associated dysfunction
sirolimus associated dysfunction acute
sirolimus associated dysfunction renal
sirolimus associated dysfunction
angiotensin use minimised close monitoring function proteinuria
angiotensin use occurs proteinuria
angiotensin blockers inhibitors converting use minimised close monitoring function proteinuria
II blockers inhibitors converting use minimised close monitoring function proteinuria
angiotensin blockers inhibitors converting use occurs proteinuria
II blockers inhibitors converting use occurs proteinuria
coniine sulfate caused deformations
coniine sulfate caused deformations flexion excessive
coniine sulfate caused deformations flexion
coniine sulfate caused deformations flexion or
coniine sulfate caused deformations flexion extension
coniine sulfate caused deformations flexion toes of
coniine sulfate caused deformations flexion toes one
coniine sulfate caused deformations flexion toes one or
coniine sulfate caused deformations flexion toes one more
coniine sulfate caused deformations flexion toes
nicotine coniine sulfate caused deformations
nicotine coniine sulfate caused deformations flexion excessive
nicotine coniine sulfate caused deformations flexion
nicotine coniine sulfate caused deformations flexion or
nicotine coniine sulfate caused deformations flexion extension
nicotine coniine sulfate caused deformations flexion toes of
nicotine coniine sulfate caused deformations flexion toes one
nicotine coniine sulfate caused deformations flexion toes one or
nicotine coniine sulfate caused deformations flexion toes one more
nicotine coniine sulfate caused deformations flexion toes
Clomipramine exposure include anxiety inflexibility behavioral
Clomipramine exposure include anxiety inflexibility
Clomipramine exposure dysfunction corticostriatal
Clomipramine exposure dysfunction
norepinephrine rate augmentation tachycardia
nitroglycerin hydralazine induced hypotension contrast observed tachycardia
hydralazine induced hypotension contrast observed tachycardia
norepinephrine rate augmentation tachycardia observed contrast hypotension
sulfonylureas reported induced hepatotoxicity
sulfonylurea reports hepatotoxicity
glyburide therapy initiation developed patients mellitus type
glyburide therapy initiation developed patients mellitus II
glyburide therapy initiation developed patients mellitus diabetes
glyburide therapy initiation developed patients mellitus
aspirin administration co carcinomas bladder
aspirin administration co carcinomas
aspirin administration co carcinomas induction tumors forestomach
aspirin administration co carcinomas induction tumors
aspirin effect due consistent experiment suggesting involved carcinogenesis
FANFT carcinogenesis
FANFT effect due consistent experiment suggesting involved carcinogenesis
Sodium status influences nephrotoxicity
oxycodone effects adults suffering chronic pain
oxycodone similar aged suggests that suffering changes chronic
oxycodone similar aged suggests that suffering changes neurocognitive pain
nicotine mg caused locomotor
nicotine mg caused hypoactivity
nicotine enhanced operated lesions significantly locomotor
nicotine enhanced operated lesions significantly locomotor caused hypoactivity
Metamizol potentiates morphine antinociception constipation
metamizol effects constipating
charcoal test used assessed using model nociception pain
metamizol potentiate suggesting produced constipation
morphine interaction show suggesting useful treatment pain chronic
morphine interaction show suggesting useful treatment pain
metamizol morphine interaction show suggesting useful treatment pain chronic
metamizol morphine interaction show suggesting useful treatment pain
adriamycin induced damage renal
adriamycin induced damage
adriamycin injection induced damage renal
adriamycin injection induced damage
adriamycin elicited proteinuria glomerulosclerosis focal
adriamycin elicited proteinuria glomerulosclerosis
adriamycin elicited proteinuria nephrotic
adriamycin elicited proteinuria damage renal
adriamycin elicited proteinuria damage interstitial
adriamycin elicited proteinuria damage
adriamycin severity damage renal
adriamycin severity damage
benzylthiouracil carbimazole reactivity hepatitis Toxic
benzylthiouracil carbimazole reactivity hepatitis
carbimazole induced hepatitis cholestatic
carbimazole induced hepatitis
N omercazole carbimazole induced hepatitis cholestatic
N omercazole carbimazole induced hepatitis
omercazole carbimazole induced hepatitis cholestatic
omercazole carbimazole induced hepatitis
Benzylthiouracil replaced appeared hepatitis
Basd ne Benzylthiouracil replaced appeared hepatitis
ne Benzylthiouracil replaced appeared hepatitis
alprazolam disorder panic
alprazolam disorder
alprazolam disorder agoraphobia
alprazolam randomised criteria disorder panic
alprazolam randomised criteria disorder
alprazolam randomised criteria disorder agoraphobia
alprazolam patients developed reactions depression aggression
alprazolam patients developed reactions effects irritability
adrenaline containing mg observed increase accompanied fibrillation loss
adrenaline containing mg observed increase accompanied fibrillation loss consciousness of
adrenaline containing mg observed increase accompanied fibrillation loss consciousness
mepivacaine 850 block performance mg observed increase accompanied fibrillation agitation
adrenaline containing mg observed increase accompanied fibrillation agitation
mepivacaine 850 block performance mg observed increase accompanied fibrillation shouts incomprehensible
mepivacaine 850 block performance mg observed increase accompanied fibrillation shouts
mepivacaine 850 block performance mg containing adrenaline contracture Dupuytren
mepivacaine 850 block performance mg containing adrenaline contracture Dupuytren '
mepivacaine 850 block performance mg containing adrenaline contracture s
mepivacaine 850 block performance mg containing adrenaline contracture
adrenaline contracture Dupuytren
adrenaline contracture Dupuytren '
adrenaline contracture s
adrenaline contracture
adrenaline containing mg observed increase accompanied fibrillation shouts incomprehensible
adrenaline containing mg observed increase accompanied fibrillation shouts
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss consciousness of
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss consciousness
dipyridamole Effects induced injury myocardial
dipyridamole Effects induced injury
hydrocortisone dipyridamole Effects induced injury myocardial
hydrocortisone dipyridamole Effects induced injury
acetylsalicylic acid Effects induced injury myocardial
acetylsalicylic acid Effects induced injury
acid Effects induced injury myocardial
acid Effects induced injury
epinephrine infusion injury producing model developed study effects alter evolution infarction myocardial
epinephrine infusion injury producing model developed study effects alter evolution infarction
chlorofluorocarbons substitutes Epidemic disease liver
chlorofluorocarbons substitutes Epidemic disease
ozone used hydrochlorofluorocarbons caused disease liver
ozone used hydrochlorofluorocarbons caused disease
hydrochlorofluorocarbons caused disease liver
hydrochlorofluorocarbons caused disease
trifluoroacetyl intermediates implicated hepatotoxicity
1 way metabolised bromo trifluoroethane form intermediates implicated hepatotoxicity
bromo trifluoroethane form intermediates implicated hepatotoxicity
1 bromo trifluoroethane form intermediates implicated hepatotoxicity
chloro - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
- 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
trifluoroethane form intermediates implicated hepatotoxicity
halothane trifluoroethane form intermediates implicated hepatotoxicity
halothane hepatotoxicity
HCFCs 123 result disease liver
HCFCs 123 result disease
123 result disease liver
123 result disease
and 123 result disease liver
and 123 result disease
124 123 result disease liver
124 123 result disease
HCFCs beings exposure result injury liver
HCFCs beings exposure result injury
123 HCFCs beings exposure result injury liver
123 HCFCs beings exposure result injury
and HCFCs beings exposure result injury liver
and HCFCs beings exposure result injury
124 HCFCs beings exposure result injury liver
124 HCFCs beings exposure result injury
trifluoroacetyl suggest known mechanism hepatotoxicity
carbidopa preparation receiving presented had onset hallucinosis
/ preparation receiving presented had onset hallucinosis
levodopa preparation receiving presented had onset hallucinosis
carbidopa preparation receiving presented had failure chronic
carbidopa preparation receiving presented had failure renal
carbidopa preparation receiving presented had failure
/ preparation receiving presented had failure chronic
/ preparation receiving presented had failure renal
/ preparation receiving presented had failure
levodopa preparation receiving presented had failure chronic
levodopa preparation receiving presented had failure renal
levodopa preparation receiving presented had failure
carbidopa preparation receiving presented had onset hallucinosis seizures
/ preparation receiving presented had onset hallucinosis seizures
levodopa preparation receiving presented had onset hallucinosis seizures
losartan administration developed case 70 man hypertensive
losartan administration developed case 70 man kidney insufficiency chronic
losartan administration developed case 70 man kidney insufficiency renal
losartan administration developed case 70 man kidney insufficiency
losartan prescribed dysfunction systolic
losartan prescribed dysfunction
furosemide high lasted anuria
amine infusion furosemide high lasted anuria
angiotensin system renin activation resulted stenosis failure heart
angiotensin system renin activation resulted stenosis failure
angiotensin system renin activation resulted stenosis renal
angiotensin system renin activation resulted stenosis artery
angiotensin system renin activation resulted stenosis
losartan cause patients disease renovascular
losartan cause patients disease
angiotensin losartan cause patients disease renovascular
angiotensin losartan cause patients disease
II losartan cause patients disease renovascular
II losartan cause patients disease
citrate toxicity
citrate toxicity
calcium gluconate treatment initiated subsided contractions muscle
calcium gluconate treatment initiated subsided contractions
gluconate treatment initiated subsided contractions muscle
gluconate treatment initiated subsided contractions
calcium chelation reaction consistent anticoagulant resulting hypocalcemia
bumetanide diuretic cause hypocalcemia
loop diuretic cause hypocalcemia
diuretic cause hypocalcemia
citrate toxicity
GABA receptor effects sensitive seizures
benzodiazepine site carboxylate injection resistance seizures
GABA agonist site carboxylate injection resistance seizures
diazepam induced seizures
diazepam test plus induced diazepam induced seizures
lopinavir related neonates toxicity cardiac
lopinavir related neonates toxicity
/ therapy lopinavir related neonates toxicity cardiac
/ therapy lopinavir related neonates toxicity
ritonavir therapy lopinavir related neonates toxicity cardiac
ritonavir therapy lopinavir related neonates toxicity
bupivacaine received None limb paralysis
argatroban elevation thrombocytopenia thrombosis
argatroban elevation thrombocytopenia
heparin history patient argatroban elevation thrombocytopenia thrombosis
heparin history patient argatroban elevation thrombocytopenia
heparin history patients HIT thrombosis HITT
heparin history patients HIT thrombosis
heparin history patients thrombocytopenia
heparin history patients thrombocytopenia HIT
heparin history patients HIT
argatroban administered year history HITT
argatroban administered year old patient critically
argatroban administered year old patient ill
argatroban concentrations measured RESULTS observed published minutes -RSB- hepatic
argatroban concentrations measured RESULTS observed published minutes -RSB- impairment
argatroban minutes measured RESULTS observed published minutes -RSB- hepatic
argatroban minutes measured RESULTS observed published minutes -RSB- impairment
argatroban concentration Correlation suggest contributed coagulopathy
argatroban levels contributed coagulopathy
argatroban concentration measure report extended coagulopathy
K Na cardiac affinities Changes ATPase hypertension
sodium affinities Changes ATPase hypertension
Na cardiac affinities Changes ATPase hypertension
ATP sodium affinities Changes ATPase hypertension
sodium level elevation documented models hypertension
K Na cardiac response induced hypertension
Na + transport disturbances basis assess studied response induced hypertension
Na cardiac response induced hypertension
N inhibition response induced hypertension
G N inhibition response induced hypertension
nitro response induced hypertension
L nitro response induced hypertension
arginine ester response induced hypertension
methyl ester response induced hypertension
ester response induced hypertension
L ester response induced hypertension
NAME L ester response induced hypertension
K Na ATPase activity increased recovery hypertension
Na ATPase activity increased recovery hypertension
ATP affinity due increased recovery hypertension
ATP value revealed site increased recovery hypertension
NO Inhibition synthase induced hypertension accompanied + depressed
K Na properties hypertension
K Na properties hypertension accompanied + depressed
Na + accompanied hypertension
Na + consequence cells extrusion hypertension
Na properties hypertension
Na + depressed
Na + consequence cells extrusion hypertension accompanied + depressed
Na properties hypertension accompanied + depressed
amiodarone treatment tachycardia atrial
amiodarone treatment tachycardia
amiodarone treatment occurring abnormalities intraventricular
amiodarone treatment occurring abnormalities conduction
amiodarone treatment occurring abnormalities
amiodarone discontinuation days showed flutter atrial
amiodarone discontinuation days showed flutter
modafinil effect sleepiness daytime
modafinil effect sleepiness
Modafinil associated latency decrease sleepiness daytime
Modafinil associated latency decrease sleepiness
modafinil promotes decreases sleepiness daytime
modafinil promotes decreases sleepiness
cocaine use associated Stroke
cocaine use related stroke
cocaine use followed Stroke
cocaine use related incidence increasing indicate exceeds stroke frequency hemorrhage intracranial
cocaine use related incidence increasing indicate exceeds stroke frequency hemorrhage
cocaine - indicate exceeds stroke frequency hemorrhage intracranial
cocaine - indicate exceeds stroke frequency hemorrhage
cocaine administration route follow indicate exceeds stroke frequency hemorrhage intracranial
cocaine administration route follow indicate exceeds stroke frequency hemorrhage
cocaine use associated indicate exceeds stroke frequency hemorrhage intracranial
cocaine use associated indicate exceeds stroke frequency hemorrhage
cocaine 5 stroke frequency hemorrhage intracranial
cocaine 5 stroke frequency hemorrhage
cocaine use related incidence stroke
cocaine use related incidence increasing indicate - occurs stroke
cocaine use related incidence increasing indicate follow stroke
cocaine use related incidence increasing indicate associated stroke
cocaine use related incidence increasing indicate exceeds stroke
cocaine - indicate increasing incidence stroke
cocaine - occurs stroke
cocaine - indicate follow stroke
cocaine - indicate associated stroke
cocaine - indicate exceeds stroke
cocaine administration route follow indicate increasing incidence stroke
cocaine administration route follow indicate - occurs stroke
cocaine administration route follow stroke
cocaine administration route follow indicate associated stroke
cocaine administration route follow indicate exceeds stroke
cocaine use associated indicate increasing incidence stroke
cocaine use associated indicate - occurs stroke
cocaine use associated indicate follow stroke
cocaine use associated stroke
cocaine use associated indicate exceeds stroke
cocaine 5 stroke exceeds indicate increasing incidence stroke
cocaine 5 stroke exceeds indicate - occurs stroke
cocaine 5 stroke exceeds indicate follow stroke
cocaine 5 stroke exceeds indicate associated stroke
cocaine 5 stroke
cocaine use related incidence increasing indicate associated aneurysms intracranial
cocaine use related incidence increasing indicate associated aneurysms
cocaine - indicate associated aneurysms intracranial
cocaine - indicate associated aneurysms
cocaine administration route follow indicate associated aneurysms intracranial
cocaine administration route follow indicate associated aneurysms
cocaine use associated aneurysms intracranial
cocaine use associated aneurysms
cocaine 5 stroke exceeds indicate associated aneurysms intracranial
cocaine 5 stroke exceeds indicate associated aneurysms
cocaine use related incidence increasing indicate associated arteriovenous
cocaine use related incidence increasing indicate associated arteriovenous malformations
cocaine - indicate associated arteriovenous
cocaine - indicate associated arteriovenous malformations
cocaine administration route follow indicate associated arteriovenous
cocaine administration route follow indicate associated arteriovenous malformations
cocaine use associated arteriovenous
cocaine use associated arteriovenous malformations
cocaine 5 stroke exceeds indicate associated arteriovenous
cocaine 5 stroke exceeds indicate associated arteriovenous malformations
99 mTc induced infarction myocardial
99 mTc induced infarction
mTc induced infarction myocardial
mTc induced infarction
glucarate detection mTc induced infarction myocardial
glucarate detection mTc induced infarction
isoproterenol obtained implies model used produce infarction
glucaric acid based radiopharmaceutical infarct
acid based radiopharmaceutical infarct
99 mTc induced infarction myocardial
99 mTc induced infarction
mTc induced infarction myocardial
mTc induced infarction
glucarate easy mTc induced infarction myocardial
glucarate easy mTc induced infarction
isoproterenol administration developed h infarct
bromocriptine treatment prolactinomas
bromocriptine effects clarify cells prolactinoma
bromocriptine effects clarify applied induced h cells prolactinoma
bromocriptine injection applied clarify cells prolactinoma
bromocriptine injection applied induced h cells prolactinoma
bromocriptine treatment cells adenoma
venlafaxine overdose took woman depression major
venlafaxine overdose took woman depression
Ketoconazole induced sequelae neurologic
Ketoconazole induced sequelae
gum Arabic nephrotoxicity
Arabic nephrotoxicity
gentamicin nephrotoxicity
gum rats treatment effect assessed Arabic failure induced gentamicin nephrotoxicity
Arabic failure induced gentamicin nephrotoxicity
gentamicin nephrotoxicity
GM gentamicin nephrotoxicity
glutathione plasma measuring assessed Nephrotoxicity
GSH glutathione plasma measuring assessed Nephrotoxicity
urea creatinine concentrations measuring assessed Nephrotoxicity
creatinine concentrations measuring assessed Nephrotoxicity
GSH that decreased % GM necrosis tubular
GSH that decreased % GM necrosis
urea creatinine increased gum indicated decreased % GM necrosis tubular
urea creatinine increased gum indicated decreased % GM necrosis
GM Arabic increased gum indicated decreased % GM necrosis tubular
GM Arabic increased gum indicated decreased % GM necrosis
GM cellulose treated rats compared gum indicated decreased % GM necrosis tubular
GM cellulose treated rats compared gum indicated decreased % GM necrosis
GM cellulose group % % GM necrosis tubular
GM cellulose group % % GM necrosis
GM necrosis tubular
GM necrosis
GM given rats severe appeared necrosis tubular
GM given rats severe appeared necrosis
GM than severe appeared necrosis tubular
GM than severe appeared necrosis
creatinine increased gum indicated decreased % GM necrosis tubular
creatinine increased gum indicated decreased % GM necrosis
gum indicated decreased % GM necrosis tubular
gum indicated decreased % GM necrosis
Arabic increased gum indicated decreased % GM necrosis tubular
Arabic increased gum indicated decreased % GM necrosis
gum Arabic given rats severe appeared necrosis tubular
gum Arabic given rats severe appeared necrosis
Arabic given rats severe appeared necrosis tubular
Arabic given rats severe appeared necrosis
gum treatment induced nephrotoxicity
Arabic treatment induced nephrotoxicity
GM indices some amelioration induced nephrotoxicity
everolimus associated neuritis brachial
everolimus associated neuritis
aminophylline threshold initiating failure respiratory
aminophylline threshold initiating failure
aminophylline threshold threshold failure respiratory
aminophylline threshold threshold failure
PO oxygen pressures kept reduced threshold ventricular
PO oxygen pressures kept reduced threshold fibrillation
2 PO oxygen pressures kept reduced threshold ventricular
2 PO oxygen pressures kept reduced threshold fibrillation
carbon dioxide oxygen pressures kept reduced threshold ventricular
carbon dioxide oxygen pressures kept reduced threshold fibrillation
dioxide oxygen pressures kept reduced threshold ventricular
dioxide oxygen pressures kept reduced threshold fibrillation
CO 2 oxygen pressures kept reduced threshold ventricular
CO 2 oxygen pressures kept reduced threshold fibrillation
2 oxygen pressures kept reduced threshold ventricular
2 oxygen pressures kept reduced threshold fibrillation
oxygen pressures kept reduced threshold ventricular
oxygen pressures kept reduced threshold fibrillation
aminophylline infusion resulted produced failure respiratory
aminophylline infusion resulted produced failure
aminophylline infusion resulted produced hypoventilation
aminophylline agents play contribute incidence arrhythmias failure respiratory
aminophylline agents play contribute incidence arrhythmias failure
aminophylline agents play contribute incidence arrhythmias ventricular
aminophylline agents play contribute incidence arrhythmias
tranexamic acid containing sealants application seizures Epileptic
tranexamic acid containing sealants application seizures
acid containing sealants application seizures Epileptic
acid containing sealants application seizures
tAMCA shown cause seizures epileptic
tAMCA shown cause seizures
octreotide analog function patients acromegalic
octreotide day 2 13 somatostatin injection treated acromegaly
octreotide therapy cholecystitis
octreotide therapy patients acromegalic
octreotide therapy patients acromegalic
timolol 0 treated glaucomatous
betaxolol less depression
Triazolam induced patient depressed
triazolam doses induced woman depressed
atropine glycopyrrolate i Comparison bradycardia
suxamethonium doses Comparison bradycardia arrhythmias
glycopyrrolate i Comparison bradycardia arrhythmias
atropine glycopyrrolate i Comparison bradycardia arrhythmias
glycopyrrolate i Comparison bradycardia
atropine 1 administration effectiveness micrograms studied prevent arrhythmia bradycardia
suxamethonium doses arrhythmia
glycopyrrolate kg administration effectiveness micrograms studied prevent arrhythmia
atropine 1 administration effectiveness micrograms studied prevent arrhythmia
glycopyrrolate kg administration effectiveness micrograms studied prevent arrhythmia bradycardia
phenytoin treatment due psychosis Acute
phenytoin treatment due psychosis
phenytoin treatment neuralgia trigeminal
phenytoin treatment neuralgia
phenytoin treatment psychosis
phenytoin treatment occur symptoms result unrelated seizures
phenytoin treatment patients epileptic
phenytoin treatment occur symptoms psychotic
phenytoin treatment occur symptoms
sulpiride reported dyskinesia parkinsonism
sulpiride reported dyskinesia tardive
sulpiride reported dyskinesia
chloroacetaldehyde metabolite indicating carried elucidate development cystitis hemorrhagic
chloroacetaldehyde metabolite indicating carried elucidate development cystitis
CAA chloroacetaldehyde metabolite indicating carried elucidate development cystitis hemorrhagic
CAA chloroacetaldehyde metabolite indicating carried elucidate development cystitis
CAA role elucidate development cystitis hemorrhagic
CAA role elucidate development cystitis
CAA contribute damage bladder
CAA contribute damage
methotrexate nitrogranulogen drugs action nephrotoxic
MTX methotrexate nitrogranulogen drugs action nephrotoxic
MTX + or administered action nephrotoxic
cyclophosphamide nitrogranulogen drugs action nephrotoxic
CY cyclophosphamide nitrogranulogen drugs action nephrotoxic
CY -RSB- evaluated action nephrotoxic
nitrogranulogen drugs action nephrotoxic
NG nitrogranulogen drugs action nephrotoxic
5 nitrogranulogen drugs action nephrotoxic
fluorouracil 5 nitrogranulogen drugs action nephrotoxic
5 fluorouracil 5 nitrogranulogen drugs action nephrotoxic
FU 5 fluorouracil 5 nitrogranulogen drugs action nephrotoxic
5 + or administered action nephrotoxic
FU -RSB- evaluated action nephrotoxic
5 combined cause caused cystitis hemorrhagic
5 combined cause caused cystitis
FU 5 combined cause caused cystitis hemorrhagic
FU 5 combined cause caused cystitis
MTX FU 5 combined cause caused cystitis hemorrhagic
MTX FU 5 combined cause caused cystitis
CY caused cystitis hemorrhagic
CY caused cystitis
MTX + nephrotoxicity
CY monotherapy indicate nephrotoxicity
5 + nephrotoxicity
FU CY monotherapy indicate nephrotoxicity
amphotericin B coccidioidomycosis
B coccidioidomycosis
AmB B coccidioidomycosis
posaconazole resolved abnormalities failure heart
posaconazole resolved abnormalities failure
AmB toxicity
oxygen increase result infarction acute
oxygen increase result infarction myocardial
oxygen increase result infarction
cocaine locus remains circumstantial regard spasm
cocaine effect thrombotic
calcium blocker discontinuation showed patients signs neurotoxicity
methylphenidate intake reported stroke ischaemic
methylphenidate intake reported stroke
methylphenidate intake reported documented vasculitis associated abuse amphetamine
methylphenidate intake reported documented vasculitis associated abuse
methylphenidate treated suffered strokes ischaemic
methylphenidate treated suffered strokes
methylphenidate hyperactivity
methylphenidate vasculitis
methylphenidate therapy history patients considered vasculitis
Antithymocyte globulin induced anemia aplastic
Antithymocyte globulin induced anemia
globulin induced anemia aplastic
globulin induced anemia
antithymocyte therapy anemia aplastic
antithymocyte therapy anemia
globulin therapy anemia aplastic
globulin therapy anemia
antithymocyte globulin Use treatment D induced anemia aplastic
antithymocyte globulin Use treatment D induced anemia
globulin Use treatment D induced anemia aplastic
globulin Use treatment D induced anemia
adriamycin Effect induced nephropathy
enalapril effect assessed Munich rats nephrosis
enalapril reduced reducing albuminuria
enalapril effect assess progression injury renal
enalapril effect assess progression injury
enalapril effect assess nephrosis
adriamycin nephrosis assess progression injury renal
adriamycin nephrosis assess progression injury
enalapril treatment reduced reducing albuminuria
sulphasalazine arthritis rheumatoid
sulphasalazine arthritis
levodopa dyskinesias monkeys parkinsonian
Levodopa induced present problem patients long management disease Parkinson
Levodopa induced present problem patients long management disease Parkinson '
Levodopa induced present problem patients long management disease s
Levodopa induced present problem patients long management disease
Levodopa induced present problem patients long management disease PD
MPTP types Using parkinsonism study evaluated degree involved development LIDs
levodopa therapy duration progression rate involved degree evaluated study parkinsonism
MPTP exposure Monkeys developed dyskinesia
MPTP exposure monkeys resistant LIDs
MPTP exposure monkeys resistant LIDs e developed dyskinesia
Dipyridamole induced ischemia myocardial
Dipyridamole induced ischemia
dipyridamole therapy effect reported demonstrated occur disease coronary
dipyridamole therapy effect reported demonstrated occur disease artery
dipyridamole therapy effect reported demonstrated occur disease
dipyridamole demonstrated occur disease coronary
dipyridamole demonstrated occur disease artery
dipyridamole demonstrated occur disease
dipyridamole therapy effect reported demonstrated dipyridamole ischemia myocardial
dipyridamole therapy effect reported demonstrated dipyridamole ischemia
dipyridamole ischemia myocardial
dipyridamole ischemia
dipyridamole mechanism demonstrated observed ischemia
levodopa effect reflect incidence haemorrhage cause death
noradrenaline levels reflect incidence haemorrhage cause death patients disease Parkinson
noradrenaline levels reflect incidence haemorrhage cause death patients disease Parkinson '
noradrenaline levels reflect incidence haemorrhage cause death patients disease s
noradrenaline levels reflect incidence haemorrhage cause death patients disease
noradrenaline levels brain parkinsonian
levodopa effect reflect incidence haemorrhage cause death patients disease Parkinson
levodopa effect reflect incidence haemorrhage cause death patients disease Parkinson '
levodopa effect reflect incidence haemorrhage cause death patients disease s
levodopa effect reflect incidence haemorrhage cause death patients disease
levodopa effect reflect levels brain parkinsonian
noradrenaline levels reflect effect hypotensive
noradrenaline levels reflect effect levodopa mechanism hypotensive
noradrenaline levels reflect incidence haemorrhage cause death
levodopa effect reflect incidence haemorrhage cerebral
levodopa effect reflect incidence haemorrhage
noradrenaline levels reflect incidence haemorrhage cerebral
noradrenaline levels reflect incidence haemorrhage
adriamycin Effect combined tissues tumor
adriamycin Effect combined hyperthermia
Adriamycin enhancement mediated activity toxicities
Adriamycin enhancement mediated hyperthermia
Adriamycin enhanced hyperthermia
Adriamycin enhances increased toxicity
Adriamycin enhances hyperthermia
riboflavin thiamine deficiency nutritional
riboflavin thiamine deficiency
thiamine deficiency nutritional
thiamine deficiency
Isoniazid agent neuropathy
Vitamin D toxicity
D toxicity
3 toxicity
vitamin D treated cows None showed signs fever milk
vitamin D treated cows None showed signs fever
D treated cows None showed signs fever milk
D treated cows None showed signs fever
3 D treated cows None showed signs fever milk
3 D treated cows None showed signs fever
vitamin D treated cows None showed developed signs fever milk
vitamin D treated cows None showed developed signs fever
D treated cows None showed developed signs fever milk
D treated cows None showed developed signs fever
3 D treated cows None showed developed signs fever milk
3 D treated cows None showed developed signs fever
vitamin toxicity
D toxicity
3 toxicity
vitamin toxicity Signs observed developed died signs D toxicity
D toxicity Signs observed developed died signs D toxicity
3 toxicity Signs observed developed died signs D toxicity
vitamin D signs died developed observed Signs toxicity
D signs died developed observed Signs toxicity
3 toxicity D signs died developed observed Signs toxicity
vitamin D toxicity
D toxicity
3 toxicity
vitamin toxicity
D toxicity
3 D toxicity
vitamin D doses safety margin cows D toxicity
D doses safety margin cows D toxicity
3 D doses safety margin cows D toxicity
vitamin cannot used concluded D toxicity
D cannot used concluded D toxicity
3 cannot used concluded D toxicity
vitamin toxicity D cows margin prevent fever milk
vitamin toxicity D cows margin prevent fever
D cows margin prevent fever milk
D cows margin prevent fever
3 D cows margin prevent fever milk
3 D cows margin prevent fever
vitamin toxicity D doses induce fever milk
vitamin toxicity D doses induce fever
D doses induce fever milk
D doses induce fever
3 D doses induce fever milk
3 D doses induce fever
vitamin toxicity D concluded used prevent fever milk
vitamin toxicity D concluded used prevent fever
D concluded used prevent fever milk
D concluded used prevent fever
3 D concluded used prevent fever milk
3 D concluded used prevent fever
vitamin D doses safety margin prevent fever milk
vitamin D doses safety margin prevent fever
D doses safety margin prevent fever milk
D doses safety margin prevent fever
3 D doses safety margin prevent fever milk
3 D doses safety margin prevent fever
vitamin D doses safety margin cows D doses induce fever milk
vitamin D doses safety margin cows D doses induce fever
D doses safety margin cows D doses induce fever milk
D doses safety margin cows D doses induce fever
3 D doses safety margin cows D doses induce fever milk
3 D doses safety margin cows D doses induce fever
vitamin D doses safety margin cows D concluded used prevent fever milk
vitamin D doses safety margin cows D concluded used prevent fever
D doses safety margin cows D concluded used prevent fever milk
D doses safety margin cows D concluded used prevent fever
3 D doses safety margin cows D concluded used prevent fever milk
3 D doses safety margin cows D concluded used prevent fever
vitamin cannot used concluded D cows margin prevent fever milk
vitamin cannot used concluded D cows margin prevent fever
D cannot used concluded D cows margin prevent fever milk
D cannot used concluded D cows margin prevent fever
3 cannot used concluded D cows margin prevent fever milk
3 cannot used concluded D cows margin prevent fever
vitamin cannot used concluded D doses induce fever milk
vitamin cannot used concluded D doses induce fever
D cannot used concluded D doses induce fever milk
D cannot used concluded D doses induce fever
3 cannot used concluded D doses induce fever milk
3 cannot used concluded D doses induce fever
vitamin cannot used prevent fever milk
vitamin cannot used prevent fever
D cannot used prevent fever milk
D cannot used prevent fever
3 cannot used prevent fever milk
3 cannot used prevent fever
atropine administration Pro pre abolished increases
atropine administration Pro pre abolished increases flow in
atropine administration Pro pre abolished increases flow dural
atropine administration Pro pre abolished increases flow blood
atropine administration Pro pre abolished increases flow
thyroxine abuse considered reminds illustrates derangements function seen eating
thyroxine abuse considered reminds illustrates derangements function seen eating disorders
ketoconazole treatment associated deaths
bradykinin receptors activation Role barrier hypertension
bradykinin release role barrier hypertension
Hoe vehicle treated rats induced hypertension
140 microM vehicle treated rats induced hypertension
dextran labeled quantitated induced hypertension
bradykinin release related barrier hypertension
ketoconazole taking developed disease coronary
ketoconazole taking developed disease artery
ketoconazole taking developed disease
ketoconazole taking treatment infection fungal
ketoconazole taking treatment infection
phenylephrine Reversal patients infarction acute
phenylephrine Reversal patients infarction myocardial
phenylephrine Reversal patients infarction
nitroglycerin effects phenylephrine Reversal patients infarction acute
nitroglycerin effects phenylephrine Reversal patients infarction myocardial
nitroglycerin effects phenylephrine Reversal patients infarction
Nitroglycerin shown reduce ST elevation infarction acute
Nitroglycerin shown reduce ST elevation infarction myocardial
Nitroglycerin shown reduce ST elevation infarction
nitroglycerin reverse agents potentiated elevation infarction acute
nitroglycerin reverse agents potentiated elevation infarction myocardial
nitroglycerin reverse agents potentiated elevation infarction
nitroglycerin received patients infarctions myocardial
nitroglycerin received patients infarctions
phenylephrine addition beneficial treatment patients infarction acute
phenylephrine addition beneficial treatment patients infarction myocardial
phenylephrine addition beneficial treatment patients infarction
nitroglycerin phenylephrine addition beneficial treatment patients infarction acute
nitroglycerin phenylephrine addition beneficial treatment patients infarction myocardial
nitroglycerin phenylephrine addition beneficial treatment patients infarction
zidovudine toxicity
vitamin B role supplementation preventing toxicity
B role supplementation preventing toxicity
12 B role supplementation preventing toxicity
folinic supplementation preventing toxicity
acid supplementation preventing toxicity
folinic supplementation preventing zidovudine suppression bone
folinic supplementation preventing zidovudine suppression marrow
folinic supplementation preventing zidovudine suppression
acid supplementation preventing zidovudine suppression bone
acid supplementation preventing zidovudine suppression marrow
acid supplementation preventing zidovudine suppression
vitamin B role supplementation preventing zidovudine suppression bone
vitamin B role supplementation preventing zidovudine suppression marrow
vitamin B role supplementation preventing zidovudine suppression
B role supplementation preventing zidovudine suppression bone
B role supplementation preventing zidovudine suppression marrow
B role supplementation preventing zidovudine suppression
12 B role supplementation preventing zidovudine suppression bone
12 B role supplementation preventing zidovudine suppression marrow
12 B role supplementation preventing zidovudine suppression
folinic acid combination randomized 500 counts virus human
folinic acid combination randomized 500 counts virus immunodeficiency
folinic acid combination randomized 500 counts virus
folinic acid combination randomized 500 counts virus HIV
folinic acid combination randomized 500 counts patients infected
acid combination randomized 500 counts virus human
acid combination randomized 500 counts virus immunodeficiency
acid combination randomized 500 counts virus
acid combination randomized 500 counts virus HIV
acid combination randomized 500 counts patients infected
ZDV receive randomized 500 counts virus human
ZDV receive randomized 500 counts virus immunodeficiency
ZDV receive randomized 500 counts virus
ZDV receive randomized 500 counts virus HIV
ZDV receive randomized 500 counts patients infected
vitamin acid combination randomized 500 counts virus human
vitamin acid combination randomized 500 counts virus immunodeficiency
vitamin acid combination randomized 500 counts virus
vitamin acid combination randomized 500 counts virus HIV
vitamin acid combination randomized 500 counts patients infected
B counts virus human
B counts virus immunodeficiency
B counts virus
B counts virus HIV
B counts patients infected
12 B counts virus human
12 B counts virus immunodeficiency
12 B counts virus
12 B counts virus HIV
12 B counts patients infected
folate levels myelosuppression
vitamin B correlation levels myelosuppression
B correlation levels myelosuppression
12 B correlation levels myelosuppression
folinic supplementation 12 seem B induced myelotoxicity
acid supplementation 12 seem B induced myelotoxicity
Vitamin B induced myelotoxicity
B induced myelotoxicity
12 seem B induced myelotoxicity
phenytoin patients epileptic
phenytoin medication atrophy cerebellar
phenytoin medication atrophy
phenytoin levels elevation duration seizure
phenytoin overdosage result atrophy cerebellar
phenytoin overdosage result atrophy
phenytoin overdosage result conclude unlikely cause atrophy cerebellar
phenytoin overdosage result conclude unlikely cause atrophy
phenytoin medication cause unlikely conclude result atrophy cerebellar
phenytoin medication cause unlikely conclude result atrophy
phenytoin medication cause atrophy cerebellar
phenytoin medication cause atrophy
capsaicin intensity pain
capsaicin attention affected ratings pain
capsaicin treatment interaction suggest showing affect pain
capsaicin suggest showing affect pain
sirolmus lacks effects nephrotoxic
Srl sirolmus lacks effects nephrotoxic
Srl associated proteinuria reported lacks effects nephrotoxic
angiotensin inhibitor blocker reduced development proteinuria
releasing blocker reduced development proteinuria
blocker reduced development proteinuria
ARB blocker reduced development proteinuria
ACE inhibitor blocker reduced development proteinuria
inhibitor blocker reduced development proteinuria
Srl used monitored proteinuria dysfunction renal
Srl used monitored proteinuria dysfunction
ARB therapy used monitored proteinuria
ARB therapy used monitored proteinuria dysfunction renal
ARB therapy used monitored proteinuria dysfunction
ACEi therapy used monitored proteinuria
ACEi therapy used monitored proteinuria dysfunction renal
ACEi therapy used monitored proteinuria dysfunction
PG 9 able prevent amnesia
9 able prevent amnesia
PG profiles Affinity 2 effect amnesic
9 shown PG profiles Affinity 2 effect amnesic
PG 2 effect amnesic
9 PG 2 effect amnesic
acetylcholine levels increase 9 PG 2 effect amnesic
Sch mg exceeded was stimulation tetanic
co treatment pneumonia Pneumocystis
co treatment pneumonia
trimoxazole treatment pneumonia Pneumocystis
trimoxazole treatment pneumonia
co lasting cholestasis
trimoxazole treatment co lasting cholestasis
co treatment pneumonia HIV
co patients infected
trimoxazole treatment pneumonia HIV
trimoxazole treatment co patients infected
co doses treated pneumonia Pneumocystis
co doses treated pneumonia
trimoxazole doses treated pneumonia Pneumocystis
trimoxazole doses treated pneumonia
co doses treated pneumonia PCP
trimoxazole doses treated pneumonia PCP
co doses treated pneumonia infection opportunistic
co doses treated pneumonia infection
trimoxazole doses treated pneumonia infection opportunistic
trimoxazole doses treated pneumonia infection
co doses treated pneumonia infection HIV
co doses treated pneumonia infection individuals infected
trimoxazole doses treated pneumonia infection HIV
trimoxazole doses treated pneumonia infection individuals infected
co exams formation treatment PCP
trimoxazole treatment PCP
co exams formation liver
co exams formation abscess
trimoxazole treatment formation liver
trimoxazole treatment formation abscess
co exams formation cases HIV
co exams formation cases patients infected
trimoxazole treatment formation cases HIV
trimoxazole treatment formation cases patients infected
sodium channel subunit syndrome nephrotic
sodium channel subunit syndrome
sodium excretion decreased syndrome nephrotic
sodium excretion decreased syndrome
aldosterone concentration excretion proteinuria
sodium excretion proteinuria
sodium excretion appearance proteinuria
aldosterone escape appears increased phase syndrome nephrotic
aldosterone escape appears increased phase syndrome
Sirolimus agent used have nephrotoxicity
creatinine ratios samples assessed magnitude proteinuria
creatinine ratios samples estimate grams proteinuria
sirolimus initiation development nephrotic
nifedipine receiving patients hypertensive
nifedipine receiving comprising other patients hypertensive
nifedipine reducing nephrotoxicity
tacrolimus associated nephrotoxicity
nifedipine recipients impact factor selecting agent treat hypertension
fluoxetine receiving treatment disorder depression major
fluoxetine receiving treatment disorder depression
fluoxetine receiving treatment disorder obsessive
fluoxetine receiving treatment disorder compulsive
fluoxetine receiving treatment disorder
fluoxetine purposeless indistinguishable anxiety
propranolol beta responded appeared Akathisia
antidepressant akathisia jitteriness pathophysiology identical caused fluoxetine akathisia
antidepressant akathisia
verapamil ablation induced syndrome patient White Wolff
verapamil ablation induced syndrome patient White Parkinson
verapamil ablation induced syndrome patient White
verapamil ablation induced syndrome
verapamil ablation induced syndrome cardiomyopathy idiopathic
verapamil ablation induced syndrome cardiomyopathy dilated
verapamil ablation induced syndrome cardiomyopathy
Sodium alleviates penile pain induced injections dysfunction erectile
Sodium alleviates penile pain induced injections dysfunction
bicarbonate alleviates penile pain induced injections dysfunction erectile
bicarbonate alleviates penile pain induced injections dysfunction
Sodium alleviates penile
Sodium alleviates penile pain
bicarbonate alleviates penile
bicarbonate alleviates penile pain
sodium bicarbonate addition performed attempt determine due pain penile
sodium bicarbonate addition performed attempt determine due pain
bicarbonate addition performed attempt determine due pain penile
bicarbonate addition performed attempt determine due pain
sodium bicarbonate addition performed study comparing incidence pain penile
sodium bicarbonate addition performed study comparing incidence pain
bicarbonate addition performed study comparing incidence pain penile
bicarbonate addition performed study comparing incidence pain
papaverine total patients presented received clinic impotence
sodium bicarbonate patients complained pain penile
sodium bicarbonate patients complained pain
bicarbonate patients complained pain penile
bicarbonate patients complained pain
sodium bicarbonate patients complained complained pain penile
sodium bicarbonate patients complained complained pain
bicarbonate patients complained complained pain penile
bicarbonate patients complained complained pain
sodium bicarbonate received men 1 complained complained pain penile
sodium bicarbonate received men 1 complained complained pain
bicarbonate received men 1 complained complained pain penile
bicarbonate received men 1 complained complained pain
sodium bicarbonate received men 1 complained pain penile
sodium bicarbonate received men 1 complained pain
bicarbonate received men 1 complained pain penile
bicarbonate received men 1 complained pain
prochlorperazine headache nausea
prochlorperazine headache
prochlorperazine headache vomiting
prochlorperazine treatment headache nausea
prochlorperazine treatment headache
vinorelbine Gemcitabine patients nonsmall
vinorelbine Gemcitabine patients cell
vinorelbine Gemcitabine patients lung
vinorelbine Gemcitabine patients carcinoma
Gemcitabine patients nonsmall
Gemcitabine patients cell
Gemcitabine patients lung
Gemcitabine patients carcinoma
cisplatin receive cannot patients years age Gemcitabine patients nonsmall
cisplatin receive cannot patients years age Gemcitabine patients cell
cisplatin receive cannot patients years age Gemcitabine patients lung
cisplatin receive cannot patients years age Gemcitabine patients carcinoma
gemcitabine vinorelbine therapy obtain rate toxicity
GEM vinorelbine therapy obtain rate toxicity
vinorelbine therapy obtain rate toxicity
VNB vinorelbine therapy obtain rate toxicity
GEM combination efficacy toxicity
VNB GEM combination efficacy toxicity
VNB GEM combination patients NSCLC
GEM combination patients NSCLC
cisplatin contraindication those combination efficacy toxicity
cisplatin contraindication those combination patients NSCLC
cisplatin receiving contraindication had age included patients NSCLC
H O CPAP produced increased rate output decreased
H O CPAP produced increased rate output cardiac
H O CPAP produced increased rate output
2 O CPAP produced increased rate output decreased
2 O CPAP produced increased rate output cardiac
2 O CPAP produced increased rate output
O CPAP produced increased rate output decreased
O CPAP produced increased rate output cardiac
O CPAP produced increased rate output
nitroprusside infusion produced increased rate output decreased
nitroprusside infusion produced increased rate output cardiac
nitroprusside infusion produced increased rate output
H O CPAP produced decrease
H O CPAP produced pressure in
H O CPAP produced pressure arterial
H O CPAP produced pressure blood
H O CPAP produced pressure
2 O CPAP produced decrease
2 O CPAP produced pressure in
2 O CPAP produced pressure arterial
2 O CPAP produced pressure blood
2 O CPAP produced pressure
O CPAP produced decrease
O CPAP produced pressure in
O CPAP produced pressure arterial
O CPAP produced pressure blood
O CPAP produced pressure
H O 10 levels produce decreases
H O 10 levels produce pressure in
H O 10 levels produce pressure arterial
H O 10 levels produce pressure blood
H O 10 levels produce pressure
H O 10 levels produce pressure and
H O 10 levels produce pressure output cardiac
H O 10 levels produce pressure output
2 O 10 levels produce decreases
2 O 10 levels produce pressure in
2 O 10 levels produce pressure arterial
2 O 10 levels produce pressure blood
2 O 10 levels produce pressure
2 O 10 levels produce pressure and
2 O 10 levels produce pressure output cardiac
2 O 10 levels produce pressure output
O 10 levels produce decreases
O 10 levels produce pressure in
O 10 levels produce pressure arterial
O 10 levels produce pressure blood
O 10 levels produce pressure
O 10 levels produce pressure and
O 10 levels produce pressure output cardiac
O 10 levels produce pressure output
nitroprusside infusion alter produce decreases
nitroprusside infusion alter produce pressure in
nitroprusside infusion alter produce pressure arterial
nitroprusside infusion alter produce pressure blood
nitroprusside infusion alter produce pressure
nitroprusside infusion alter produce pressure and
nitroprusside infusion alter produce pressure output cardiac
nitroprusside infusion alter produce pressure output
ribavirin effect patients fever Argentine
ribavirin effect patients fever hemorrhagic
ribavirin effect patients fever
ribavirin effect studied patients fever Argentine
ribavirin effect studied patients fever hemorrhagic
ribavirin effect studied patients fever
ribavirin effect studied patients fever AHF
ribavirin Administration resulted neutralization viremia
ribavirin has effect cases AHF
ribavirin days AHF
bupropion dysfunction sexual
bupropion dysfunction
selective serotonin induced dysfunction sexual
selective serotonin induced dysfunction
serotonin induced dysfunction sexual
serotonin induced dysfunction
reuptake effects bupropion dysfunction sexual
reuptake effects bupropion dysfunction
inhibitor reuptake effects bupropion dysfunction sexual
inhibitor reuptake effects bupropion dysfunction
bupropion release dysfunction sexual
bupropion release dysfunction
bupropion release dysfunction SD
bupropion release dysfunction induced side SD
selective inhibitor induced dysfunction sexual
selective inhibitor induced dysfunction
serotonin inhibitor induced dysfunction sexual
serotonin inhibitor induced dysfunction
reuptake inhibitor induced dysfunction sexual
reuptake inhibitor induced dysfunction
inhibitor induced dysfunction sexual
inhibitor induced dysfunction
selective inhibitor induced dysfunction SD
serotonin inhibitor induced dysfunction SD
reuptake inhibitor induced dysfunction SD
inhibitor induced dysfunction SD
selective inhibitor induced side SD
serotonin inhibitor induced side SD
reuptake inhibitor induced side SD
inhibitor induced side SD
SSRI inhibitor induced dysfunction sexual
SSRI inhibitor induced dysfunction
SSRI inhibitor induced dysfunction SD
SSRI inhibitor induced side SD
SSRIs effect bupropion release dysfunction sexual
SSRIs effect bupropion release dysfunction
SSRIs effect bupropion release dysfunction SD
SSRIs effect bupropion release dysfunction induced side SD
SSRI type used affected duration SD
Bupropion treatment SD
SSRIs induced SD
acetylcholine release seizure
acetylcholine release relationship seizure
alcohol examined sensitivity METHODS Prone ve Seizure
carbachol nicotine administered recorded latencies onset tremor
neostigmine nicotine administered recorded latencies onset tremor
nicotine administered recorded latencies onset tremor
ACh measured testing handling convulsions
ACh measured testing handling convulsions
ACh elevated measured testing handling convulsions
ethanol severity associated differences activity convulsants
alcohol withdrawal implicate associated differences activity convulsants
bleomycin cisplatin treatment alkaloid developed microangiopathy thrombotic
bleomycin cisplatin treatment alkaloid developed microangiopathy
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia
alkaloid developed characterized insufficiency anemia microangiopathic
alkaloid developed characterized insufficiency anemia hemolytic
alkaloid developed characterized insufficiency anemia
vinca cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
alkaloid developed characterized insufficiency thrombocytopenia
bleomycin cisplatin treatment alkaloid developed characterized insufficiency renal
bleomycin cisplatin treatment alkaloid developed characterized insufficiency
vinca cisplatin treatment alkaloid developed microangiopathy thrombotic
vinca cisplatin treatment alkaloid developed microangiopathy
alkaloid developed microangiopathy thrombotic
alkaloid developed microangiopathy
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia
bleomycin cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
cisplatin treatment alkaloid developed microangiopathy thrombotic
cisplatin treatment alkaloid developed microangiopathy
cisplatin treatment alkaloid developed characterized insufficiency renal
cisplatin treatment alkaloid developed characterized insufficiency
vinca cisplatin treatment alkaloid developed characterized insufficiency renal
vinca cisplatin treatment alkaloid developed characterized insufficiency
alkaloid developed characterized insufficiency renal
alkaloid developed characterized insufficiency
bleomycin cisplatin treatment alkaloid developed patients carcinoma
vinca cisplatin treatment alkaloid developed patients carcinoma
alkaloid developed patients carcinoma
cisplatin treatment alkaloid developed patients carcinoma
cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
cisplatin treatment alkaloid developed characterized insufficiency anemia
cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
cisplatin nephrotoxicity ascribed examined suppression bone
cisplatin nephrotoxicity ascribed examined suppression marrow
cisplatin nephrotoxicity ascribed examined suppression
cisplatin nephrotoxicity anemia
cisplatin nephrotoxicity ascribed failure renal
cisplatin nephrotoxicity ascribed failure
cisplatin nephrotoxicity anemia thrombocytopenia
lactate infusion produced injury
lactate infusion produced injury cortex in
lactate infusion produced injury cortex the
lactate infusion produced injury cortex
creatine development arrhythmia
glutamate supplementation failed protect neurotoxicity peripheral
glutamate supplementation failed protect neurotoxicity
glutamate claimed ameliorate neurotoxicity
glutamine glutamate claimed ameliorate neurotoxicity
amino glutamine glutamate claimed ameliorate neurotoxicity
acid glutamine glutamate claimed ameliorate neurotoxicity
glutamate claimed factor neuropathy peripheral
glutamate claimed factor neuropathy
glutamine glutamate claimed factor neuropathy peripheral
glutamine glutamate claimed factor neuropathy
paclitaxel chemotherapy factor claimed ameliorate neurotoxicity
PAC paclitaxel chemotherapy factor claimed ameliorate neurotoxicity
PAC ameliorate neurotoxicity
amino glutamine glutamate claimed factor neuropathy peripheral
amino glutamine glutamate claimed factor neuropathy
acid glutamine glutamate claimed factor neuropathy peripheral
acid glutamine glutamate claimed factor neuropathy
glutamate supplementation role evaluate aimed induced neuropathy peripheral
glutamate supplementation role evaluate aimed induced neuropathy
glutamate mg supplemented 23 regimen available patients ovarian
glutamate mg supplemented 23 regimen available patients cancer
PAC cycles regimen available patients ovarian
PAC cycles regimen available patients cancer
glutamate supplementation fails protect neurotoxicity peripheral
glutamate supplementation fails protect neurotoxicity
Suxamethonium induced arrest death
suxamethonium use hyperkalaemia result death
suxamethonium caused death
isoproterenol pretreatment Effects tachycardia
isoproterenol pretreatment reduced ii activation mediated tachycardia
dopamine activation mediated tachycardia
isoproterenol pretreatment abolish bromocriptine tachycardia
isoproterenol pretreatment unaffected reversed tachycardia
isoproterenol pretreatment unaffected hypotension
Bromocriptine induced unaffected reversed bradycardia
domperidone i reduced effect bradycardia reversed unaffected hypotension
domperidone i reduced effect bradycardia reversed tachycardia
isoproterenol pretreatment abolished 15 induced tachycardia
bromocriptine reversed abolished 15 induced bradycardia
dopamine receptors mask bradycardia
bromocriptine tachycardia appears predominate mask bradycardia
dopamine receptors mask predominate appears tachycardia
calcium chloride injury arterial
calcium chloride injury
chloride injury arterial
chloride injury
CaCl chloride injury arterial
CaCl chloride injury
2 NNS chloride injury arterial
2 NNS chloride injury
ribavirin associated anemia hemolytic
ribavirin associated anemia
ribavirin found found cause hemolysis
pegylated interferon treated patients infected chronically
pegylated interferon treated patients infected
pegylated interferon treated patients infected virus with
pegylated interferon treated patients infected virus hepatitis
pegylated interferon treated patients infected virus C
pegylated interferon treated patients infected virus
interferon treated patients infected chronically
interferon treated patients infected
interferon treated patients infected virus with
interferon treated patients infected virus hepatitis
interferon treated patients infected virus C
interferon treated patients infected virus
alpha interferon treated patients infected chronically
alpha interferon treated patients infected
alpha interferon treated patients infected virus with
alpha interferon treated patients infected virus hepatitis
alpha interferon treated patients infected virus C
alpha interferon treated patients infected virus
2 alpha interferon treated patients infected chronically
2 alpha interferon treated patients infected
2 alpha interferon treated patients infected virus with
2 alpha interferon treated patients infected virus hepatitis
2 alpha interferon treated patients infected virus C
2 alpha interferon treated patients infected virus
a interferon treated patients infected chronically
a interferon treated patients infected
a interferon treated patients infected virus with
a interferon treated patients infected virus hepatitis
a interferon treated patients infected virus C
a interferon treated patients infected virus
ribavirin a interferon treated patients infected chronically
ribavirin a interferon treated patients infected
ribavirin a interferon treated patients infected virus with
ribavirin a interferon treated patients infected virus hepatitis
ribavirin a interferon treated patients infected virus C
ribavirin a interferon treated patients infected virus
ribavirin anemia patients C hepatitis
ribavirin anemia patients C
ribavirin anemia
timolol treatment infarction myocardial
timolol treatment infarction
timolol treatment evaluated infarction myocardial
timolol treatment evaluated infarction
timolol placebo study effect treatment evaluated infarction myocardial
timolol placebo study effect treatment evaluated infarction
timolol bradycardia
timolol group remained increased re infarction
BCNU chemotherapy treatment gliomas malignant
BCNU chemotherapy treatment gliomas
BCNU clearance 1 provide treatment gliomas malignant
BCNU clearance 1 provide treatment gliomas
1 BCNU clearance 1 provide treatment gliomas malignant
1 BCNU clearance 1 provide treatment gliomas
3 BCNU clearance 1 provide treatment gliomas malignant
3 BCNU clearance 1 provide treatment gliomas
bis 3 BCNU clearance 1 provide treatment gliomas malignant
bis 3 BCNU clearance 1 provide treatment gliomas
2 BCNU clearance 1 provide treatment gliomas malignant
2 BCNU clearance 1 provide treatment gliomas
chloroethyl 2 BCNU clearance 1 provide treatment gliomas malignant
chloroethyl 2 BCNU clearance 1 provide treatment gliomas
1 provide treatment gliomas malignant
1 provide treatment gliomas
nitrosourea 1 provide treatment gliomas malignant
nitrosourea 1 provide treatment gliomas
BCNU therapy courses received Twenty patients recurrent Grade astrocytomas
ethanol diluent concentration lowered decreased frequency loss visual
ethanol diluent concentration lowered decreased frequency loss
penicillamine therapy caused arthritis rheumatoid
penicillamine therapy caused arthritis
chloroquine penicillamine therapy caused arthritis rheumatoid
chloroquine penicillamine therapy caused arthritis
penicillamine therapy arthritis rheumatoid
penicillamine therapy arthritis
chloroquine penicillamine therapy arthritis rheumatoid
chloroquine penicillamine therapy arthritis
mefloquine prophylaxis malaria
Ticlopidine induced hepatitis cholestatic
Ticlopidine induced hepatitis
ticlopidine cases report induced hepatitis cholestatic
ticlopidine cases report induced hepatitis
ticlopidine percutaneous receiving developed hepatitis cholestatic
ticlopidine percutaneous receiving developed hepatitis
ticlopidine complication hepatitis Cholestatic
ticlopidine complication hepatitis
ticlopidine developed showed characteristics hepatitis cholestatic
ticlopidine developed showed characteristics hepatitis
ticlopidine effect hepatitis Cholestatic
ticlopidine effect hepatitis
methylprednisolone administration assess space end surgery cataract
gentamicin methylprednisolone administration assess space end surgery cataract
Ketamine sedation fractures
ketamine safety examine treatment fractures
ketamine manipulation fracture dislocation
ketamine manipulation fracture
Ketamine provided sedation facilitate reduction fractures
gabapentin drug patients neuropathic
gabapentin drug patients pain
gabapentin induced hyperalgesia secondary
gabapentin induced hyperalgesia
dopamine neurons induced neurotoxicity
LY induced neurotoxicity
274614 LY induced neurotoxicity
amino antagonist Protection induced neurotoxicity
acid antagonist Protection induced neurotoxicity
dopamine neurons compounds effect neurotoxic
LY 274614 antagonist involves effect neurotoxic
274614 antagonist involves effect neurotoxic
NMDA receptors involves effect neurotoxic
NMDA antagonist involves effect neurotoxic
lithium Rats induced nephropathy
lithium Rats induced feeding uninephrectomy combination these attempt induce hyperfiltration failure renal
lithium Rats induced feeding uninephrectomy combination these attempt induce hyperfiltration failure
Lithium caused absence glomerulosclerosis
lithium rats decrease increase tended fact failed failed progression failure renal
lithium rats decrease increase tended fact failed failed progression failure
creatinine levels decrease increase tended fact failed failed progression failure renal
creatinine levels decrease increase tended fact failed failed progression failure
Li nephropathy
Capsaicin induced alters muscle
Capsaicin induced alters pain
Busulfan induced cystitis hemorrhagic
Busulfan induced cystitis
busulfan induced cystitis hemorrhage
busulfan induced cystitis
cyclophosphamide radiation appearances cystitis
cyclophosphamide radiation cystitis
busulfan tendency induce atypia carcinoma
sodium application valproate revealed disorders neurological
sodium application valproate revealed disorders
valproate revealed disorders neurological
valproate revealed disorders
valproate revealed disorders neurological
valproate revealed disorders
sodium application valproate revealed indicating damage cerebellum
sodium application valproate revealed indicating damage
valproate revealed indicating damage cerebellum
valproate revealed indicating damage
valproate revealed indicating damage cerebellum
valproate revealed indicating damage
valproate encephalopathy development damage hepatic
valproate encephalopathy development damage
valproate encephalopathy development damage hyperammonemia
vincristin administration due myeloencephalopathy
vincristine instillation girl leucemia acute
vincristine instillation girl leucemia lymphoblastic
vincristine instillation girl leucemia
vincristine instillation 57 man lymphoma lymphoblastic
vincristine instillation 57 man lymphoma
vincristine transformation pseudocystic
vincristine transformation
vincristine transformation degeneration
vincristine transformation degeneration myelin of
vincristine transformation degeneration myelin
vincristine transformation degeneration myelin and
vincristine transformation degeneration myelin axons
estradiol dependent levels inhibition hyperprolactinemic
ribonucleic levels inhibition hyperprolactinemic
acid levels inhibition hyperprolactinemic
estrogen secretion fertility necessary induced inhibited hyperprolactinemia
estradiol levels presence frequency frequency caused hyperprolactinemia
dopamine sulpiride induced hyperprolactinemia
steroid manner hyperprolactinemia
molindone administration failure rhabdomyolysis illustrate reported case patient schizophrenic
epinephrine overdose accidental due systolic left
epinephrine overdose accidental due systolic ventricular
epinephrine overdose accidental due systolic
epinephrine overdose accidental due systolic and
epinephrine overdose accidental due systolic dysfunction diastolic
epinephrine overdose accidental due systolic dysfunction
epinephrine overdose
Catecholamine induced recognized catecholamines due cardiomyopathy
catecholamines due cardiomyopathy
epinephrine mg injected woman year left elevated markers necrosis myocardial
epinephrine mg injected woman year left elevated markers necrosis
epinephrine mg injected woman year left
epinephrine mg injected woman year left dysfunction ventricular
epinephrine mg injected woman year left dysfunction systolic
epinephrine mg injected woman year left dysfunction systolic and
epinephrine mg injected woman year left dysfunction systolic diastolic
epinephrine mg injected woman year left dysfunction
sevoflurane effects convulsions
sevoflurane influence studied convulsions
sevoflurane concentration 0 end lidocaine / was threshold convulsive
sevoflurane threshold convulsive
enflurane sevoflurane threshold convulsive
sevoflurane concentrations administered decreased pressure convulsions
sevoflurane enflurane marked administered decreased pressure convulsions
enflurane sevoflurane concentrations administered decreased pressure convulsions
enflurane marked administered decreased pressure convulsions
Apamin had decrease threshold convulsive
lidocaine toxicity
sevoflurane reduces effect toxicity
sevoflurane reduces effect convulsive
sevoflurane reduces carries due depression
lidocaine toxicity effect reduces carries due depression
vinorelbine squamous
vinorelbine cell
vinorelbine cell trial esophageal
vinorelbine cell trial esophageal carcinoma
vinorelbine cell administered agent squamous
vinorelbine cell
vinorelbine cell carcinoma esophageal
vinorelbine cell carcinoma
VNB cell administered agent squamous
VNB cell
VNB cell carcinoma esophageal
VNB cell carcinoma
cisplatin pretreated assessable toxicity
VNB tolerated occurred instances toxicity
VNB agent carcinoma esophageal
VNB agent carcinoma squamous
VNB agent carcinoma cell
VNB agent carcinoma
VNB evaluation warranted profile toxicity
nitroglycerin effect inducing seems depend stimulation site pain
BD mice treatment pre induced convulsions
1063 BD mice treatment pre induced convulsions
BD mice treatment pre induced convulsions
1018 BD mice treatment pre induced convulsions
LR mice treatment pre induced convulsions
132 LR mice treatment pre induced convulsions
BD agonist tolylguanidine o agonist well worsened toxicity
1031 BD agonist tolylguanidine o agonist well worsened toxicity
3 R BD agonist tolylguanidine o agonist well worsened toxicity
R BD agonist tolylguanidine o agonist well worsened toxicity
1 R BD agonist tolylguanidine o agonist well worsened toxicity
-LSB- 2 1 R BD agonist tolylguanidine o agonist well worsened toxicity
2 1 R BD agonist tolylguanidine o agonist well worsened toxicity
3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
dichlorophenyl 3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
ethyl -RSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-RSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
1 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 1 1 R BD agonist tolylguanidine o agonist well worsened toxicity
diazabicyclo -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
3 -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
0 -RSB- nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-RSB- nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
cocaine toxicity
di agonist well worsened toxicity
o agonist well worsened toxicity
tolylguanidine o agonist well worsened toxicity
DTG tolylguanidine o agonist well worsened toxicity
oligodeoxynucleotide shown attenuate effects convulsive
salvianolic A effect infarction myocardial
salvianolic A effect infarction
acid A effect infarction myocardial
acid A effect infarction
A effect infarction myocardial
A effect infarction
salvianolic A potential evaluate isoproterenol induced infarction myocardial
salvianolic A potential evaluate isoproterenol induced infarction
acid A potential evaluate isoproterenol induced infarction myocardial
acid A potential evaluate isoproterenol induced infarction
A potential evaluate isoproterenol induced infarction myocardial
A potential evaluate isoproterenol induced infarction
isoproterenol observed ADP ratio characterized dysfunction respiratory
isoproterenol observed ADP ratio characterized dysfunction
ADP ratio characterized dysfunction respiratory
ADP ratio characterized dysfunction
isoproterenol dysfunction cardiac
isoproterenol dysfunction
salvianolic A Administration attenuated isoproterenol dysfunction injury myocardial
salvianolic A Administration attenuated isoproterenol dysfunction injury
acid A Administration attenuated isoproterenol dysfunction injury myocardial
acid A Administration attenuated isoproterenol dysfunction injury
A Administration attenuated isoproterenol dysfunction injury myocardial
A Administration attenuated isoproterenol dysfunction injury
salvianolic A Administration attenuated isoproterenol dysfunction cardiac
salvianolic A Administration attenuated isoproterenol dysfunction
acid A Administration attenuated isoproterenol dysfunction cardiac
acid A Administration attenuated isoproterenol dysfunction
A Administration attenuated isoproterenol dysfunction cardiac
A Administration attenuated isoproterenol dysfunction
isoproterenol dysfunction injury myocardial
isoproterenol dysfunction injury
salvianolic A damage myocardial
salvianolic A damage
acid A damage myocardial
acid A damage
A damage myocardial
A damage
isoproterenol A damage myocardial
isoproterenol A damage
salvianolic acid has effect isoproterenol induced infarction myocardial
salvianolic acid has effect isoproterenol induced infarction
acid has effect isoproterenol induced infarction myocardial
acid has effect isoproterenol induced infarction
A activity acid has effect isoproterenol induced infarction myocardial
A activity acid has effect isoproterenol induced infarction
propranolol diazepam effects patients disorder panic
propranolol diazepam effects patients disorder
diazepam effects patients disorder panic
diazepam effects patients disorder
propranolol diazepam effects patients disorder agoraphobia
diazepam effects patients disorder agoraphobia
propranolol diazepam doses performance patients disorders panic
propranolol diazepam doses performance patients disorders
diazepam doses performance patients disorders panic
diazepam doses performance patients disorders
propranolol diazepam doses performance patients disorders agoraphobia
diazepam doses performance patients disorders agoraphobia
clonidine produced pressure decrease rats hypertensive
nalozone inhibited micrograms rats hypertensive
naloxone reversed effect hypotensive
clonidine influence membranes rats hypertensive
clonidine dihydroergocryptine influence influence membranes rats hypertensive
-LSB- -RSB- stereoselective influence membranes rats hypertensive
3 -RSB- stereoselective influence membranes rats hypertensive
H -RSB- stereoselective influence membranes rats hypertensive
-RSB- stereoselective influence membranes rats hypertensive
naloxone -RSB- stereoselective influence membranes rats hypertensive
-LSB- binding -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
3 -LSB- binding -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
H -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
-RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
dihydroergocryptine influence influence membranes rats hypertensive
naloxone influence influence membranes rats hypertensive
Lamivudine antigen seropositive undergoing patients cancer
Lamivudine prevention reactivation hepatitis
Lamivudine prevention reactivation B
hepatitis reactivation prevention Lamivudine antigen seropositive undergoing patients cancer
B antigen seropositive undergoing patients cancer
surface antigen seropositive undergoing patients cancer
antigen seropositive undergoing patients cancer
HBSAG antigen seropositive undergoing patients cancer
lamivudine received patients cancer
lamivudine receive group received patients cancer
lamivudine received patients have malignancies solid hematological
lamivudine received patients have malignancies
lamivudine receive group received patients have malignancies solid hematological
lamivudine receive group received patients have malignancies
lamivudine received patients have malignancies infection HBV
lamivudine received patients have malignancies infection
lamivudine receive group received patients have malignancies infection HBV
lamivudine receive group received patients have malignancies infection
lamivudine group observed hepatitis
lamivudine decreases incidence morbidity patients cancer
methylergonovine Effect patients angina variant
methylergonovine Effect patients angina
methylergonovine administration effects studied pectoris angina
methylergonovine administration effects studied pectoris
methylergonovine administration effects studied patients angina variant
methylergonovine administration effects studied patients angina
methylergonovine administration effects studied patients patients pain chest
methylergonovine administration effects studied patients patients pain
methylergonovine dose injection use tests spasm
methylergonovine dose injection use tests have sensitivity angina variant
methylergonovine dose injection use tests have sensitivity angina
etoposide A effect observed patient T acute
etoposide A effect observed patient T
etoposide A effect observed patient leukemia lymphocytic
etoposide A effect observed patient leukemia
cyclosporin etoposide A effect observed patient T acute
cyclosporin etoposide A effect observed patient T
cyclosporin etoposide A effect observed patient leukemia lymphocytic
cyclosporin etoposide A effect observed patient leukemia
A effect observed patient T acute
A effect observed patient T
A effect observed patient leukemia lymphocytic
A effect observed patient leukemia
cyclosporin etoposide A administration resulted eradication infiltration leukemic
cyclosporin etoposide A administration resulted eradication infiltration
A administration resulted eradication infiltration leukemic
A administration resulted eradication infiltration
etoposide A administration resulted eradication infiltration leukemic
etoposide A administration resulted eradication infiltration
debrisoquine polymorphism belonging patients experience reactions adverse
debrisoquine polymorphism belonging patients experience reactions drug
debrisoquine polymorphism belonging patients experience reactions
sparteine phenotype polymorphism belonging patients experience reactions adverse
sparteine phenotype polymorphism belonging patients experience reactions drug
sparteine phenotype polymorphism belonging patients experience reactions
Propylthiouracil induced staining autoantibody vasculitis
propylthiouracil case describe induced vasculitis
propylthiouracil treated hyperthyroidism
propylthio associated vasculitis
uracil pANCA vasculitis
propylthio attributable vasculitis
uracil therapy manifestation induced attributable vasculitis
Adriamycin induced plays death
3 methyladenine used model heart
3 methyladenine used model failure
methyladenine used model heart
methyladenine used model failure
3 MA methyladenine used model heart
3 MA methyladenine used model failure
MA methyladenine used model heart
MA methyladenine used model failure
adriamycin induced rats plays death
estrogen Characterization tumors adenohypophyseal
estrogen Characterization tumors
DES establishing induced tumor
adriamycin toxicity
polyethylene Effect glycol toxicity
glycol toxicity
400 glycol toxicity
ADR activity tumor L
ADR activity tumor leukemia 1210
ADR activity tumor leukemia
ADR activity tumor leukemia ascites Ehrlich
ADR activity tumor leukemia ascites
ADR activity tumor
salt angiotensinogen hypertension
Testosterone hypertension
testosterone causes increases BP injury renal
testosterone causes increases BP injury
Testosterone replacement increased BP injury renal
Testosterone replacement increased BP injury
angiotensin system upregulation contributes development hypertension
angiotensin system upregulation contributes development injury renal
angiotensin system upregulation contributes development injury
Testosterone contributes development injury renal
Testosterone contributes development injury
Testosterone contributes development hypertension
pentazocine due myopathy fibrous
pentazocine due myopathy
pentazocine due neuropathy Compression
pentazocine due neuropathy
pentazocine due neuropathy nerve of
pentazocine due neuropathy nerve the
pentazocine due neuropathy nerve radial
pentazocine due neuropathy nerve
pentazocine injection effect Fibrous
pentazocine injection effect myopathy
pentazocine woman 37 fibrous
pentazocine woman 37 fibrous bilaterally myopathy
pentazocine woman 37 showed myopathy fibrous
pentazocine woman 37 showed myopathy
Paracetamol associated coma
Paracetamol associated coma renal
Paracetamol associated coma and
Paracetamol associated coma failure hepatic
Paracetamol associated coma failure
paracetamol ingestion failure acidosis failure acute
paracetamol ingestion failure acidosis failure renal
paracetamol ingestion failure acidosis failure
paracetamol ingestion failure acidosis and
paracetamol ingestion failure hepatic
paracetamol ingestion failure
pergolide treated disease disease patients Parkinson
pergolide treated disease disease patients Parkinson '
pergolide treated disease s
pergolide treated disease
pergolide treated disease disease Valvular
pergolide treated disease disease heart
pergolide treated disease disease
pergolide treated patients disease Parkinson
pergolide treated patients disease Parkinson '
pergolide treated patients disease s
pergolide treated patients disease
pergolide treated patients disease PD
pergolide treated patients reported abnormalities Valvular
pergolide treated patients reported abnormalities heart
pergolide treated patients reported abnormalities
pergolide treated area patients PD
pergolide role suggestive pattern observed patients two failure heart
pergolide role suggestive pattern observed patients two failure
pergolide role suggestive pattern regurgitation valvular
pergolide role suggestive pattern regurgitation
Pergolide discontinued resulting failure heart
Pergolide discontinued resulting failure
Pergolide discontinued disease valvular
Pergolide discontinued disease heart
Pergolide discontinued disease
dopamine agonists non converted usual reveals supports frequency regurgitation valve
dopamine agonists non converted usual reveals supports frequency regurgitation
dopamine agonists non converted usual reveals supports frequency regurgitation patients PD
pergolide treated patients PD
pergolide treated patients regurgitation valve
pergolide treated patients regurgitation
Lamivudine added infection hepatitis
Lamivudine added infection B
Lamivudine added infection
sirolimus replaced transplant acidosis
sirolimus replaced transplant acidosis
tacrolimus suspected acidosis transplant acidosis
tacrolimus suspected acidosis
lamivudine augmented triggered dysfunction mitochondrial
lamivudine augmented triggered dysfunction
tacrolimus triggered dysfunction mitochondrial
tacrolimus triggered dysfunction
DCE reversed amnesia
DCE prove remedy management dysfunctions cognitive
DCE prove remedy management dysfunctions
cholesterol property improving remedy management dysfunctions cognitive
cholesterol property improving remedy management dysfunctions
Indomethacin induced insufficiency renal
Indomethacin induced insufficiency
indomethacin therapy pulmonale reported case failure renal
indomethacin therapy pulmonale reported case failure
bicuculline containing medium Mg resulted pilocarpine treated mice experience SE
Mg resulted pilocarpine treated mice experience SE
glutamate antagonists blocked duration afterdischarges shifts followed spike resulted survivors SE
glutamate photostimulation distant duration slices survivors SE
carbidopa levodopa point normality lead toxicity
levodopa therapy starting is started carbidopa levodopa point normality lead toxicity
levodopa point normality lead toxicity
levodopa psychosis
levodopa psychosis disturbances sleep
levodopa psychosis disturbances
nitroglycerin Provocation neuropathy diabetic
nitroglycerin Provocation neuropathy autonomic
nitroglycerin Provocation neuropathy
nitroglycerin effect compared subjects subjects neuropathy autonomic
nitroglycerin effect compared subjects subjects neuropathy
nitroglycerin effect compared neuropathy autonomic
nitroglycerin effect compared neuropathy
nitroglycerin effect compared subjects subjects diabetic
nitroglycerin effect compared subjects subjects diabetic
nitroglycerin pressure decrease increase course similar neuropathy autonomic
nitroglycerin pressure decrease increase course similar neuropathy
nitroglycerin pressure decrease increase course similar occurred neuropathy autonomic
nitroglycerin pressure decrease increase course similar occurred neuropathy
nitroglycerin pressure decrease increase course similar subjects normal diabetic
nitroglycerin pressure decrease increase course similar occurred subjects diabetic
magnesium administration preeclampsia
magnesium administration became quadriplegic
magnesium administration became history disease neuromuscular
magnesium administration became history disease
magnesium administration paralysis
magnesium effects sensitive Patients suspected having disorder
magnesium effects sensitive Patients suspected having disorder transmission of
magnesium effects sensitive Patients suspected having disorder transmission neuromuscular
magnesium effects sensitive Patients suspected having disorder transmission
disulfiram overdose
disulfiram intoxication axonal superimposed case palsy
disulfiram intoxication axonal caused polyneuropathy
vitamin D growth accelerated calcification artery
vitamin D growth accelerated calcification
D growth accelerated calcification artery
D growth accelerated calcification
vitamin treatment growth enhance extent calcification artery
vitamin treatment growth enhance extent calcification
D treatment growth enhance extent calcification artery
D treatment growth enhance extent calcification
Warfarin doses given rats enhance carboxylation protein inhibitor calcification
vitamin treatment growth enhance carboxylation protein inhibitor calcification
D treatment growth enhance carboxylation protein inhibitor calcification
Warfarin weeks Treatment caused 20 rats calcification
phosphate serum relationship was determined explanation association calcification artery
phosphate serum relationship was determined explanation association calcification
phosphate serum relationship was calcification artery
phosphate serum relationship was calcification
phosphate serum relationship was levels induced calcification artery
phosphate serum relationship was levels induced calcification
phosphate levels was determined explanation association calcification artery
phosphate levels was determined explanation association calcification
phosphate levels was calcification artery
phosphate levels was calcification
phosphate levels induced calcification artery
phosphate levels induced calcification
phosphate levels related calcification artery
phosphate levels related calcification
vitamin D synergy examined calcification artery
vitamin D synergy examined calcification
D synergy examined calcification artery
D synergy examined calcification
vitamin D doses known cause calcification
vitamin D doses known cause calcification media of
vitamin D doses known cause calcification media the
vitamin D doses known cause calcification media artery
D doses known cause calcification
D doses known cause calcification media of
D doses known cause calcification media the
D doses known cause calcification media artery
vitamin Warfarin doses known calcification
vitamin Warfarin doses known calcification media of
vitamin Warfarin doses known calcification media the
vitamin Warfarin doses known calcification media artery
K Warfarin doses known calcification
K Warfarin doses known calcification media of
K Warfarin doses known calcification media the
K Warfarin doses known calcification media artery
Warfarin administration increased extent calcification
vitamin D media increased extent calcification
D media increased extent calcification
vitamin dose calcification artery
vitamin dose calcification
D dose calcification artery
D dose calcification
vitamin dose effect parallel elevation calcium suggests induce calcification artery
vitamin dose effect parallel elevation calcium suggests induce calcification
D dose effect parallel elevation calcium suggests induce calcification artery
D dose effect parallel elevation calcium suggests induce calcification
vitamin dose effect dose calcification artery
vitamin dose effect dose calcification
D dose effect dose calcification artery
D dose effect dose calcification
vitamin dose effect dose effect parallel elevation calcium suggests induce calcification artery
vitamin dose effect dose effect parallel elevation calcium suggests induce calcification
D dose effect dose effect parallel elevation calcium suggests induce calcification artery
D dose effect dose effect parallel elevation calcium suggests induce calcification
vitamin D induce suggests calcium elevation parallel effect dose calcification artery
vitamin D induce suggests calcium elevation parallel effect dose calcification
D induce suggests calcium elevation parallel effect dose calcification artery
D induce suggests calcium elevation parallel effect dose calcification
vitamin D induce calcification artery
vitamin D induce calcification
D induce calcification artery
D induce calcification
calcium elevation parallel effect dose calcification artery
calcium elevation parallel effect dose calcification
calcium suggests induce calcification artery
calcium suggests induce calcification
calcium effect induce suggests calcium elevation parallel effect dose calcification artery
calcium effect induce suggests calcium elevation parallel effect dose calcification
calcium effect induce calcification artery
calcium effect induce calcification
calcium had explained inhibits activity protein inhibitor calcification
Warfarin treatment had explained inhibits activity protein inhibitor calcification
Warfarin D synergy explained inhibits activity protein inhibitor calcification
Warfarin inhibits activity protein inhibitor calcification
vitamin D produced calcium had explained inhibits activity protein inhibitor calcification
D produced calcium had explained inhibits activity protein inhibitor calcification
vitamin Warfarin D synergy explained inhibits activity protein inhibitor calcification
D synergy explained inhibits activity protein inhibitor calcification
vitamin D treated rats found sites calcification artery
vitamin D treated rats found sites calcification
D treated rats found sites calcification artery
D treated rats found sites calcification
gamma showed found sites calcification artery
gamma showed found sites calcification
carboxylated gamma showed found sites calcification artery
carboxylated gamma showed found sites calcification
gamma protein required inhibitor calcification
carboxyglutamate residues gamma protein required inhibitor calcification
gamma protein required required sites calcification
carboxyglutamate residues gamma protein required required sites calcification
SRL treated therapy sarcoma cancers carsinom renal
SRL treated therapy sarcoma cancers carsinom cell
SRL treated therapy sarcoma cancers carsinom
SRL treated therapy neoplasia due nephropathy CAN
SRL treated therapy sarcoma nephropathy
SRL treated therapy neoplasia
SRL treated therapy sarcoma cancers tumors intestinal
SRL treated therapy sarcoma cancers tumors
SRL treated therapy sarcoma Kaposi
SRL treated therapy sarcoma Kaposi '
SRL treated therapy sarcoma s
SRL treated therapy sarcoma
SRL treated therapy sarcoma cancers skin
SRL treated therapy sarcoma cancers
SRL treated therapy neoplasia due nephropathy chronic
SRL treated therapy neoplasia due nephropathy allograft
SRL treated therapy neoplasia due nephropathy
DFO other factor ototoxic
DFO role development impairment hearing
DFO role development impairment
amphetamine dose sensitization diet promoting causes sugar
amphetamine dose sensitization diet promoting causes dependency
cocaine revealed period METHODS aneurysms
cocaine patients outcome predictors aneurysms
Cocaine use predisposed predisposed aneurysms
nelarabine therapy T
nelarabine therapy T leukaemia cell
nelarabine therapy T leukaemia lymphoblastic
nelarabine therapy T leukaemia
nelarabine therapy T leukaemia and
nelarabine therapy T leukaemia lymphoma
cyclophosphamide nelarabine therapy T
cyclophosphamide nelarabine therapy T leukaemia cell
cyclophosphamide nelarabine therapy T leukaemia lymphoblastic
cyclophosphamide nelarabine therapy T leukaemia
cyclophosphamide nelarabine therapy T leukaemia and
cyclophosphamide nelarabine therapy T leukaemia lymphoma
etoposide nelarabine therapy T
etoposide nelarabine therapy T leukaemia cell
etoposide nelarabine therapy T leukaemia lymphoblastic
etoposide nelarabine therapy T leukaemia
etoposide nelarabine therapy T leukaemia and
etoposide nelarabine therapy T leukaemia lymphoma
nelarabine d combination used children T
nelarabine d combination used children leukaemia cell
nelarabine d combination used children leukaemia
nelarabine d combination used children leukaemia or
nelarabine d combination used children leukaemia lymphoma
AraG nelarabine d combination used children T
AraG nelarabine d combination used children leukaemia cell
AraG nelarabine d combination used children leukaemia
AraG nelarabine d combination used children leukaemia or
AraG nelarabine d combination used children leukaemia lymphoma
cyclophosphamide etoposide d nelarabine d combination used children T
cyclophosphamide etoposide d nelarabine d combination used children leukaemia cell
cyclophosphamide etoposide d nelarabine d combination used children leukaemia
cyclophosphamide etoposide d nelarabine d combination used children leukaemia or
cyclophosphamide etoposide d nelarabine d combination used children leukaemia lymphoma
CPM etoposide d nelarabine d combination used children T
CPM etoposide d nelarabine d combination used children leukaemia cell
CPM etoposide d nelarabine d combination used children leukaemia
CPM etoposide d nelarabine d combination used children leukaemia or
CPM etoposide d nelarabine d combination used children leukaemia lymphoma
etoposide d nelarabine d combination used children T
etoposide d nelarabine d combination used children leukaemia cell
etoposide d nelarabine d combination used children leukaemia
etoposide d nelarabine d combination used children leukaemia or
etoposide d nelarabine d combination used children leukaemia lymphoma
VP etoposide d nelarabine d combination used children T
VP etoposide d nelarabine d combination used children leukaemia cell
VP etoposide d nelarabine d combination used children leukaemia
VP etoposide d nelarabine d combination used children leukaemia or
VP etoposide d nelarabine d combination used children leukaemia lymphoma
cyclophosphamide etoposide giving safety supports monitored toxicity neurological
cyclophosphamide etoposide giving safety supports monitored toxicity
etoposide giving safety supports monitored toxicity neurological
etoposide giving safety supports monitored toxicity
imidazoline modulation hypotension
estrogen modulation hypotension
clonidine effect hypotensive
estrogen modulates effect hypotensive
alpha rats paralleled SDRR activity a
alpha rats paralleled SDRR activity reduced
alpha rats paralleled SDRR activity locomotor
alpha rats paralleled SDRR activity
methyldopa hypotension alpha rats paralleled SDRR activity a
methyldopa hypotension alpha rats paralleled SDRR activity reduced
methyldopa hypotension alpha rats paralleled SDRR activity locomotor
methyldopa hypotension alpha rats paralleled SDRR activity
estrogen downregulates mediated hypotension
estrogen interaction hypotension
rapamycin inhibitors target observed recipients nephropathy chronic
rapamycin inhibitors target observed recipients nephropathy allograft
rapamycin inhibitors target observed recipients nephropathy
sirolimus target observed recipients nephropathy chronic
sirolimus target observed recipients nephropathy allograft
sirolimus target observed recipients nephropathy
mipafox inhibition correlation damage neuropathic
mipafox inhibition correlation damage
mipafox inhibition esterase neurotoxic
organophosphate Mipafox exposed rats examined correlation esterase neurotoxic
organophosphate neurotoxic
Mipafox exposed rats examined correlation damage neuropathic
Mipafox exposed rats examined correlation damage
Mipafox exposed rats examined correlation esterase enzyme neuropathy
N Mipafox exposed rats examined correlation damage neuropathic
N Mipafox exposed rats examined correlation damage
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
N Mipafox exposed rats examined correlation esterase enzyme neuropathy
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
Mipafox exposed rats examined correlation esterase neurotoxic
Mipafox organophosphate neurotoxic
N Mipafox exposed rats examined correlation esterase neurotoxic
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
N Mipafox organophosphate neurotoxic
N diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
' N diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
- diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
organophosphate Mipafox exposed rats examined correlation damage neuropathic
organophosphate Mipafox exposed rats examined correlation damage
organophosphate Mipafox exposed rats examined correlation esterase enzyme neuropathy
Mipafox exposure sampled cord inhibition percentage predict damage neuropathic
Mipafox exposure sampled cord inhibition percentage predict damage
dopamine receptors induced hyperactivity
SCH blocked hyperactivity
23390 SCH blocked hyperactivity
fluphenazine SCH blocked hyperactivity
raclopride SCH blocked hyperactivity
SKF agonist had induced hyperactivity
38393 SKF agonist had induced hyperactivity
PHNO induced hyperactivity
isoflurane metabolism flow aneurysms cerebral
isoflurane metabolism flow aneurysms
oxygen flow measured isoflurane hypotension
oxygen flow measured isoflurane hypotension patients subjected craniotomy clipping aneurysm cerebral
oxygen flow measured isoflurane hypotension patients subjected craniotomy clipping aneurysm
isoflurane hypotension patients subjected craniotomy clipping aneurysm cerebral
isoflurane hypotension patients subjected craniotomy clipping aneurysm
xenon Schmidt 5 days haemorrhage subarachnoid
xenon Schmidt 5 days haemorrhage
Hg induced MAP hypotension
isoflurane concentration reduced clipping aneurysm
Spironolactone induced patients failure heart
Spironolactone induced patients failure
spironolactone use evaluating patients heart
spironolactone use evaluating patients failure
spironolactone benefits reported changed treatments failure heart
spironolactone benefits reported changed treatments failure
spironolactone treated patients heart
spironolactone treated patients failure
spironolactone treated patients heart
spironolactone treated patients failure
K > mg dL developed hyperkalemia
K > insufficiency renal
K > insufficiency
Cr > insufficiency renal
Cr > insufficiency
Cr > insufficiency > mg dL developed hyperkalemia
potassium levels had Patients developed older hyperkalemia
potassium doses levels had Patients developed older hyperkalemia
potassium levels had Patients developed older likely have diabetes
potassium doses levels had Patients developed older likely have diabetes
thiazide diuretics treated likely had Patients developed insufficiency renal
thiazide diuretics treated likely had Patients developed insufficiency
creatinine weight had Patients developed insufficiency renal
creatinine weight had Patients developed insufficiency
MDMA users reported deficits memory
MDMA users reported deficits
3 MDMA users reported deficits memory
3 MDMA users reported deficits
4 3 MDMA users reported deficits memory
4 3 MDMA users reported deficits
methylenedioxymethamphetamine 3 MDMA users reported deficits memory
methylenedioxymethamphetamine 3 MDMA users reported deficits
ecstasy methylenedioxymethamphetamine 3 MDMA users reported deficits memory
ecstasy methylenedioxymethamphetamine 3 MDMA users reported deficits
diclofenac therapy associated hepatitis Chronic
diclofenac therapy associated hepatitis active
diclofenac therapy associated hepatitis
sodium therapy associated hepatitis Chronic
sodium therapy associated hepatitis active
sodium therapy associated hepatitis
diclofenac sodium therapy developed hepatitis chronic
diclofenac sodium therapy developed hepatitis active
diclofenac sodium therapy developed hepatitis
sodium therapy developed hepatitis chronic
sodium therapy developed hepatitis active
sodium therapy developed hepatitis
neurotensin Effects catalepsy parkinsonian
neurotensin Effects catalepsy
haloperidol induced symptoms parkinsonian
haloperidol induced symptoms
neurotensin effects investigate haloperidol induced symptoms parkinsonian
neurotensin effects investigate haloperidol induced symptoms
neurotensin pallidus infusions RESULTS catalepsy parkinsonian
neurotensin pallidus infusions RESULTS catalepsy
citalopram adolescent depressed
citalopram boy treatment report depression major
citalopram boy treatment report depression
GNC H immunotherapy overdose cocaine
GNC H immunotherapy overdose
92 H immunotherapy overdose cocaine
92 H immunotherapy overdose
H immunotherapy overdose cocaine
H immunotherapy overdose
2 H immunotherapy overdose cocaine
2 H immunotherapy overdose
cocaine use continues remains treatment overdose cocaine
cocaine use continues remains treatment overdose
GNC H potential examined using model overdose cocaine
GNC H potential examined using model overdose
92 H potential examined using model overdose cocaine
92 H potential examined using model overdose
H potential examined using model overdose cocaine
H potential examined using model overdose
2 H potential examined using model overdose cocaine
2 H potential examined using model overdose
cocaine toxicity blockade observed H reduced up % death
GNC dose observed blockade toxicity
92 GNC dose observed blockade toxicity
H observed blockade toxicity
2 H observed blockade toxicity
GNC dose observed H reduced up seizures
92 GNC dose observed H reduced up seizures
H reduced up seizures
2 H reduced up seizures
cocaine toxicity
GNC dose observed H reduced up % death
92 GNC dose observed H reduced up % death
H reduced up % death
2 H reduced up % death
cocaine injection post prevented death
GNC H prevented death
92 H prevented death
H prevented death
2 H prevented death
GNC potential support H tool overdose cocaine
GNC potential support H tool overdose
92 GNC potential support H tool overdose cocaine
92 GNC potential support H tool overdose
H tool overdose cocaine
H tool overdose
2 H tool overdose cocaine
2 H tool overdose
naloxone administered animals facilitated reversed Amnesia
morphine min reversed Amnesia
morphine facilitated reversed Amnesia
morphine infusion patients compared incidence apnoea
bupivacaine patients patients compared incidence apnoea
morphine infusion had patients occurred obstructive
morphine infusion had patients occurred obstructive 05 less P
morphine infusion had patients occurred obstructive 05 less
morphine infusion had patients occurred obstructive 05 than
morphine infusion had patients occurred obstructive 05 0
morphine infusion had patients occurred obstructive 05
morphine infusion had patients occurred obstructive and
morphine infusion had patients occurred obstructive apnoea central
morphine infusion had patients occurred obstructive apnoea
morphine group incidence tachyarrhythmias
Dup 753 prevents development nephrosis
753 prevents development nephrosis
puromycin aminonucleoside development nephrosis
aminonucleoside development nephrosis
blood urea syndromes proteinuria
nitrogen urea syndromes proteinuria
urea syndromes proteinuria
angiotensin II antagonist administration inhibited appearance syndromes nephrotic
angiotensin II antagonist administration inhibited appearance syndromes
II antagonist administration inhibited appearance syndromes nephrotic
II antagonist administration inhibited appearance syndromes
blood urea syndromes nephrotic
blood urea syndromes
nitrogen urea syndromes nephrotic
nitrogen urea syndromes
urea syndromes nephrotic
urea syndromes
Dup administration inhibited appearance syndromes proteinuria hypoalbuminemia
753 Dup administration inhibited appearance syndromes proteinuria hypoalbuminemia
losartan administration inhibited appearance syndromes proteinuria hypoalbuminemia
angiotensin II antagonist administration inhibited appearance syndromes proteinuria
II antagonist administration inhibited appearance syndromes proteinuria
angiotensin II antagonist administration inhibited appearance syndromes proteinuria hypercholesterolemia
II antagonist administration inhibited appearance syndromes proteinuria hypercholesterolemia
blood urea syndromes proteinuria hypoalbuminemia
nitrogen urea syndromes proteinuria hypoalbuminemia
urea syndromes proteinuria hypoalbuminemia
Dup administration inhibited appearance syndromes nephrotic
Dup administration inhibited appearance syndromes
753 Dup administration inhibited appearance syndromes nephrotic
753 Dup administration inhibited appearance syndromes
losartan administration inhibited appearance syndromes nephrotic
losartan administration inhibited appearance syndromes
angiotensin II antagonist administration inhibited appearance syndromes proteinuria hypoalbuminemia
II antagonist administration inhibited appearance syndromes proteinuria hypoalbuminemia
blood urea syndromes proteinuria hypercholesterolemia
nitrogen urea syndromes proteinuria hypercholesterolemia
urea syndromes proteinuria hypercholesterolemia
Dup administration inhibited appearance syndromes proteinuria
753 Dup administration inhibited appearance syndromes proteinuria
losartan administration inhibited appearance syndromes proteinuria
Dup administration inhibited appearance syndromes proteinuria hypercholesterolemia
753 Dup administration inhibited appearance syndromes proteinuria hypercholesterolemia
losartan administration inhibited appearance syndromes proteinuria hypercholesterolemia
puromycin aminonucleoside development system renin induced nephrosis
aminonucleoside development system renin induced nephrosis
angiotensin system renin induced nephrosis
amikacin toxicity
aminoglycosides improved impair infarction
aminoglycosides improved endophthalmitis
vancomycin amikacin treatment toxicity retinal
vancomycin amikacin treatment toxicity
amikacin toxicity treatment endophthalmitis streptococcal
amikacin toxicity treatment endophthalmitis
amikacin treatment endophthalmitis streptococcal
amikacin treatment endophthalmitis
vancomycin amikacin treatment endophthalmitis streptococcal
vancomycin amikacin treatment endophthalmitis
fluorescein confirmed telangiectasis
lamivudine use therapy disorders rheumatologic
lamivudine use therapy disorders
lamivudine patients disease rheumatologic
lamivudine patients disease
hepatitis antigen lamivudine patients disease rheumatologic
hepatitis antigen lamivudine patients disease
B antigen lamivudine patients disease rheumatologic
B antigen lamivudine patients disease
virus antigen lamivudine patients disease rheumatologic
virus antigen lamivudine patients disease
surface antigen lamivudine patients disease rheumatologic
surface antigen lamivudine patients disease
antigen lamivudine patients disease rheumatologic
antigen lamivudine patients disease
HBs Ag antigen lamivudine patients disease rheumatologic
HBs Ag antigen lamivudine patients disease
Ag antigen lamivudine patients disease rheumatologic
Ag antigen lamivudine patients disease
lamivudine therapies patients diseases rheumatologic
lamivudine therapies patients diseases
HBs patients diseases rheumatologic
HBs patients diseases
Ag patients diseases rheumatologic
Ag patients diseases
ecstasy users deficits Learning
ecstasy users deficits Learning and
ecstasy users deficits memory
ecstasy users deficits
ecstasy users display impairments
ecstasy users display impairments performance in
ecstasy users display impairments performance learning
ecstasy users display impairments performance learning and
ecstasy users display impairments performance learning memory
cannabis users hyperactivity Deficits
cannabis users hyperactivity Deficits learning in
cannabis users hyperactivity Deficits learning
cannabis users hyperactivity Deficits learning and
cannabis users hyperactivity Deficits learning memory
cannabis users hyperactivity
ecstasy revealed task phases analysis hyperactivity
ecstasy related effects neurotoxic
ecstasy effects neurotoxic
minoxidil use Pseudoacromegaly
minoxidil resulted patient pseudoacromegaly
minoxidil use effect pseudoacromegaly
WR cisplatin trial amifostine carcinoma breast
WR cisplatin trial amifostine carcinoma
2721 amifostine carcinoma breast
2721 amifostine carcinoma
amifostine carcinoma breast
amifostine carcinoma
cisplatin trial amifostine carcinoma breast
cisplatin trial amifostine carcinoma
Cisplatin has activity line treatment carcinoma breast
Cisplatin has activity line treatment carcinoma
cisplatin observed limited dose e g nephrotoxicity neurotoxicity
cisplatin associated toxicities dose e g nephrotoxicity neurotoxicity
cisplatin observed limited treatment carcinoma breast
cisplatin observed limited treatment carcinoma
cisplatin associated toxicities dose limited treatment carcinoma breast
cisplatin associated toxicities dose limited treatment carcinoma
cisplatin observed limited dose toxicities
cisplatin associated toxicities
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity neuropathy
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity ototoxicity
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity
amifostine cisplatin conducted carcinoma breast
amifostine cisplatin conducted carcinoma
cisplatin conducted carcinoma breast
cisplatin conducted carcinoma
amifostine addition observed tumor
cisplatin observed tumor effect toxicity
cisplatin observed tumor
amifostine addition observed tumor effect toxicity
phenobarbital containing diet fed rats developed fed rats developed nodules carcinomas hepatocellular
phenobarbital containing diet fed rats developed fed rats developed nodules carcinomas
phenobarbital containing diet fed rats developed nodule carcinoma hepatocellular
phenobarbital containing diet fed rats developed nodule carcinoma
phenobarbital diet fed rats fed rats % carcinomas incidence hepatocellular
phenobarbital diet fed rats fed rats % carcinomas
dothiepin hydrochloride treatment disorder depressive
dothiepin hydrochloride treatment disorder
hydrochloride treatment disorder depressive
hydrochloride treatment disorder
amitriptyline study placebo treatment outpatients depressed
dothiepin study placebo treatment outpatients depressed
amitriptyline Dothiepin effective alleviating symptoms illness depressive
amitriptyline Dothiepin effective alleviating symptoms illness
Dothiepin effective alleviating symptoms illness depressive
Dothiepin effective alleviating symptoms illness
dothiepin less incidence frequency vision blurred
dothiepin less incidence frequency vision
dothiepin less incidence frequency vision mouth dry
dothiepin less incidence frequency vision mouth
antidepressant drug associated treatment outpatients depressed
amitriptyline effects associated treatment outpatients depressed
Dothiepin found drug associated treatment outpatients depressed
propylthiouracil caused disease Liver
propylthiouracil caused disease
gamma transmitted part neurophysiology epilepsy absence
gamma transmitted part neurophysiology epilepsy
aminobutyric acid gamma transmitted part neurophysiology epilepsy absence
aminobutyric acid gamma transmitted part neurophysiology epilepsy
acid gamma transmitted part neurophysiology epilepsy absence
acid gamma transmitted part neurophysiology epilepsy
saralasin prevented hypertensive
sodium nitroprusside prevented hypertensive
nitroprusside prevented hypertensive
angiotensin system hypotension
saralasin treated demonstrated increase
saralasin treated demonstrated pressure in
saralasin treated demonstrated pressure blood
saralasin treated demonstrated pressure
SNP infusion demonstrated increase
SNP infusion demonstrated pressure in
SNP infusion demonstrated pressure blood
SNP infusion demonstrated pressure
angiotensin system antagonizing effects hypotensive
bilirubin mortality predicted presentation encephalopathy
fentanyl reduces pain
fentanyl reduces nausea
fentanyl reduces nausea vomiting
sevoflurane reduces pain
sevoflurane reduces nausea
sevoflurane reduces nausea vomiting
sevoflurane anaesthesia induction advantages occurs nausea postoperative
sevoflurane anaesthesia induction advantages occurs nausea
sevoflurane anaesthesia induction advantages occurs nausea and
sevoflurane anaesthesia induction advantages occurs nausea vomiting
sevoflurane anaesthesia vomiting study examined incidence nausea postoperative
sevoflurane anaesthesia vomiting study examined incidence nausea
sevoflurane anaesthesia vomiting study and
sevoflurane anaesthesia vomiting
sevoflurane anaesthesia vomiting pain
fentanyl Omission reduce did reduce moderate nausea
fentanyl % discharge moderate nausea
fentanyl fentanyl % discharge moderate nausea
fentanyl Omission reduce did reduce incidence vomiting
fentanyl % discharge moderate reduce incidence vomiting
fentanyl fentanyl % discharge moderate reduce incidence vomiting
dexamethasone reduce did reduce incidence nausea postoperative
dexamethasone reduce did reduce incidence nausea
dexamethasone reduce did reduce incidence nausea and
dexamethasone reduce did reduce incidence nausea vomiting
dexamethasone reduce incidence vomiting
dexamethasone reduce moderate nausea
Dexamethasone had effect incidence nausea postoperative
Dexamethasone had effect incidence nausea
Dexamethasone had effect incidence nausea and
Dexamethasone had effect incidence nausea vomiting
fentanyl groups Combining revealed reducing nausea
fentanyl groups Combining revealed reducing nausea prior discharge decreased nausea
fentanyl omission unaffected severity Pain
sevoflurane had reduce increased respiratory
sevoflurane had reduce increased depression
sevoflurane had reduce increased depression hypotension
sevoflurane had reduce increased depression bradycardia
sevoflurane supplement appears exacerbated nausea postoperative
sevoflurane supplement appears exacerbated nausea
sevoflurane supplement appears exacerbated nausea and
sevoflurane supplement appears exacerbated nausea vomiting
sevoflurane supplement appears exacerbated improvement pain postoperative
sevoflurane supplement appears exacerbated improvement pain
fentanyl exacerbated improvement pain postoperative
fentanyl exacerbated improvement pain
iopamidol patients disease chronic
iopamidol patients disease kidney
iopamidol patients disease
iodixanol iopamidol patients disease chronic
iodixanol iopamidol patients disease kidney
iodixanol iopamidol patients disease
N use mellitus diabetes
N use mellitus
acetylcysteine use mellitus diabetes
acetylcysteine use mellitus
iopamidol % mg increases patients diabetes
iodixanol % mg increases patients diabetes
iopamidol less all 0 patients diabetes
iopamidol patients administration different mellitus diabetes
iopamidol patients administration different mellitus
iodixanol high iopamidol patients administration different mellitus diabetes
iodixanol high iopamidol patients administration different mellitus
methotrexate dose induction leukemia meningeal
methotrexate dose induction leukemia
methotrexate regimen high treated developed leukemia acute
methotrexate regimen high treated developed leukemia lymphoblastic
methotrexate regimen high treated developed leukemia
methotrexate concentrations achieve designed regimen high treated developed leukemia acute
methotrexate concentrations achieve designed regimen high treated developed leukemia lymphoblastic
methotrexate concentrations achieve designed regimen high treated developed leukemia
methotrexate regimen high treated disease meningeal
methotrexate regimen high treated disease
methotrexate concentrations achieve designed regimen high treated disease meningeal
methotrexate concentrations achieve designed regimen high treated disease
bilirubin elevations transaminase neutropenia
bilirubin elevations transaminase encountered toxicities
bilirubin elevations transaminase mucositis
methotrexate treatment induction remission relapse leukemia acute
methotrexate treatment induction remission relapse leukemia lymphoblastic
methotrexate treatment induction remission relapse leukemia
